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Abstract 
Metabolic syndrome (MetS), the development of which is associated with high-caloric Western 
diet intake, represents a risk factor for mild cognitive impairment (MCI) and Alzheimer’s disease 
(AD) and appears to contribute to AD progression when MetS and AD are comorbid. The 
interaction between AD and MetS might be through white matter inflammation, since white matter 
abnormalities and inflammation are important early events in the etiopathogenesis of both diseases. 
In these investigations, the effect of a high-caloric diet (HCD), to induce metabolic disturbances, 
on white matter neuroinflammation and cognitive function was investigated in a transgenic (TG) 
rat model of prodromal AD and MCI (APP21 TG). Rats maintained on the HCD developed 
obesity, dyslipidemia, hyperinsulinemia and glucose intolerance, but not hypertension. HCD-
driven metabolic perturbations significantly exacerbated white matter microglia, but not astrocyte, 
activation in the TG rats. There were significant deficits in spatial reference memory in the 
comorbid TG HCD group compared to wildtype control rats. There were no changes in 
hippocampal neuronal or synaptic density in the comorbid group. In addition, single-regimen 
chronic prophylactic treatment with a novel brain-targeted NSAID prodrug Ketoprofen-lysine was 
not able to decrease the activation of white matter microglia and alleviate cognitive deficits in the 
comorbid model. In fact, the prodrug treatment alone was associated with two deaths and 
widespread neuroinflammation and neurodegeneration in a subset of rats further associated with a 
spatial working memory decline and cognitive inflexibility. Finally, white matter microglia 
activation was positively associated with visceral fat deposition and with transgene presence. 
Dyslipidemia was related to the greater white matter inflammation in the entire rat sample, 
however, showed an unexpected inverse association in the comorbid model. Thus, the APP21 TG 
rat combined with the HCD represents a good model for future studies on prodromal AD pathology 
and MetS. It can be used to study related cognitive dysfunction including effects of various 
comorbidities on the disease presentation, as well as provide a platform for testing treatment 
strategies and biomarker identification. The results support an important role of white matter 
inflammation in the interaction between prodromal AD and MetS and as a contributor to cognitive 
impairment.  
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Summary for Lay Audience  
Alzheimer's disease (AD) is a highly prevalent and incurable brain disease in the elderly resulting  
in difficulty in thinking and communicating as well as memory loss. Metabolic syndrome (MetS), 
is another common disease in the elderly, largely due to the consumption of a hypercaloric Western 
diet high in fat and sugar. MetS represents a modifiable risk factor for AD. It can coexist with and 
likely interacts with AD, contributing to cognitive impairment. Investigating the pathological links 
between AD, especially at the very early stage, and MetS will advance our understanding of early 
disease processes, highlight therapeutic targets for early intervention and prevention, and identify 
markers of prodromal AD to aid early diagnosis and timely treatment. White matter abnormalities 
in brain are associated with cognitive dysfunction and inflammation and are important features of 
the initial stage of AD and MetS. Inflammation occurring in the white matter could be the basis of 
the interaction between AD and MetS. The studies in this thesis examined the contribution of a 
high-caloric (HCD)-induced MetS to the early AD pathology and changes in cognitive function 
using a novel genetically engineered rat carrying a human protein implicated in human AD. The 
combined model of AD predisposition and MetS demonstrated greater white matter inflammation 
which was caused by microglia (resident brain immune cells) and resulted in memory impairment. 
A novel brain-targeted chronic prophylactic anti-inflammatory treatment was not able to disrupt 
the detrimental interaction of early AD and MetS on white matter inflammation and to preserve 
cognitive function. However, serious neurological side effects were observed in several rats on the 
treatment. Accumulation of fat around the internal organs and blood lipid abnormalities were 
identified as potential biomarkers of increased white matter inflammation. However, abnormal 
blood lipids were associated with lower white matter inflammation in the combination of the early 
AD and MetS in the rats. In conclusion, the findings support the suggestion that white matter 
inflammation is a link between early AD and MetS. This rat model, closely mimicking human 
pathological conditions, represents a good platform for future studies on the complex relationships 
between AD and comorbidities, therapeutic approaches and biomarkers.   
  
v 
 
Co-Authorship Statement  
The work presented in Chapter 2: Comorbidity of Prodromal Alzheimer’s Disease and Metabolic 
Syndrome in the APP21 Transgenic Rat is co-authored by Qingfan Liu, Cansu Agca, Yuksel Agca, 
Earl G Noble, Shawn N Whitehead, David F Cechetto and is under review for Journal of 
Neuroinflammation under the title White Matter Inflammation and Cognitive Function in a 
Comorbid Metabolic Syndrome and Prodromal Alzheimer’s Disease Rat Model.  
The work presented in Chapter 3: Effect of the Novel Anti-inflammatory Prodrug Ketoprofen-
lysine in Comorbid APP21 Transgenic Rat and Diet-induced Metabolic Syndrome is co-authored 
by Cansu Agca, Yuksel Agca, Earl G Noble, Markus Forsberg, Jarkko Rautio, Jukka Leppänen, 
Shawn N Whitehead, David F Cechetto and is not yet submitted for publication. 
The work presented in Chapter 4: Negative Impact of Ketoprofen-lysine Treatment on Cerebral 
Pathology and Cognition in a Comorbid APP21 Transgenic Rat and Diet-induced Metabolic 
Syndrome is co-authored by Cansu Agca, Yuksel Agca, Earl G Noble, Markus Forsberg, Jarkko 
Rautio, Jukka Leppänen, Shawn N Whitehead, David F Cechetto and is not yet submitted for 
publication. 
The work presented in Chapter 5: Relationship between the White Matter Inflammation and 
Metabolic and Physiological Parameters in a Comorbid Rat Model of Prodromal Alzheimer’s 
Disease and Metabolic Syndrome is co-authored by Cansu Agca, Yuksel Agca, Shawn N 
Whitehead, David F Cechetto and is not yet submitted for publication. 
NI participated in design of the work, acquisition, analysis, interpretation of data and drafting the 
manuscript. QL participated in immunohistological staining and analysis. CA and YA developed 
the AD animal model. JL synthesized the KL prodrug. JR and MMF provided the prodrug and 
participated in the dose determination and development of administration protocol. EGN 
participated in design of the work related to MetS, and interpretation of the data, in particular 
providing the expertise in physiology. SNW participated in the design of the study, interpretation 
of the data. DFC had primary role in design of the study, participated in the analysis and 
interpretation of the data and the writing of the manuscript and overall supervision of the work. 
vi 
 
 
Epigraph 
“Success is not final, failure is not fatal. It is the courage to continue that counts”. 
Attributed to Winston Churchill…  
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Chapter 1: Introduction 
This chapter introduces the main concepts and current views on Alzheimer’s disease (AD) and 
metabolic syndrome (MetS) with a focus on white matter pathology and neuroinflammation in the 
pathogenesis of both diseases. AD and MetS often co-exist in elderly individuals and likely interact 
contributing to the decline in cognitive status. Investigating the underlying basis of this interaction, 
particularly at an early stage, and its effect on the cognitive function will advance our 
understanding of AD pathology and highlight potential therapeutic targets and strategies for the 
prevention of AD. 
This section first addresses the general issues of ageing, mild cognitive impairment (MCI), 
dementia and metabolic vascular disorders. This section then provides a detailed description of 
many aspects of AD. Thirdly, there is an examination of clinical and pathological aspects of MetS. 
Finally, the interaction of AD and MetS is discussed.  
 
1.1 The Problem of Ageing 
Aging is a natural and integral part of a human life. Every organ system of a human body undergoes 
changes as we age and the brain is no exception. The aging brain changes in morphology, 
physiology and function. This may lead to a minor but noticeable general reduction of cognitive 
abilities, particularly information processing speed, attention and memory, which together 
constitute a so-called normal cognitive aging. Physiological changes in the aging brain including 
vascular and metabolic alterations, as well as imbalance in oxidant-antioxidant systems and 
dysfunction of the immune system make the brain highly vulnerable and sensitive to disease and 
injury. As a result of the overlay of multiple chronic or acute disorders, there may be an 
acceleration in impairment of cognitive function leading to a substantial decrease in quality of life 
and even loss of independence. 
The aging world population has become a major concern. It is estimated that by 2050, 21.1 per 
cent of the world’s population will be 60 years or older and the number of older persons  from this 
age group will increase to more than 2 billion1. Normal healthy aging is not the only course and 
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the number of chronic pathologies is growing and greatly affecting the quality of life of older 
people. Two of these chronic disorders that interfere with cognition and furthermore with a daily 
living are MCI and dementia. Another group of chronic diseases associated with a high mortality 
rate is a group of vascular disorders and related metabolic conditions. 
 
1.1.1 Mild Cognitive Impairment  
MCI or mild neurocognitive disorder (as per Diagnostic and Statistical Manual of mental disorders, 
fifth edition (DSM-5) classification)2, represents a “transitional” or intermediate state between 
normal cognition and dementia 3. MCI may improve or remain stable for many years4. MCI is 
defined as a condition of a more severe decline in cognitive domains, usually memory (amnestic 
MCI) or generally across multiple domains, than that expected at a given age. Nevertheless, 
individuals experiencing a negative change from their usual cognitive level, remain functional and 
independent in the daily life tasks with a minimal aid from others.  
 
1.1.2 Dementia  
Dementia, or major neurocognitive disorder as per DSM-5 classification2, is a syndrome of severe 
deterioration in an individual’s mental status which includes a substantial decline in memory, 
attention, executive function (such as planning, organizing, problem solving and multi-tasking), 
inappropriate social behavior and severely compromised everyday functioning. The symptoms 
presented by an individual may also include language and mood disturbances, more commonly 
depression, apathy and anxiety. 
Dementia remains one of the biggest global public health challenges. The approximate number of 
individuals living with this diagnosis worldwide today is estimated at 47 million and is set to grow 
almost twofold in the next decade 5. In Canada, the numbers are expected to be nearly 1 million 
people in the next decade according to Alzheimer Society of Canada 2018 facts. 
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There are multiple diseases that are manifested as dementia syndrome, but the most commonly 
diagnosed form is dementia due to AD which accounts for 60-70% of all cases. The second most 
common cause of dementia is vascular dementia.   
 
1.1.3 Metabolic Vascular Disorders 
Metabolic vascular disorders represent a group of diseases featuring dysfunction of metabolism 
and pathological alterations to the vascular system, representing risk factors for cardio-, cerebro- 
and peripheral vascular diseases6,7. This group includes such major conditions as type 2 diabetes 
mellitus (T2DM) and its precursors, obesity and MetS. MetS is a cluster of several conditions 
including overweight status, defined by a body mass index (BMI) >25 kg/m2, and obesity (BMI 
≥30 kg/m2), hyper- and dyslipidemia, glucose metabolism perturbations, insulin resistance, and 
hypertension.  
The incidence of these chronic pathological conditions has markedly increased over the past few 
decades in the adult population and the prevalence has reached epidemic status particularly from 
a global ageing perspective8–12. This growth appears to be primarily associated with unhealthy 
lifestyle choices, such as chronic consumption of Western diets high in fat, sugar and salt and low 
physical activity13–18. The estimated prevalence of obesity is currently 650 million people 
worldwide19. People diagnosed with diabetes, 90% of whom have T2DM, account for 425 million 
worldwide20,21.  
The global prevalence of MetS, which is difficult to measure, was estimated to be at about one 
quarter of the world population, roughly over a billion people8. In Canada, roughly 6 million people 
were reported to be obese between 2001-201222.  Canada-wide statistics indicated that in 2016-
2017,  64% of adults older than 18 years were overweight and obese23. Obesity accounted for 27% 
of this statistic which is approximately 8 million people indicating a progressive increase over the 
past 5 years24. Canadian statistics in 2017 on diabetes indicated that more than 2 million people 
were diagnosed with diabetes and about 22% of population aged 12-79 had symptoms of MetS 25–
27. The seriousness of the situation behind these numbers is that these diseases not only represent 
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a public health issue and increased incidence of vascular morbidities, but also impose a great risk 
for dementia, including AD later in life13,14,17,28–38. 
 
1.2 Alzheimer’s Disease 
Alzheimer's disease (AD) is a neurodegenerative disease that leads to severe mental health decline 
and incapability to function independently in everyday life. There are two known forms of this 
disease. The first and most common form (about 95% AD cases) is sporadic form of the disease  
that in most cases presents as senile or late-onset AD (LOAD) in late 60-80s years of life with 
occasional early onset AD (EOAD) cases39. The second is a familial form (FAD) with an 
autosomal dominant inheritance of genetic mutations that typically has an early-onset, before 65 
years, although some later in life onset cases are described40. The progressive, irreversible and 
incurable character of this disease, regardless of the form, is a major societal concern given the 
high prevalence of this type of age-related dementing disorder in the population. Despite the 
extensive research conducted in the AD field, our comprehension of the causal events and 
pathological presentation, especially in the very early stages of the disease, is still incomplete and 
is an impediment to the development of therapeutic advancements. The search for biomarkers of 
the disease to aid in early capture has been developing intensively, and yet a timely and accurate 
diagnosis of AD that is essential for early intervention and better prognosis remains a great 
challenge.  
 
1.2.1 Diagnosis of Alzheimer’s Disease  
Accurate life-time clinical diagnostics of AD is very challenging, even with the existence of 
detailed criteria available to healthcare providers and clinical researchers. The diagnosis is mainly 
based on the patient’s complaints and their close relatives’ observations of gradually developing 
progressive cognitive decline from a previous cognitive level; as well as the patients’ performance 
on general cognitive and more sophisticated neuropsychological testing. Patient anamnesis and the 
family history provide additional information related to genetic, medical and life-style risk factors 
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which can further aid in diagnosis. Laboratory and instrumental diagnostics, including structural 
and functional magnetic resonance imaging (MRI), computer tomography and positron emission 
tomography (PET) is becoming more critical for early and differential diagnosis. However the 
methods are unstandardized and not widely available and therefore are not recommended for 
clinical use41. Nevertheless, neuroimaging has become a very useful tool in clinical and pre-clinical 
research that has significantly advanced our understanding of pathological processes, particularly 
associated with the early stages of AD and MCI. 
The core criteria outlined in the DSM-5, and recommended by the National Institute on Aging 
(NIA) and Alzheimer’s Association (AA) workgroups, allow for the identification of probable and 
possible AD2,42. To qualify for the most typical amnestic type of probable AD, the patient must 
present with a decline in memory, and with at minimum, an impairment in one other cognitive 
domain. Alternatively, in non-amnestic case at least two cognitive domains from language, 
visuospatial and executive functioning should be impaired. The diagnosis of probable AD also 
requires no evidence of concomitant substantial cerebrovascular disease, major psychiatric 
disorder, or other neurological or systemic conditions that could explain the cognitive 
symptomatology. Evidence of autosomal dominant FAD increases the certainty of the probable 
AD case. If probable AD is not confirmed, possible AD should be diagnosed. The antemortem 
diagnosis is mainly verified during autopsy by the presence of amyloid plaques, neurofibrillary 
tangles (NFT) and cortical atrophy in the brain tissue.  
 
1.2.2 Clinical Presentation of Alzheimer’s Disease 
Cognitive presentation of AD varies, and it is recognized that variable cognitive domains may be 
affected. The two disease forms, sporadic and familial, are largely similar in clinical and 
pathological representation, though they have some differences in symptomatology and 
progression with a more rapid deterioration in the early-onset form. 
Episodic memory impairment is considered the primary and early feature of the disease43. It is 
characterized by difficulties in recollection of recent events and recent personal past experiences 
embedded in a spatiotemporal context as well as difficulty with learning and encoding new 
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information43–45. Semantic or context-free memory undergoes decline during AD. In fact, semantic 
or context-free memory has been proposed to be affected at prodromal stages of the disease 
possibly preceding changes in episodic memory46. This hypothesis is confirmed by pathological 
findings of an early NFT accumulation in the entorhinal cortex, a region primarily associated with 
semantic memory, as well as in the perirhinal cortex. This pathology can precede changes in the 
hippocampus, a key structure for context-rich spatial and episodic memory47. Entorhinal cortical 
atrophy is suggested to be a better predictor for the conversion from MCI to AD48. However, these 
two memory systems are in fact very closely interrelated and therefore it might be difficult to 
distinguish which one is solely or early impaired when interpreting the common cognitive 
tests46,49,50.  
In addition to declarative memory deficits, executive dysfunction is a recognized variant of AD 
manifestation and often occurs in a combination with a decline in other domains. Moreover, some 
clinical studies suggest it develops early in the course of the disease at a prodromal or mild AD 
stage51–57. Individuals with AD show impairment on various executive function processes 
including working memory, response inhibition, selective attention and resistance to distraction, 
problem solving, set shifting and cognitive flexibility52,55,57.  
As the disease progresses, impairments may spread to non-cognitive functions including 
visuoconstructional and perceptual abilities, social function and personality changes such as 
increased irritability, aggression, combativeness, and inappropriate behavior. Psychiatric 
symptoms such as depression and apathy may appear very early and accompany any stage of the 
disease58. Very late in the disease sleep disorders, appetite loss, motor and gait disturbances, and 
deterioration of vital functions may be evident58. 
The early onset familial form of the disease has heterogenic clinical features with certain symptoms 
more attributed to the specific genetic profile. As in the sporadic variant, it also presents with 
episodic memory, context-free recognition, verbal memory impairment and executive 
dysfunctions59,60. Various non-cognitive symptoms are characteristic of the FAD and occur more 
frequently than in sporadic AD 60.  These can include behavioral, psychiatric, motor dysfunctions 
(e.g. extrapyramidal signs, myoclonus, spastic paraparesis), seizures, cerebral haemorrhage. 
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1.2.3 Mild Cognitive Impairment Preceding Alzheimer’s Disease  
AD is a progressive disease and clinical symptoms develop over many years, even decades. The 
early phase of the disease when the symptoms start to appear and are yet not severe enough to 
qualify for AD diagnosis is defined as MCI61. Most commonly this phase is characterized by a 
mild memory impairment. An additional simultaneous decline very often occurs in overall 
executive functioning and in executive function individual components62. Typically decline is 
evident in working memory, response inhibition, divided attention and manipulation, task 
switching, cognitive flexibility and problem solving62–66. Individuals with MCI, particularly with 
decline in multiple cognitive domains, are at a high risk of progression towards dementia including 
AD. Executive dysfunction is among the strongest predictors of the progressive decline64,67,68. 
There are different patterns and rates of decline in various cognitive domains, which some 
gradually deteriorate (e.g. immediate recall, inhibition) while others show a rapid decline just prior 
to AD diagnosis after a relatively long stable phase (e.g. delayed recall, episodic, spatial and 
working memory)69. From a clinical and therapeutic prospective, the MCI stage preceding AD 
appears to be the critical phase for early recognition, intervention and potential delay of the disease 
progression. However, negative results of clinical trials with potential treatment agents that were 
initiated at the MCI stage, point to the fact that even at this mild stage the pathological processes 
in the brain might already be too advanced and largely irreversible. This clinical failure is the 
impetus for research on the identification the earliest prodromal phases from both a pathological 
and possibly clinical prospective. This prodromal phase of the disease is asymptomatic and is 
characterized by developing pathological changes in the brain that can be detected using laboratory 
diagnostic measures in blood and cerebral spinal fluid (CSF) and neuroimaging. The NIA and AA 
group has developed recommendations for defining the earliest pre-clinical stage of AD that 
currently have only research application70.  
 
1.2.4 Risk factors of Alzheimer’s Disease 
The biggest risk factors for AD are age and genotype, conditions that cannot be changed. Some 
risk factors (i.e. lifestyle) can be controlled and modulated in order to reduce the chance of 
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developing metabolic dysfunction and consequently decrease the risk for MCI, AD or progression 
of cognitive decline58,71.  
One of the most critical factors for developing the most common form of AD, sporadic LOAD, is 
age72,73. With increased age our brain homeostatic systems become less functional and many 
defense mechanisms weaken, thus creating a favorable environment for development of pathology 
in response to a triggering event or injury.  
AD has a strong genetic predisposition74–77. Early-onset FAD has been causatively linked to 
mutations in three genes encoding amyloid precursor protein (APP) and presenilin proteins 
(PSEN1,2), that are directly involved in the amyloid pathway central to AD development60. PSEN1 
mutations account for the majority of AD cases60,78. The contribution of genetics to LOAD is also 
substantial and heritability accounts for 60-80% of cases79. Sporadic and familial LOAD forms 
and sporadic non-familial EOAD have shown a very similar profile to FAD 40,80–84. Known genetic 
mutations in APP and PSEN have been found in approximately 2% of sporadic LOAD cases, 
although they are unlikely to have a major role in LOAD predisposition81,85.  
The only major gene underlying susceptibility to both LOAD types is the APOEε4 gene, which 
encodes Apoliporotein E (APOE). APOEε4 is present in more than half of AD cases79,86–91. 
Homozygous carriers for this allele have a 10 fold increase in the risk of AD and have an earlier 
onset of the disease79,87,88,92. Genome-wide studies have identified rare and more common 
mutations in more than 30 genome loci associated with LOAD75,76,80,81,93–96. Most of the genes 
found encode proteins involved in cholesterol metabolism, the immune system, endocytosis and 
amyloid beta metabolism. However, these genes explain only a small part of  LOAD genetic profile  
and impose a much smaller effect than that of APOEε4 81,97.  
There also appears to be a combinatorial effect of mutations on the risk, age of onset and course 
of LOAD, such as was seen in the presence of both APOEε4 and PSEN1 mutations84,98. Thus, 
genetics is considered to be an important risk factor for senile AD, however, no causative 
mutations have been identified. This suggests there are other conditions such as lifestyle, medical 
conditions and environmental factors that impact the onset of the disease. The role of these other 
factors is confirmed by a study on twins in which not every individual developed the disease 
despite having the exact same genome 77.  
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Unhealthy lifestyle choices including cigarette smoking, alcoholism, lack of physical activity and 
dietary preferences, that are also linked to the development of vascular and metabolic disorders, 
represent a group of modifiable risk factors for AD99–104. Dietary choices are associated with both 
high and low risk of AD. Epidemiological and experimental studies indicate that a Western diet, 
characterized by high content of saturated fat, simple carbohydrates and salt, has been linked to 
cognitive impairment and increased risk of AD 16,18,105–109. On the contrary, adherence to the 
Mediterranean diet, which includes abundance of fruits, vegetables and whole grains, showed an 
association with reduced risk for dementia110,111. It has been demonstrated that not only 
macronutrient composition of the diet (i.e. fat, protein and carbohydrate) is important, but also a 
content of micronutrients. Several vitamin deficiencies including vitamins D, B12, B6 and E have 
been linked to AD increased risk101,112–115. The amount of the calories is as important as the nutrient 
source. High caloric intake exceeding energy expenditure is associated with MCI and AD15,116–118. 
Animal studies have demonstrated that caloric restriction and low percentage of carbohydrates and 
fat in foods play a role in a reduced risk for AD119,120. 
Many medical conditions, developed throughout the lifespan and particularly during middle age, 
represent risk factors for AD36. These conditions include hypercholesterolemia, 
hyperhomocysteinemia,  atherosclerosis, cardiovascular and cerebrovascular diseases, 
inflammatory diseases such as arthritis, T2DM and MetS that can result in hypertension, obesity 
and insulin resistance 33,121–137. Most of these disorders are tightly linked to lifestyle choices 
including dietary preferences, are chronic conditions, and progress with aging. In addition, they 
often co-exist with MCI or dementia. Psychological stress, depression, infection and head injury 
can also have a significant contribution to the risk for AD36,138,139. 
Greater brain or cognitive reserve (largely formed by level of education), complexity of the 
working environment, socioeconomic status, social interaction, and involvement in leisure 
activities which may be related to higher mental stimulation have been positively related to a 
reduced risk for AD risk and may delay cognitive deterioration140–142.  
None of these risk factors alone have been proven to be necessary or sufficient for AD 
development. However, the more factors that accumulate can have a cumulative effect and increase 
the chances of manifestation of the disease pathology143.  
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1.2.5 Neuropathology of Alzheimer’s Disease  
1.2.5.1 Current Mechanistic Hypotheses 
Various pathological mechanisms are implicated in the etiopathogenesis of AD. The accumulation 
of amyloid plaques and formation of NFT are considered to be the hallmarks of AD74,144,145. Other 
processes associated with the development of AD include glial activation, excessive 
neuroinflammation and oxidative stress, synaptic loss, neuronal degeneration and disruption to the 
white matter, as well as vascular and metabolic abnormalities, such as brain insulin resistance and 
abnormal glucose metabolism 144,146.  
Amyloid hypothesis 
Amyloid plaque accumulation in the brain tissue is a core feature of AD. The main component of 
these plaques is amyloid-β peptide (Aβ) produced through an altered enzymatic cleavage from 
(APP), endogenously expressed throughout the brain, formed by β- and γ-secretases144,147,148. 
Amyloid peptide exists in multiple molecular forms starting with soluble monomers Aβ40 and 
Aβ42 which self-aggregate into oligomers, then into fibrils which form diffuse and later insoluble 
extracellular plaques. While Aβ42 composes the core of the senile cortical plaque, a more abundant 
Aβ40 species has a high affinity to the wall of cortical microvasculature and is associated with a 
cerebral amyloid angiopathy (CAA)149,150. Oligomeric forms are considered to be the most 
neurotoxic and are associated with synaptic dysfunction and loss151–154. Increased production of 
Aβ and its decreased clearance from the brain are both considered to be implicated in the disease 
pathogenesis74. Support for the amyloid hypothesis as the core origin of AD comes from the 
causative role of genetic mutations of APP and amyloidogenic pathway enzymes genes PSEN1,2 
in FAD60,78. However, a major limitation of this theory arises with evidence from studies of human 
brain showing a lack of correlation between amyloid plaque burden and presence or severity of 
dementia symptoms155–157.  
Tau hypothesis  
NFTs in pyramidal neurons constitute a second proteinopathy occurring in AD144,147. Their 
formation is a result of an aggregation of dysfunctional insoluble hyperphosphorylated tau protein, 
which normally exists in unphosphorylated form and promotes microtubule stabilization and aids 
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axonal vesicle transport. Unlike amyloid plaque burden, tau pathology in the neocortex is highly 
correlated with cognitive performance158. Nonetheless, amyloid and tau pathologies interact with 
each other, both are integral to AD pathology and both exist in the complex pathological network 
interconnected with other processes such as synaptic dysfunction, inflammation, oxidative stress. 
Synaptic dysfunction 
Synaptic dysfunction is another AD pathology and is related to the disruption of communication 
between neurons and has been proposed as an explanation of the early signs of mental 
deterioration144. Synaptic loss, particularly in the hippocampus, a structure relevant to learning and 
memory, and in the neocortex occurs in MCI and AD and correlates with cognitive 
dysfunction159,160.   
Cholinergic hypothesis 
The brain cholinergic system and its main neurotransmitter acetylcholine (ACh) plays a crucial 
role in learning and memory in a complex manner161. ACh promotes neuronal plasticity, 
neuroprotection and neurogenesis mainly via nicotinic ACh receptors. It modulates neurotrophin 
expression (e.g. brain derived neurotrophic factor (BDNF), nerve and fibroblast growth factors), 
interacts with glia cells, including blocking excessive inflammation derived from microglia pro-
inflammatory cytokine production, a pathology that can be detrimental to memory processing161. 
A substantial reduction in brain ACh levels through changes in the activity of the main ACh 
enzymes (i.e. choline acetyltransferase, acetylcholinesterase), axonal pathology of cholinergic 
neurons occurring in the early stages and the loss of these cells in the later stages are evident in 
AD162–164. Loss of cholinergic synapses contributes to the dysfunction in the cholinergic system. 
The cholinergic hypothesis of AD has led to the development of therapies for AD and are currently 
the only drug group approved for symptomatic treatment of the disease165.  
Mitochondrial dysfunction and oxidative stress hypothesis  
Oxidative stress is a pathological condition in which there is an elevation of toxic free radicals 
such as reactive oxygen (ROS) and nitrogen (NOS) species naturally produced by cells. These free 
radicals bind to DNA, RNA, protein and lipid molecules leading to cell damage. Mitochondria is 
a primary site of oxygen free radical production. Studies investigating the oxidant system in AD 
12 
 
patients’ brain tissue samples have concluded that mitochondrial damage and oxidative stress are 
common and early events in AD, occurring before the hallmark proteinopathies of AD are 
established and then gradually decreasing with the disease advancement166. The changes include 
mitochondrial DNA alterations, mutations in an oxidative environment, proteasome dysfunction 
and low cytochromeoxidase activity144,145,167. Thus, these changes have been proposed to drive 
amyloid accumulation and promote tau pathologies. In turn, these misfolded proteins further feed 
the oxidative process by inhibiting mitochondrial functioning directly and activating glia cells 
which contribute to the free radical pool and drive related inflammatory processes168.  
Metabolic dysregulation 
Insulin and insulin growth factor 1 resistance, impaired downstream insulin signaling and altered 
cerebral glucose metabolism have been consistently reported in AD and accompany NFT 
formation, Aβ accumulation, inflammation and oxidative stress 169–177. Evidence has been provided 
that brain insulin, locally produced or from peripheral organs, has several effects on the brain 
including, positive effects on amyloid metabolism (degradation via insulin degrading enzyme 
action); apoptosis (via NFκB pathway) and memory and learning due to changes in various 
underlying mechanisms (synaptic plasticity, long-term potentiation and depression, glucose 
metabolism, downstream insulin signaling etc.)37,38,178. Studies on cognitive decline associated 
with AD and T2DM, with either pathology alone or in a comorbid situation, have shown improved 
cognitive performance by memory facilitation with treatment with insulin delivered to the central 
nervous system (CNS)179.  
Cholesterol and lipid metabolism are also thought to be implicated in AD pathophysiology 
primarily via involvement with amyloid metabolism. However, the relationship of lipid 
metabolism with AD are complicated and largely debatable180–184. There is an inconsistency in 
reports whether hypercholesterolemia and lipid dyshomeostasis in AD are a risk factor for AD184. 
The cholesterol hypothesis of the disease has been questioned due to the fact that peripheral 
cholesterol does not cross the blood-brain barrier (BBB). Thus, the cholesterol changes outside of 
the brain are unlikely to directly contribute to brain homeostatic changes. Furthermore, changes in 
fluid cholesterol concentration of AD patients were reported to be low, high or the same as in non-
diseased controls185.  
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Animal research, using models of high-fat/high-cholesterol diet-induced peripheral metabolic 
disorders that develop dyslipidemia and are associated with impairments to cognition, have been 
supportive of a role for cholesterol in AD pathogenesis. This could happen via various mechanisms 
such as altered brain lipid and cholesterol profiles, increased accumulation of amyloid and 
phosphorylated tau proteins, oxidative stress, inflammation, and disruption to the BBB and 
microvasculature186–193. The support for a role of cholesterol in AD also comes from the strong 
genetic link of APOEe4 allele and high risk of AD development91. APOE encoded by this gene is 
an important regulator of lipoprotein metabolism and cholesterol transport. APOE is also related 
to the insulin pathway, is involved in Aβ metabolism, including  clearance of soluble Aβ and the 
Aβ aggregation, and is associated with inflammation and neuroplasticity93,194.  
Considerable attention has been granted to the oxysterols as the pathogenic component of AD195. 
Oxysterols are products of cholesterol oxygenation, mainly by ROS, which are generated within 
the brain and in the periphery and are able to cross BBB180,196,197. They show involvement in the 
modulation of cholesterol metabolism, neuroinflammation, apoptosis and Aβ accumulation198. 
High blood and CSF oxysterol levels, particularly 24(S)-hydroxycholesterol (24S-OHC) which is 
excreted by the brain, have been reported in AD patients and are linked to amyloid cascade and 
neuronal stress198–201. Metabolic conditions such as obesity are also associated with the increase in 
oxysterols and 27-OHC in particular is viewed as a candidate modulator entering the brain and 
interfering with cerebral homeostasis202–204. In the highly interactive pathological environment in 
AD, inflammation greatly affects oxysterol levels and these substances in turn effect glial 
activation197,203. 
Neuroinflammation  
Neuroinflammation is one of the earliest and most critical events occurring in the brain in response 
to insult and plays an important and likely a key role in the pathogenesis of AD205–208. Microglia 
are the key cellular component of the inflammatory processes occurring in the brain and are the 
first cells to become activated and proliferate in response to disturbances in cerebral 
homeostasis209. Astrocytes play a major role in maintaining brain health and get readily involved 
in inflammatory reactions210. A more detailed look at the role of neuroinflammation in AD is 
contained in a separate sub-chapter. 
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Neurovascular hypothesis  
The sophisticated organization of the brain vascular system allows it to maintain its unique strictly 
regulated microenvironment. The larger caliber vessels can autoregulate cerebral blood flow via 
dilation-constriction mechanisms keeping the brain independent from systemic changes in the 
blood pressure. Capillaries are a part of the functional unit of the system called the neurovascular 
unit (NVU). NVU consists of anatomically and functionally closely linked endothelial, smooth 
muscle cells, pericytes, neurons, interneurons, astrocytes, microglia, and an extracellular 
compartment211. Capillary endothelial cells, pericytes and astrocyte end feet contacting endothelial 
basal lamina comprise the crucial NVU subunit forming the BBB and is sealed by intercellular 
tight junctions212. Each of these components crucially contributes to the proper functioning of the 
unit. The NVU serves as a regulator of blood supply with respect to the brain energy needs, a 
process called neurovascular coupling213.  
The BBB physically separates the CNS microenvironment from the peripheral circulation and 
regulates microvascular permeability for selective flux of substances to protect the brain from 
peripheral toxins and metabolites. Abluminal and soluble forms of low-density lipoprotein 
receptor–related proteins (LRP1) in conjunction with APOE regulate the efflux of brain Aβ42 and 
Aβ40 to the systemic circulation. Receptors for advanced glycation end products (RAGE), 
normally expressed in low amounts, mediate the influx of molecules from the peripheral blood, 
including Aβ. Glucose transporters such as GLUT1 primarily maintain the necessary high glucose 
concentrations, but also contribute to the BBB integrity and maintenance of cerebral blood flow214.  
AD is associated with both structural and functional alterations of the cerebrovasculature215–222. 
Microvascular abnormalities include decreased density, increased tortuosity, deposition of 
circulating lipids, and collagen, fibrinogen, amyloid and leukocyte adhesion to the vascular wall 
causing damage to the NVU such as endothelial inflammation and pericyte degeneration 217,223–230. 
These changes are accompanied by increased vascular reactivity and neurovascular uncoupling, 
vasoconstriction, hypoperfusion and ischemia creating a toxic oxidative, pro-inflammatory 
environment which further propagates BBB leakage149,220,225,231–234. There is evidence of the loss 
of LRP1 and GLUT1 receptors with a parallel upregulation of RAGE235,236. APOEe4 genotype, 
associated with the high risk of AD, has been linked to the BBB breakdown194,237,238. Blood-
15 
 
derived proteins such as fibrinogen, immunoglobulin IgG and circulating Aβ enter the brain easier 
when the BBB is compromised221,233,239–242. Alternatively, clearance of cerebral Aβ is impaired 
which leads to its accumulation and amplification of the NVU damage, glia activation and 
inflammation, and ultimately axonal and neuronal damage221,228,240,243–249.  
The neurovascular hypothesis of AD provides an explanation for the sequential pathology seen in 
the disease starting with a diminished Aβ clearance and age-related alterations to the 
cerebrovascular system that could initiate neurovascular uncoupling, microvascular inflammation 
and degeneration, hypoperfusion and hypoxia. These changes which affect BBB integrity, 
compromise the brain biochemical microenvironment leading to synaptic and neuronal damage 
and loss216.  
The proposed two-hit concept of pathology development in AD implies that there is initial damage 
to the neurovascular system, such as by cerebrovascular insults, cardiovascular diseases and other 
risk conditions as well as age-related alterations, that leads to damage to the BBB and 
microvasculature. The impaired BBB and microvasculature subsequently induce oligemia or blood 
supply reduction, hypoxia and create a toxic environment. These vascular changes initiate early 
neuronal dysfunction and also promote Aβ deposition via reduced vascular clearance from the 
CNS and increased generation of Aβ that in turn exacerbates vascular and neuronal damage215. 
While it is still debatable whether cerebrovascular abnormalities are a cause or a consequence of 
AD, it is very likely that in fact it is both and NVU dysfunction is a significant contributor from 
the very initial to the end stage of the disease250. 
White matter changes 
AD is a disease impacting both the gray and white matter of the brain251. While changes to the 
gray matter in the pathogenesis of AD are well known and continued to be heavily investigated, 
the neuropathology of white matter abnormalities still remains not fully understood. White matter 
pathology is mainly attributed to cerebral small vessel degeneration and BBB deregulation with a 
contribution from inflammatory events, leading to loss of myelin and axonal fibers252–254. White 
matter changes in AD are described in a separate sub-chapter.  
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1.2.5.2 Neuroinflammation and Role of Glia Cells in Alzheimer’s Disease 
Neuroinflammation is a complex process thought to be implicated in the early stages of AD 
development largely contributing to its progression205,207,208,255–260. Moreover, it interacts with all 
other mechanistic processes in AD pathogenesis and is a component linking these multiple 
pathological events. Patients with AD exhibit upregulation of genes associated with inflammation 
regulation (e.g. triggering receptor expressed on myeloid cells 2 (TREM2) mutations, cluster of 
differentiation (CD) 33, tumor necrosis factor alpha (TNF-α), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB), cyclooxygenases (COX) 1 and 2) and elevation of 
circulating and brain tissue cytokines, particularly TNF-α and interleukin IL-6, acute phase 
proteins, chemokines, complement and glial activation80,206–208,255,258,260–264. Epidemiological 
studies show a decreased risk of AD associated with the long-term use of non-steroidal anti-
inflammatory drugs (NSAIDs) which further supports the inflammatory hypothesis of AD and 
suggests inflammation is a critical therapeutic target265,266.  
Brain inflammation is largely mediated by the resident innate immune cells,  microglia, 
perivascular macrophages and immunocompetent astrocytes260. Microglia cells conduct a constant 
surveillance of the brain environment and are readily activated when an aberrant process or 
pathogen is detected. In the AD context, the main triggers of microglia are aberrantly processed 
amyloid protein (e.g. Aβ monomers, oligomers, fibrils), injured neurons including those impacted 
by Aβ and p-tau, damaged vasculature and BBB breakdown146,257,267. These triggers activate cells 
directly or through receptor binding such as RAGE, scavenger receptors, and toll-like receptors 
(TLRs) or through cluster of differentiation. These triggers lead to microglia phenotype changes 
promoting phagocytosis of apoptotic neurons, dystrophic neurite and clearance of Aβ 
accumulates205,268,269.  
Activated microglia further communicate with astrocytes and perivascular macrophages which 
help in Aβ plaque degradation via cytokines (e.g. TNF -α, IL-6, IL-1β, IL-12, IL-23), chemokines, 
caspases, and production and release of ROS/NOS207. It has been proposed that glia cell numbers 
do not increase during AD but only undergo phenotypic change without marked proliferation270.  
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Microglia appear to be activated even at the preclinical stage, when subjective cognitive decline is 
reported, although cognitive tests show no impairment. This activation gradually increases with 
the progression from MCI to eventually AD271.   
Astrocytes show a delayed involvement, becoming reactive at the MCI stage271,272. Astrocyte 
activation and generation of the reactive phenotype, characterized by upregulation of glial 
fibrillary acidic protein (GFAP), RAGE and epidermal growth factor receptor (EGFR) are 
associated with Aβ plaques in AD273,274. Reactive astrocytes aid in Aβ clearance and likely help in 
restriction of the focal damage though without a glial scar formation275,276. They also interact with 
microglia cells and are able to modulate their activity and help down-regulate inflammatory 
reaction via release of anti-inflammatory factors277–279. However, the main functions of astrocytes 
are metabolic support for neurons, their survival and outgrowth, synaptogenesis, myelination and 
BBB maintenance. During chronic inflammation, associated with triggering events, these primary 
functions of astrocytes are likely compromised which contributes to the propagation of the 
pathology280,281. Furthermore, under pathological conditions reactive astrocytes upregulate the NF-
kB pathway, overexpressing IL-1β, IL-6, mediator S100β, release pro-inflammatory cytokines and 
chemokines, which further activate microglial cells and propagate tissue damage including plaque 
formation277.   
The relationship between neuroinflammation and AD appears to be very complicated and not 
simply either beneficial or detrimental205,208,256,260. While inflammation is a natural response to an 
injury directed toward resolving the pathological event, persistent inflammation - chronic cell 
overactivation by the trigger and unsuppressed pro-inflammatory cytokine release – can lead to 
failure of protective mechanisms, disease development and propagation. Thus, in pre-clinical 
studies microglial overactivation has been shown to result in decreased phagocytotic efficiency, 
leading to a reduced degradation of amyloid aggregates, while pro-inflammatory cytokine 
production was unaffected269,282–284. However, even when microglia are overactivated, amyloid 
peptide toxicity, especially of oligomers, acts on glial cells to induce dystrophic state in microglia 
and loss of proper function146,285. 
The relationship in LOAD is further complicated by the effects of ageing on the immune system. 
The term inflammaging describes the age-related chronic low grade pro-inflammatory 
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environment in the brain which is associated with increased inflammasome generation and 
secretion of IL-1β and IL-18 and may contribute to age-related cognitive decline286,287. 
Immunosenescence is viewed as a part of normal aging that presents as changes to cell 
morphology, physiology and function, and in a balance between inflammatory initiation-resolution 
mechanisms that might lead to cell priming and increased susceptibility to injury288–290.  
Microglia senescence is characterized by morphological changes, decreased mobility, loss of 
homogenous tissue distribution, altered protein expression (e.g. increased major histocompatibility 
class (MHCII) and reduced TREM2), increased oxidative stress and mitochondrial dysfunction291. 
These changes result in less effective monitoring, defective phagocytosis and impaired 
communication with neurons leading to diminished response to injury, while at the same time 
maintaining pro-inflammatory cytokine production and release292. Diminished amyloid peptide 
clearance from the brain that occurs with age further triggers activated microglia initiating a 
pathological inflammatory response286,293. Experimental data indicates that senescent cell 
dysfunction is related to AD pathogenesis. The results show dystrophic microglial cells surround 
neurons with NFT pathology, suggesting this association precedes tau pathology and likely 
neurodegeneration in AD294,295.  
An adaptive immune system is also involved in AD and it may be recruited when resident 
microglia cells are not able to manage the pathological process. Circulating monocytes, attracted 
by microglia, can infiltrate the brain and participate in Aβ clearance267,296–299. Furthermore, the 
perivascular space contains macrophages that act as antigen-presenting cells (APC) and are 
regularly renewed by infiltrating monocyte differentiation300.  
To support the immune system, pericytes are capable of transformation into microglia and acquire 
their function301. T- lymphocytes migration into the brain has also been suggested to be involved 
in the AD process296. Microglia in AD show upregulation of genes involved in APC-T-cell 
interaction and express MHCII, encoded by the human leukocyte antigens (HLA) genes which 
can modify the susceptibility to LOAD268,302. MHCII expression is linked to antigen-presentation 
function and could potentially attract T-cells initiating their migration to microglia locations303,304. 
Amyloid peptides and cellular debris are potential antigens presented to T-cells which show 
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increased reactivity to Aβ305. CD8+ T-cells are thought to be involved in apoptosis, while CD4+ 
T-helpers can modulate microglial responses.  
 
1.2.5.3 White Matter Changes in Alzheimer’s Disease 
There is more white matter than gray matter in the brain and it consists of myelinated and 
unmyelinated axons, glia (including microglia, astrocytes, oligodendrocytes) and blood vessels. 
The white matter plays an important role in brain connectivity and cognitive function306. Similar 
to the gray matter, it undergoes atrophy and structural changes with ageing and is not spared by 
neurodegenerative disorders, including AD251,306–311. Eventually, white matter damage results in 
the loss of connectivity between gray matter regions and contributes to cognitive decline. These 
changes can be seen on T2 - MRI scans as hyperintensities (WMH) known as leukoaraiosis. 
Diffuse tensor imaging (DTI-MRI) allows an estimate of white matter spatial area and integrity. 
DTI-MRI can detect changes that appear normal in MRI and in histopathological 
examination252,312,313. WMH increase with aging, are often present in MCI and AD and have been 
shown to highly correlate with cognitive decline108,313–320. Animal models of AD have supported 
the clinical findings of white matter alterations in this disease321–324. These white matter 
abnormalities have been viewed as an early pre-clinical stage and a core pathological event in AD, 
particularly in early-onset FAD, and precede classical gray matter proteinopathies and symptom 
onset251,308,310,316,325–327.  
WMH, or leukoraiosis, are thought to have a vascular origin, caused by hypoperfusion, and 
represent small vessel cerebrovascular disease which is commonly observed in AD and suggests 
an overlap between vascular disease and AD251,328–331. WMH are also co-localized with amyloid 
pathology in AD brains and are more severe when CAA or microbleeds are present332. This 
relationship with CAA and amyloid also emphasizes the involvement of vascular system in the 
pathogenesis of AD. These findings suggest  the possibility that vascular abnormalities drive AD 
development and/or interact in an additive or synergistic way with the classical pathology as 
opposed to be independently co-existent250,332–334.  
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The prefrontal, temporal and parietal lobes show the highest vulnerability to classic AD pathology 
and neurodegeneration. Myelination of axons from these regions continues into mid-life306,335. 
These areas, the last areas to myelinate, are associated with encoding and retrieval of new 
memories, short-term memory formation and executive functions. These cortical areas are the first 
to deteriorate with normal aging and most impacted by preclinical and early AD and can explain 
the clinical profile observed in early AD54,65,306,336,337. Cortical regions that are myelinated early in 
life (primary motor, sensory cortex) appear to be more resistant to degeneration and are affected 
only in the late stages of AD. These observations fall under the neuropathological retrogenesis 
concept which implies that aging degenerative changes begin in the last developed structures. 
Atrophy of the corpus callosum is evident in MCI and mild AD, begins in the later myelinating 
anterior subregions and propagates to posterior subregions which receive axons directly from 
temporo-parietal lobe regions primarily affected in the later stage of overt protein pathology in 
AD338,339. 
White matter degeneration and associated volume loss occurs in a spatial pattern that is depending 
on the AD variant and correlates with symptomatology340,341. White matter damage and atrophy in 
rare disease variants was observed in the lateral temporal and parietal regions, including cingulum, 
posterior corpus callosum, fornix and occipital region of the brain. LOAD was associated with a 
less intensive regional involvement. However, there was damage and atrophy in frontal and 
parietal regions and the medial temporal region342. Even when the conventional MRI scans 
appeared normal, the white matter of AD patients showed abnormalities with DTI in limbic 
pathways, cortico-cortical association tracts, interhemispheric tracts, and corticospinal tracts, 
which correlated with regional gray matter atrophy337,343,344. This association between gray and 
white matter is not evident in MCI patients312,337,343,344. This data suggests that in early stages of 
the disease, white matter damage is unlikely to be caused by anterograde Wallerian degeneration 
related to neuronal damage. The white matter degeneration originates from local events directly 
damaging myelin and axons, that leads to retrograde neuronal degeneration321. Thus, 
neurodegeneration in the later stages of AD could be associated with progression in white matter 
damage. 
The underlying pathology of WMH and abnormal white matter seen with DTI may include 
demyelination and axonopathy, which can be accompanied by gliosis and glial dysfunction, 
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pathology which is also observed in animal models of AD251–254,306,311,312,314,321,327,345–354. Animal 
studies suggest that demyelination itself does not lead to axonal degeneration when normal glial 
function is maintained. However, these demyelinated and unmyelinated axons could be exposed 
to and damaged by various pathological stimuli present in AD355. Vascular events including 
hypoperfusion and ischemia associated with BBB leakage, microvascular pathology, aberrant 
neuroinflammation and oxidative stress, can all contribute significantly to axonal and myelin 
damage252–254,311,330,344,346,351,356–360.  
These pathological conditions can act on vulnerable oligodendrocytes and precursor cells and 
promote pericyte degeneration and loss that propagates white matter damage251,306,315,347,351,361–363. 
Local accumulation of Aβ40 and Aβ42 amyloid in white matter, due to increased production and/or 
impaired clearance of amyloid, can also damage glia cells and axons, aggravating axonal transport 
and demyelination, and promote vascular and BBB damage, including pericyte degeneration and 
loss, and glial overactivation251,321,351,360,364. Diminished axonal APP transport, vascular clearance 
of APP and damage to myelin can in turn contribute to amyloid accumulation 351,353,360,365. This 
pathological cascade appears to be self-propagating due to a high level of interaction and influence 
between these events. The interaction contributes to the difficulty in identifying a causative event 
in the white matter disease and AD etiology as a whole. 
   
1.2.6 Biomarkers of Alzheimer’s Disease  
The use of biomarkers can increase the specificity and accuracy of the clinical diagnosis of 
probable and possible AD by addition of pathophysiological evidence to the observed 
symptomatology42,61,366–368. There are multiple biomarkers which have long been proposed and are 
currently used, mainly in clinical research.  However, this area is continuing to be actively explored 
and various new markers have been identified41,369,370. The principle idea of a biomarker is to 
demonstrate an in-vivo pathology that can be observed at various stages of the disease including 
the prodromal asymptomatic phase. This would allow the biomarker to be used for diagnosis and 
likelihood of disease progression. The primary markers for AD are based on the key pathologies: 
amyloid deposition, NFT, oxidative stress, neuroinflammation, neurodegeneration, 
hypometabolism, BBB integrity, perfusion status, brain atrophy and WMH. These biomarkers are 
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grouped into  factors in blood and CSF, and neuroimaging markers371–373. Genetic screening for 
causative mutations associated with FAD and APOEε4 also complement diagnosis371.  
Evidence of cerebral amyloid deposition can be obtained from plasma or serum and CSF. These 
fluid measures can include Aβ1-42, Aβ1-40 and fibrinogen γ-chain levels371. Low levels of fluid 
Aβ are suggestive of increased brain amyloid accumulation. The presence of fibrillar amyloid 
plaque and amyloid angiopathy can also be detected using PET with the 11C-Pittsburg component 
B tracer (Pi-B). Elevated concentration of total (t-tau) and phosphorylated tau (p-tau) protein 
measured in blood or CSF are also associated with the ongoing neurodegenerative process. It is 
recommended to use amyloid and tau markers in combination to increase level of information and 
accuracy366. Thus, a combination of these proteins in a CSF Aβ1-42/t-tau ratio showed a high 
specificity and sensitivity as a marker371. Amyloid PET scans have shown to be good at predicting 
progression to AD from MCI and are used in parallel with or to back up fluid amyloid level 
markers. 
Inflammation and oxidative stress are two critical processes that are present from the very initial 
prodromal stages of AD, preceding protein pathologies and are promising therapeutic targets. 
These events can be detected using both fluid analysis and PET imaging technology. The PET 
imaging utilizes radiological tracers for the detection of specific proteins largely expressed by 
activated cells374. These biomarkers can be a key to treatment management and disease assessment. 
PET imaging of both microglia and astrocytes, uses tracers for a highly specific microglia 18 kDa 
translocator protein (TSPO) and less specific astrocytic monoamine oxidase B inhibitor (MAO-
B)375. Increased concentration of cytokines in blood and CSF, including c-reactive protein (CRP), 
IL-6, TNF-α, or microglia associated proteins (e.g. TREM2 receptor) have also been shown to 
reflect neuroinflammatory status372. Specific markers of brain oxidative stress, including lipid 
peroxidation products (oxysterols), can be detected in blood or urine with chromatography or mass 
spectrometry376.  
Clinically, biomarkers that can be detected in blood receive a great deal of attention since they are 
easily obtainable using minimally invasive and potentially more widely affordable methods. A 
recent study examined plasma metabolites to identify novel diagnostic markers and reported a 
group of 24 metabolites associated with preclinical LOAD373. Neurofilament light chain is another 
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promising marker of disease progression. It is specifically associated with degeneration of 
myelinated axons and can be measured in plasma or serum as well as in CSF372,377,378. Elevated 
levels and increased rates of change of neurofilament light chain in prodromal FAD were shown 
to be predictive of a faster symptomatic onset and highly correlated with cortical thinning377. AD 
patients also have significantly elevated levels compared to MCI and healthy individuals 
suggesting there is a correlation with cognitive deficits378. Another group of blood-derived 
biomarkers are autoantibodies against various neuronal proteins involved in inflammation, 
vascular and metabolic alterations that can be observed at various pathological stages  of the 
disease369.  
BBB integrity is compromised in early stages of AD and is independent of changes in amyloid or 
tau pathology. Permeability of BBB can be assessed with dynamic MRI with contrast agent and 
CSF-serum albumin ratio250. Microvascular damage, particularly in the hippocampal region is 
related to early AD and is detected in the CSF using a capillary pericyte loss marker that is a 
soluble platelet-derived growth factor receptor-β. Cerebral hypoperfusion is associated with the 
pathology of AD can be detected using single-photon emission computed tomography (SPECT) 
imaging. Another marker of late stage neurodegeneration is hypometabolism in temporoparietal 
regions and is associated with synaptic dysfunction that is detectable on PET images with a 
fluorodeoxyglucose ligand (18FDG). However, these markers are evidence of the ongoing 
advanced stage and lack specificity. 
MRI provides information on structural changes of the brain. Atrophy of the hippocampal 
formation and medial temporal and parietal lobes seen on MRI scans is a proven marker of 
progression to AD dementia. However, this atrophy is usually suggestive of a more advanced stage 
of the disease marked by neurodegeneration379. MRI fluid attenuated inversion recovery  (FLAIR) 
and T2-sequencing are able to detect WMH that are commonly present in AD and MCI and have 
been shown to highly correlate with cognitive decline108,316,318,380. Of great interest is the clinical 
finding that WMH, leukoaraiosis volume, specifically in the parietal and occipital lobe, tend to be 
present a couple of decades before symptoms of cognitive deterioration start to appear308,310,316 and 
suggest they are promising biomarkers of early disease stages for MCI and subsequent conversion 
to AD.  
24 
 
Although, often seen in AD, WMH are not specific to AD pathology. Thus, the exploration of 
WMH as a biomarker should be extended beyond the absence and presence, and look deeper at 
the underlying WMH pathology specifically associated with AD. The neuropathology of white 
matter abnormalities still remains not fully understood and is mainly attributed to cerebral small 
vessel degeneration, inflammatory events, as well as loss of myelin and axonal fibers252–254,311. 
Inflammation, as an early process in AD pathogenesis, might be also developing in the white 
matter. Markers specific to white matter inflammation including imaging and fluid-derived 
approaches should be studied. A high level of peripheral inflammatory cytokine IL-8 in the serum 
was shown to be related to WMH in AD and this further suggests an inflammatory basis of 
leukaraiosis381. 
A high priority is the detection of MCI in the elderly population and in particular those individuals 
likely to convert to dementia. The best predictors of conversion from MCI to AD are hippocampal 
volume and levels of p-tau in the CSF. In addition, these measures in combination with CSF Aβ1-
42 or blood phospholipids levels provide the highest predictive power61,371,382–385. Progression of 
an increase rate in WMH volume is a predictor of both conversion from a healthy brain to MCI 
and from MCI to dementia due to AD of either a vascular or mixed pathology386,387. 
Some of the biomarkers discussed above can show relatively high specificity and accuracy, 
although they also have certain limitations. None of them are widely accessible or have been 
clinically validated, standardized or approved. They are generally recommended for use only for 
research purposes41,42,61,367. Most of the diagnostic biomarkers reflect an advanced pathology and 
likely have limited relevance to potential disease treatment. Most of prognostic biomarkers are 
usually predictive of a conversion in cases that are already symptomatic. Comorbid conditions 
including chronic metabolic and vascular diseases, age, gender and belonging to a specific ethnic 
group may modulate the relationship of the markers to AD or MCI pathologies or change the 
specificity and sensitivity of some biomarkers, suggesting that extensive investigations in this area 
are required.  
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1.2.7 Treatment Strategies for Alzheimer’s Disease 
Currently there is no available treatment to stop AD progression and cure the disease. However, 
there are few approved treatment agents available for symptomatic relief43,58,165,388. One of the 
drugs approved for use in mild to moderate AD cases belong to the group of reversible 
acetylcholinesterase inhibitors including donepezil, rivastigmine, and galantamine389–391. The 
mechanism of action of these drugs is a prolongation of neurotransmitter ACh lifetime and its 
action at synapses, facilitating cholinergic transmission392. With the progression of pathological 
processes into more advanced stages of neurodegeneration and loss of neuronal synapses, these 
drugs lose their ability to improve cognitive deficits.   
Another agent proven beneficial in patients with mild to moderate disease stages is cerebrolysin, 
an agent that mimics properties of neurotrophic factors393. Memantine, a glutaminergic N-methyl-
D-aspartate (NMDA) receptor antagonist, is an approved pharmacological agent for moderate to 
severe AD dementia394. Beneficial effects on cognition are thought to be related to its ability to 
reduce excessive stimulation of cortical and hippocampal neurons by glutamate via calcium cell 
entry reduction and diminish cell apoptosis and also increase long-term synaptic potentiation 
associated with memory formation. While the drugs described above show some benefit in overt 
AD, few or none were found to be of use in MCI395. The final class of drugs that is prescribed are 
antidepressants used to alleviate psychiatric and behavioral symptoms of AD patients, including 
depression, anxiety and agitation. However, their use provides very modest beneficial effect and 
is associated with increased cerebrovascular complications and mortality, therefore their inclusion 
in clinical practice should be done with great caution165. 
With the increased evidence for the association between AD and metabolic disorder, including 
T2DM and MetS, drugs used in the treatment plan of these disorders is receiving greater attention. 
The peroxisome proliferator activated receptor γ (PPARγ) agonists pioglitazone and rosiglitazone, 
which are conventional T2DM drugs, did not demonstrate any benefit over placebo in randomized 
clinical trials (RCT) when used in mild to moderate AD396,397. A pilot study on insulin sensitizing 
via intranasal insulin administration have shown beneficial effects in early AD398. RCT on the 
potential for nasal insulin therapy has recently ended in 2018 and results are pending. Statins or 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (e.g. pravastatin, 
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simvastatin, atorvastatin) demonstrated no positive effects in preventing cognitive deterioration in 
the elderly399,400. Nilvadipine, a calcium channel blocker, is widely used for the management of 
hypertension, showed promising results preclinically, however, there was no benefit in patients 
with mild-to-moderate AD401. 
Currently, experimental pathology-modulating treatments are being increasingly developed388,402. 
The main preclinical and clinical research directions are chosen based on the key AD pathologies 
– amyloid and tau pathology, inflammation and oxidative stress403.   
Inhibition of β- (BACE) or γ-secretase and promotion of α-secretase activity are the key ways to 
reduce Aβ production and accumulation404. Treatment agents with such mechanism of action have 
failed to show beneficial effects in clinical trials, although clinical trials on several new agents 
inhibiting BACE activity are ongoing403,405. Vaccination with Aβ42 or passive immunization with 
antibodies against Aβ as well as intravenous gamma globulin which can promote clearance of 
amyloid from the brain, have also been studied. Although, this approach led to cognitive 
improvement in early trials, it did not stop further decline and, moreover, was associated with 
serious adverse effects406–408. However, immunization against amyloid is being further 
investigated and a few antibodies, including crenezumab, gantenerumab, and aducanumab, are 
currently in phase II-III clinical trials involving early and mild AD stages403.   
Another way to interfere with the amyloid aggregation pathway is based on soluble Aβ42 binding 
reducing oligomerization and subsequent deposition. A small glycosaminoglycan-like molecule, 
Tramiprosate, with this mechanism of action failed to show clinical efficacy in a phase III clinical 
trial, although it unexpectedly showed benefits in APOE4 carriers409–411.  
Modulation of tau proteinopathy can be achieved by tau phosphorylation inhibitors, prevention of 
aggregation, microtubule stabilization or active immunization403. The tau aggregation inhibitor, 
TRx0237, is currently in a phase III clinical trial in mild AD patients.  Other trials completed with 
this agent produced negative results or indicated a high rate of side effects incompatible with a 
clinical use of these drugs403. Tau immunization is also currently under clinical testing.  
Another pathway of intervention is enhancement of the brain serotonergic system, which is 
disturbed in the AD and greatly contributes to behavioral and also cognitive symptoms of the 
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disease, using 5-HT6 serotonin receptor antagonists (e.g. intepirdine) which is currently being 
clinically tested for mild-to-moderate AD treatment412–414.  
The strategies to reduce oxidative stress associated with AD pathology throughout the entire course 
of the disease and particularly at the early prodromal stages, can include the use of the natural or 
human-made antioxidants and modulation of oxidative-inflammatory pathways. Antioxidants 
comprise a large group of natural or synthesized substances able to reduce cell damage by free 
radicals due to oxidative stress415. Vegetables and fruits are enriched with these substances and 
when included in the diet are thought to be beneficial for mental health. Epidemiological studies 
suggested a positive effect of such diets with natural substances or supplements with antioxidant 
properties. These studies examined the impact of antioxidants on cognitive function and lowering 
the risk for dementia. The preclinical research demonstrated the capability of antioxidants to 
reduce cellular pathology and improve cognitive outcome, however, clinical research indicated a 
questionable benefit and even opposite effects415–419. 
One trial with an antioxidant indicated that patients with probable AD benefitted cognitively from 
the N-acetylcysteine supplement420. Trials with resveratrol and curcumin have produced either 
mild positive or neutral results402,421. However, a combination of antioxidants including vitamins 
C, E, α-lipoic acid and coenzyme Q3 in an RCT involving patients with mild-to-moderate stages 
of AD raised the  concern that there might be a faster cognitive decline despite lower levels of 
selective, but not all CSF, markers of oxidative stress422.  
Targeting neuroinflammation appears to be one of the most promising approaches to slowing or 
preventing some forms of dementia, including AD, since it has been shown to be one of the earliest 
processes related to the disease pathogenesis. Epidemiological, neuropathological and animal 
studies have shown a long-term treatment with NSAIDs that inhibit cyclooxygenase (COX) 
activity, either selectively (COX2) or non-selectively, and that reduce the synthesis of 
prostaglandins, are associated with a reduced risk of AD 265,423–436. However, clinical trials with 
NSAIDs have produced controversial results with some studies reporting positive effects and 
others indicating no significant cognitive improvement in MCI and AD425,427,437–447. 
It appears that with NSAID treatment, an absence of initial cognitive symptoms and earlier 
intervention were the factors defining success of the study. It is likely, that initiation of NSAIDs 
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treatment prior to major pathology development (i.e. very early stages) of the disease and in 
asymptomatic phase might have a potential to prevent or slow down the progression and delay 
clinical onset of AD424,425,437,439,443. Thus, NSAIDs can be viewed as a preventive measure rather 
than a treatment per se. However, there are clinical reports with evidence of serious adverse 
cardiovascular and cerebrovascular effects using this group of drugs irrespective of the selectivity 
of the NSAID, although the COX-2 selective drugs appeared more implicated in the adverse effects 
438,448–463.  
Based on these mixed results, of great importance is the question of the safety of these agents in 
the general population as well as those with concurrent vascular or metabolic diseases such as 
T2DM and MetS. This latter group are in a high-risk group for vascular complications and may 
already have cardiovascular diagnoses and/or cerebrovascular history448,451. Further studies 
carefully investigating the exact conditions of the treatment, including the timing, dosage and 
duration and determining overall safety are required to understand the treatment potential of this 
large class of agents. Innovative drug design to enhance delivery to the brain to allow the use of 
lower doses and to minimize of adverse effects are needed.  
Aspirin is another drug with COX enzyme inhibiting properties, was also shown to modulate 
oxidative and inflammatory pathology preclinically464,465. However, no positive effects were seen 
in clinical trials and the treatment was also associated with increased risk of cerebrovascular 
events440,466.  
Experimental anti-inflammatory drug treatment is being continuously examined in preclinical 
research and the research yields results supportive of the anti-inflammatory hypothesis of AD risk 
reduction. Novel NSAIDs, as well as drug agents form various other classes have been tested467. 
Some promising treatments such as CHF 5074, a modulator of microglial activation profile 
towards the M2 phenotype, have proceeded to the clinical trials for MCI.  Unfortunately, this drug 
did not show statistically significant cognitive improvement468,469.   
Inhibitors of RAGE, which is a critical component of the inflammatory pathway, including PF-
04494700 and Azeliragon, were proposed as therapeutic agents for AD and again failed in clinical 
trials470. Triflusal, a platelet aggregation inhibitor, has shown good results in preclinical models 
and treatment delayed progression of MCI to AD in one clinical study465,471–473. The drugs targeting 
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TNF-α such as etanercept infliximab have shown positive cognitive dynamics in mild – to – severe 
AD cases474–479. Minocycline, a tetracycline antibiotic able to cross the BBB, has been increasingly 
reported to have good anti-inflammatory and anti-oxidant effects with positive effects on amyloid 
and tau-pathology in preclinical models mainly via inhibition of the NF-κB and MAPK 
pathways480–483. Furthermore, this agent is associated with the white matter protection, which in 
light of the early stage pathology and cognitive function relationship of white matter inflammation 
to AD, is extremely relevant and favorable484,485.  
In conclusion, nearly all proposed treatment strategies for AD failed in clinical trials likely due to 
the use of agents at the advanced stage of the disease when pathology is too severe and likely 
irreversible. Thus, it is important to focus on the early stages of the disease, shifting the focus from 
advanced pathologies to that presented at the prodromal stage, a few decades before the clinical 
onset, and at stage correlating with cognitive deficits due to white matter disease (i.e. WMH) and 
its specific pathology486.  
Moreover, in many cases dementia is not the only disease present in these patients, and other 
chronic pathologies, such as vascular and metabolic diseases, contribute to the mixed pathology 
underlying cognitive decline, and consequently can influence the success in treating dementia. 
Many of these other chronic disorders begin in individual’s middle age and develop progressively 
over time eventually manifesting in a serious condition long after the initial signs. Thus, it is 
reasonable for prevention strategies to take into account the impact of coexisting disorders. It is 
important to explore the potential roles of those conditions that are risk factors for dementia and 
investigate mechanisms of shared pathological conditions simultaneously presenting with 
dementia. Reducing risk factors for the diseases including lifestyle modification and early 
prevention with drugs appears to be of great importance and should be pursued. Moreover, stable 
control over comorbid disorders should be achieved to increase the positive outcome of the 
treatment for dementia. A combination therapeutic approach that targets multiple links in the 
disease pathophysiological chain might be beneficial and should be seriously investigated. 
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1.3 Metabolic Vascular Disorders 
1.3.1 Comorbidities of Alzheimer’s Disease: Focus on Metabolic Syndrome  
Vascular metabolic conditions, such as T2DM and MetS, which represent risk factors for dementia 
including AD, develop in midlife and very often lead to the development of serious cardio- and 
cerebrovascular complications including myocardial infarction and stroke. Furthermore, these 
diseases accumulate with aging and are common comorbidities of AD. Increasing attention is paid 
to the interplay of AD with MetS due to the extreme prevalence of MetS in the elderly. MetS is 
also a precursor condition for the major cardiovascular diseases and T2DM and is highly 
modifiable in its nature.  
Epidemiological and clinical studies strongly suggest the existence of an interaction between MetS 
and AD and a possible synergistic or additive effect on cognitive outcomes when these pathologies 
are simultaneously present14,35. Individuals with MetS show a greater risk for developing MCI and 
AD later in life and AD patients tend to have a worse cognitive outcome and a faster progression 
or conversion to AD when MetS is also present28,29,129,134,138,487–497. Experimental data from studies 
using rodent comorbid models of overt AD and diet-induced obesity and metabolic changes yield 
evidence of poor performance in cognitive tasks and increased AD-like pathology109,188,498–504. A 
common gene, APOE, is implicated in the development of both AD and MetS, further suggesting 
a possible link between them505.  
While cerebrovascular comorbidities with AD, such as brain infarcts or strokes, are strongly and 
consistently associated with amplified cognitive impairment506,507, the association between MetS 
and AD appears to be less consistent. The complex interaction seems to be influenced by the age 
of the study participants14,508. Younger groups with age <70 years show a greater risk of AD 
development, whereas studies including older persons (>75-80 years) consistently report an 
inverse association of obesity and MCI, in which there is a slower progression and a better 
cognitive performance in comorbid demented subjects, suggesting a beneficial effect of the 
presence of metabolic changes34,509–512.  
It is possible that metabolic alterations interacting with cerebral homeostasis changes with age and 
with the development of the pathological processes. In addition, it might be that the age at which 
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vascular metabolic dysfunctions develop is a crucial factor which determines the effects on the 
cognitive function. The number of physiological and metabolic changes and their combination 
within the MetS cluster might further complicate the relationship between MetS as a whole and 
AD. Some changes may be individually related to AD risk in the same or opposite way, and the 
relationship may depend on the severity of the change. Further studies are needed to unravel the 
interactions between the two diseases, particularly investigating the early prodromal stages of AD 
where there is a greater possibility for treatment and prevention.    
 
1.3.2 Diagnosis of Metabolic Syndrome 
MetS is a cluster of components including central (i.e. abdominal) obesity, hypertension, insulin 
resistance, pre-diabetes (elevated blood glucose levels and glucose intolerance), diabetes and 
dyslipidemia (elevated triglycerides and reduced high-density lipoprotein (HDL) cholesterol)8,10. 
Central obesity is defined by measures of BMI, waist circumference or waist/hip ratio 
measurements. Criteria for MetS diagnosis vary slightly related to test-specific values and 
measurements of obesity and glucose metabolism, depending on the organization, but it always 
requires a combination of 3 conditions8. The most commonly used criteria from the World health 
organization (WHO) proposed in 1999, requires the presence of insulin resistance with glucose 
intolerance based on the 2h oral glucose tolerance test (OGTT) along with any two or more 
abnormalities (i.e. high triglycerides, low HDL cholesterol, raised blood pressure or obesity).  
The Third Adults Treatment Panel National Cholesterol Education Program (NCEP) ATP3 criteria 
from 2005 diagnoses MetS based on the presence of any three or more components from the five 
identified previously. The International Diabetes Federation (IDF) 2006 guidelines include central 
obesity and the presence of two or more components. The last two organizations do not use OGTT, 
but include raised fasting blood glucose or hypoglycemic treatment and additionally diagnosed 
T2DM in IDF.  
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1.3.3 Risk Factors of Metabolic Syndrome  
Modern lifestyle plays a big role in the etiology of obesity and MetS with a significant contribution 
from poor eating habits, particularly chronic consumption of high calorie Western diets 
characterized by high intake of saturated fat, simple carbohydrates (especially fructose) and salt, 
coupled with physical inactivity6,513–517. While environmental factors seem to be the main drivers 
of the disease, genetic predisposition to intra-abdominal fat accumulation, increased BMI, obesity, 
insulin resistance and dyslipidemia also contribute8,513,518. The role of parental obesity, intrauterine 
environment, maternal habits, diseases affecting fetal development and the postnatal environment 
are also recognized8. The development of MetS also increases with increasing age519–521. 
 
1.3.4 Clinical Presentation and Pathophysiology of Metabolic Syndrome 
Central or abdominal obesity is a core element of MetS. Obesity is a condition characterized by an 
excessive fat accumulation, especially around the internal organs (visceral fat), which is a highly 
metabolically active tissue contributing to systemic metabolic, vascular perturbations and 
development of chronic low-grade inflammation513,515,522–524. However, metabolically normal 
obese persons do not develop the syndrome, and MetS can be diagnosed without obesity, thus 
emphasizing that metabolically active visceral fat rather than subcutaneous fat increase is 
required518. Increased visceral adiposity is one of the major causes of insulin resistance which is 
characterized by the reduced sensitivity of cells to the actions of insulin such as glucose uptake 
and utilization, thus, leading to hyperglycemia and compensatory hyperinsulinemia (i.e. high blood 
levels of glucose and insulin)6,525. The main tissues developing insulin insensitivity are adipose 
tissue, liver and muscle. Exposure to the high levels of abdominal fat-secreted free fatty acids is 
thought to play a major role in the development of insulin resistance which in turn promotes fat 
accumulation creating a vicious cycle. Moreover, insulin resistance plays a major role in 
development of the pathologies that constitute MetS and defines its clinical presentation515.  
Insulin resistance promotes lipolysis in adipocytes resulting in elevation of free fatty acid levels 
that further interferes with the lipid metabolism. Abnormalities in lipid metabolism, or 
dyslipidemia, include an increase in total cholesterol, cholesterol atherogenic fractions such as 
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low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) particles and decrease in 
antiatherogenic high- density lipoproteins (HDL) and elevated triglycerides level515.  
Insulin resistance and associated hyperinsulinemia and hyperglycemia are linked to the 
development of vascular insulin resistance directly associated with endothelial dysfunction, 
vascular reactivity change, oxidative and inflammatory damage exacerbated by elevated 
circulatory cytokines6.  These changes create a prothrombotic environment which together with 
atherosclerosis promoted by dyslipidemia and associated inflammation increases the risk for 
cardio- and cerebrovascular diseases. These conditions along with hyperactivation of the renin-
angiotensin system and sympathetic nervous system by the insulin resistant state also leads to the 
development of hypertension518.  
Obesity is associated with increased NF-κB-mediated secretions of pro-inflammatory cytokines 
including interleukins IL-1 and IL-6, TNF-α and CRP by metabolic cells. These cytokines are 
triggered by excess consumption of nutrients, high caloric intake, particularly saturated free fatty 
acids and simple carbohydrates (e.g. fructose, glucose), leading to increased systemic 
inflammation that can affect multiple organs (primarily adipose tissue, liver, pancreas, muscle, 
gastrointestinal tract and brain)524,526–531. Adipocytokines including leptin, adiponectin and resistin 
secreted by adipose tissue are important regulators of energy intake, appetite, satiety, body weight, 
lipid and glucose metabolism and modulators of inflammation518,532. In morbid obesity there is 
leptin resistance with an increase in leptin production linked to hypertensive and pro-inflammatory 
actions and decreased levels of adiponectin associated with antiatherogenic and anti-inflammatory 
effects. 
MetS has deleterious effects throughout the whole body leading to many complications including 
cardiovascular pathology, retinopathy, nephropathy, non-alcoholic fatty liver disease, skin 
conditions, problems with the reproductive system and sleep and breathing disorders515. The CNS 
is not an exception and has complications, confirmed by a growing body of evidence of  brain 
insulin resistance and its neural consequences38,178. Chronic long-term development of these 
metabolic abnormalities is 5 times more likely to manifest as T2DM. The real hidden danger of 
MetS is that individuals with this condition are largely asymptomatic for a long period of time, but 
have a 2-fold increase in cardiovascular disease over the next 5 -10 years and have a 2- to 4- 
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increased risk of stroke, myocardial infarction and certain cancers resulting in a large contribution 
to mortality518,532.  
 
1.3.5 Cognitive Function in Metabolic Syndrome 
Obesity and MetS developed during midlife are involved in the perturbation of cognitive function 
and are associated with global cognitive decline16,533–536. The relationship of MetS and cognitive 
function are not mediated by a single individual component, but rather several components 
separately or in combination. Individuals with MetS show poorer scores on the mini-mental state 
examination (MMSE) measuring general cognitive ability, Raven’s progressive matrixes (RPM) 
for fluid intelligence assessment, memory assessing cognitive-affective verbal learning test 
(AVLT), impaired reasoning and executive functioning (e.g. on the Wisconsin Card Sorting Test, 
including working memory and attentional set shifting), decreased information processing speed 
and complex attention deficits135,491,537,538. Executive functioning as well as informational 
processing speed and verbal memory were the most frequently impaired cognitive domains533. As 
indicated above, it is interesting that older old adults, >85 years old, showed a better cognitive 
performance when metabolic components were present34. 
 
1.3.6 Neuropathology of Metabolic Syndrome  
Obesity and MetS affect CNS homeostasis through multiple mechanism although it is mainly via 
neuroinflammation, insulin resistance and vascular abnormalities, with effects on both gray and 
white matter539–541. The hypothalamus, especially the mediobasal region, which is a key 
neuroendocrine regulator of a large number of processes in the body including thermoregulation, 
appetite and body weight, is the most vulnerable brain structure to the vascular metabolic 
disturbances associated with MetS531.  However, other cerebral structures such as the 
hippocampus, neocortex, brainstem, amygdala, cerebellum and choroid plexus show pathological 
changes during the course of the disease531. In clinical studies, obesity has been associated with 
frontal and temporal brain atrophy, white matter alterations, frontal and prefrontal metabolic 
changes and reduced blood flow in a large cortical area, resulting in decreased cognitive 
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performance independent from the cardio- and cerebrovascular conditions534,542,543. MetS has also 
been associated with a greater incidence of silent brain infarcts that also might contribute to 
cognitive deficits544.  
The results of animal studies with Western high-fat, high-sugar diet induced obesity and MetS 
have supported the negative relation of the syndrome to learning and memory, particularly 
hippocampal dependent memory. These learning and memory deficits appear to be mediated by 
increased vascular and oxidative-inflammatory damage to the hippocampus, decreased neuronal 
plasticity and long-term potentiation and BDNF levels 16,18,107,109,187,188,499,500,535,545–559. Insulin 
resistance, hyerinsulinemia,  hyperglycemia and dyslipidemia can all affect the cerebrovasculature, 
induce oxidative stress and inflammation and modulate tau and amyloid metabolism promoting 
peptide accumulation, leading to cognitive impairment135,190,504,536,539,541,555,560–563. 
 
1.3.6.1 Neuroinflammation in Metabolic Syndrome 
One of the central mechanisms mediating MetS effects in the brain is neuroinflammation. The 
proinflammatory JNK and IKKβ/NFkB pathway appears to be upregulated in the hypothalamus 
and linked to energy imbalance, promoting obesity, as well as brain leptin and insulin resistance564–
567. High-fat diets in animals, commonly used to model obesity-related metabolic alterations, and 
increased consumption of the simple sugar fructose have been shown to increase microglial 
infiltration in the hypothalamic arcuate nucleus. The microglia are thought to be attracted and 
activated by circulating cytokines, immune cells, saturated fatty acid build up, hyperglycemia, 
thus, initiating local inflammatory reaction and recruiting astrocytes526,527,568–570. It has been 
suggested that hypothalamic reactive gliosis, cytokine release and inflammation induce local 
synaptic dysfunction and neuronal damage, thus affecting outputs to the brain structures linked 
with the hypothalamus including the hippocampus and amygdala. These brain regions contribute 
to the disease progression inducing neurodegeneration and cognitive decline107,531,548,571. 
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1.3.6.2 White Matter Changes in Metabolic Syndrome 
MetS, and obesity in particular, are associated with reduced white matter volume and disrupted 
microstructural integrity with both axonal and myelin alterations, especially in the corpus 
callosum, cingulum, external capsule, corona radiata, internal capsule and fornix542,572–580. These 
areas contribute to the development of cognitive dysfunction and in particular executive 
dysfunction 318,534,581,582. Alterations to the white matter connecting frontal and temporal, limbic 
structures and prefrontal regions are observed576,577. WMH and lacunar infarcts are also found in 
individuals with MetS, particularly temporoparietal regions which show an increased 
vulnerability108,583–588. 
 
1.3.7 Treatment Strategies for Metabolic Syndrome 
Lifestyle modification is a very effective preventive approach to the development of MetS. It 
includes changes in dietary habits, caloric restriction and regular exercise589. Pharmacological 
treatment is implemented to manage individual pathological conditions in MetS when preventive 
measures are not sufficient6,515,518,590. Weight loss medications include appetite suppression (e.g. 
phentermine, sibutramine) and nutrient absorption reducing (e.g. orlistat) agents. Bariatric surgery 
which is aimed to reduce the gastric volume is used in extreme cases of obesity in which there are 
additional health complications. Dyslipidemia can be controlled with statins, fibrates, cholesterol 
absorption inhibitors and bile acid sequestrants590. Angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers are commonly used as blood pressure regulating drugs. Glycemic 
control can be achieved with the use of anti-diabetic drugs such as metformin, thiazolidinediones, 
acarbose. Some of these drugs are able to act on multiple pathological units. Administration of 
aspirin is commonly used to reduce risk of thrombosis and linked vascular events.  
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1.4 Interaction of Alzheimer’s Disease and Metabolic Syndrome 
AD and MetS share multiple pathological features, including neuroinflammation, oxidative stress, 
alterations to the BBB, cerebrovasculature pathology, cerebral hypoperfusion, brain insulin 
resistance, and gray and white matter abnormalities176,562,591–597. These processes are also tightly 
related to the mechanisms of amyloid and tau production and degradation598.  
Neuroinflammation is a key pathological event developing at the prodromal stage of AD and drives 
the progression of the disease205,207,208,257,260. MetS is a chronic low-grade inflammatory disease 
which primarily originates from the visceral adipose tissue 513,515,522–524 and is one of the major 
causes of peripheral and brain insulin resistance which, in turn drives the clinical manifestation of 
MetS which can include cognitive dysfunction6,525,529,591,599–604.  
Systemic inflammation, such as that occurring in obesity and MetS, can modulate CNS 
inflammatory system and this interaction can have a high impact on cognitive function504,605–608. 
Resident microglia and macrophages respond to peripheral immune signals with increased 
cytokine production initiating a neuroinflammatory cascade. The peripheral immune signals such 
as pro-inflammatory cytokines and chemokines, can include ILs and TNF-α, and act via non-
disrupted NVU and circumventricular organs that lack a BBB as well as by neural afferent 
pathways609. Leukocytes, peripheral immune cells, have been shown to enter the CNS and 
aggravate gliosis contributing to neuroinflammation599,610.  
These observations suggest that neuroinflammation might be a potential early stage event linking 
these two chronic disorders which can further modulate AD-related pathology591,611–617. 
Modulation of brain amyloid metabolism in MetS has been suggested to be mediated by reduced 
degradation and clearance and increased production of Aβ. The amyloid changes are associated 
with effects of inflammation (i.e. TNFα), insulin (inhibition of insulin degrading enzyme), soluble 
LRP and leptin resistance190,618–620. Furthermore, APP is expressed not only in the brain, but in the 
peripheral tissues including adipose tissue, intestines and its expression is upregulated in 
obesity32,621,622. Aβ produced on site in these peripheral tissues in increased quantities can enter 
the blood circulation and can enter the brain contributing to the cerebral pathology and promoting 
neuroinflammation623.  
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Systemic low-grade inflammation in MetS is associated with a high circulating levels of CRP, 
lipopolysaccharide binding protein (LBP) and α1-antichymotrypsin. This low-grade inflammation 
is highly correlated with cognitive impairment, particularly cognitive flexibility, working memory 
and attentional set shifting (i.e. executive functioning) in obese subjects and the effects appear to 
be independent from the major cerebrovascular diseases538,624–627. These effects on cognitive 
performance are thought to be mediated by white matter abnormalities observed in these 
subjects584,586,587,624,628. Cerebral white matter lesions are also common in AD and have been shown 
to highly correlate with cognitive decline. Thus, white matter abnormalities represent another point 
of interaction between these comorbidities which seems to be intimately linked to inflammatory 
processes108,313–320,380. 
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1.5 Rational and Objectives 
AD and MetS are both serious disorders affecting a large elderly population worldwide. These 
conditions coexist in the population and it is likely they interact contributing to the course and 
progression of AD-pathology and cognitive decline and influence the success of experimentally 
tested treatments. However, the exact underlying processes of this interaction remain 
unclear14,28,29,134,138,487–489,491,493–497. Neuroinflammation, mainly driven by microglia and astrocyte 
activation, is a key pathological event developing at the prodromal stage of AD and a primary 
cause of disease progression207,208,257.  
AD is also a white matter disease with abnormalities in major fiber tracts including glial activation. 
This white matter pathology is present well before symptomatic onset of AD and highlights the 
potential of cerebral white matter lesions as a new biomarker of cognitive impairment in MCI and 
AD and a possible target for prevention and early therapy307,308,310,311,316.  
MetS is a chronic systemic inflammatory condition and is also associated with neuroinflammation 
and white matter changes, which appear to contribute to cognitive impairment319,531,538,564,624–628. 
Furthermore, aging which is highly associated with white matter alterations and increased risk of 
AD preceded by white matter lesions, also is associated with the development of metabolic 
disorders313,317,519–521.  
Research data suggests that aging, and particularly age-related brain neuroinflammatory 
dysregulation288,289, may exacerbate existing metabolic, vascular and neuroinflammatory 
conditions and aggravate white matter degeneration629–632. Thus, it is likely that an early interaction 
between the comorbid conditions of preclinical AD and MetS is mediated though the white matter 
inflammation occurring at prodromal stage of AD. This represents a critical area for research and 
deserves a great attention and requires extensive investigations. In order to conduct these types of 
investigations, there is a demand for comorbid preclinical animal models. Development of just 
such a model was a part of this work. 
In these investigations a high calorie high-fat, high sugar diet-induced MetS was combined with 
an APP21 transgenic rat model of prodromal Aβ plaque-negative AD 633–637.  This comorbid model 
was studied to test the research hypothesis. The hypothesis is that the comorbid condition of 
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preclinical AD and MetS will result in increased white matter inflammation and cognitive 
dysfunction which can be prevented by anti-inflammatory treatment. The following objectives 
were addressed:  
1) To determine the impact of comorbid metabolic abnormalities (MetS) and increased pathogenic 
APP environment on white matter neuroinflammation, specifically on microglia and astrocytes, 
and on cognitive function; thus, defining possible targets for early therapeutic intervention 
(Chapter 2). 
2) To examine the therapeutic potential of a brain targeted anti-inflammatory agent by examining 
the effect of the drug on the increased white matter inflammation and cognitive deficits in the 
comorbid model of prodromal AD and MetS (Chapter 3).  
3) To analyze the possible negative effects of a brain targeted anti-inflammatory agent tested as a 
potential therapeutic strategy to target increased white matter inflammation (Chapter 4). 
4) To identify potential biomarkers of white matter inflammation by characterizing the 
relationship between the white matter inflammation and the observed systemic metabolic and 
physiological parameters (Chapter 5). 
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Chapter 2: Comorbidity of Prodromal Alzheimer’s Disease and Metabolic 
Syndrome in the APP21 Transgenic Rat 
The aim of this study was to investigate the impact of the comorbid conditions of MetS and 
prodromal AD (TG for hAPP) on white matter neuroinflammation and on cognitive function 
(Objective 1). The manuscript for this investigation is currently under review for Journal of 
Neuroinflammation. 
 
2.1 Introduction 
Among age-related diseases, dementias are particular serious given their prevalence, severity and 
progressive and incurable characteristics. Alzheimer's disease (AD) is the most commonly 
diagnosed form of dementia. The accumulation of amyloid-β peptide (Aβ), produced through an 
altered cleavage of amyloid precursor protein (APP), and formation of neurofibrillary tangles are 
considered to be the hallmarks of AD 1. The processes associated with the development of AD 
include glial activation, excessive neuroinflammation and oxidative stress, as well as vascular and 
metabolic abnormalities 1,2. AD is a disease impacting both the gray and white matter of the brain. 
While changes to the gray matter in the pathogenesis of AD are well known and continued to be 
heavily investigated, the neuropathology of white matter abnormalities still remains not fully 
understood and is mainly attributed to cerebral small vessel degeneration, inflammatory events, as 
well as loss of myelin and axonal fibers 3–6. However, white matter changes have been shown to 
develop very early, in prodromal phase and precede the onset of clinical symptoms of dementia, 
highlighting the importance of their further  investigation7,8.  
The complex etiology and pathology of AD alone remains a focus of research, but increasing 
attention is paid to the interplay of AD with comorbidities such as stroke and metabolic disorders 
including diabetes and metabolic syndrome (MetS) 9. MetS, which is a focus of our research work, 
represents a combination of conditions such as obesity, dyslipidemia, glucose intolerance, insulin 
resistance and hypertension. Unhealthy lifestyle choices play a big role in etiology of MetS, with 
chronic intake of high calorie Western diets rich in saturated fat and simple carbohydrates coupled 
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with a sedentary lifestyle being the most common risk factors 10,11. MetS is a serious public health 
issue 12. It begins in middle age and continues to develop over time manifesting in serious 
conditions such as type 2 diabetes, cardio- and cerebrovascular diseases. Moreover, it represents a 
risk factor for dementia, including AD 13–16, and often coexist with it in one individual likely 
contributing to the course and progression of dementia 17.  
Epidemiological and clinical studies strongly suggest the existence of an interaction between MetS 
and dementia, including mild cognitive impairment (MCI) and AD. Individuals obese and 
diagnosed with MetS show a greater risk for developing cognitive decline later in life 18–20 and AD 
patients tend to have a poorer prognosis when MetS is also present 21. Experimental data from 
studies using rodent models of well-developed AD fed a high-fat diet yield evidence of poor 
performance in cognitive tasks and increased AD-like pathology including neuroinflammation 22–
26. In contrast to the earlier studies, our present study aimed to examine the early processes and 
interactions occurring at the prodromal phase of AD using a novel transgenic model of high 
cerebral amyloid levels as a predisposing environment.  
Inflammation as an event associated with both dementia, including AD, and MetS has been 
suggested to be one of the shared mechanisms contributing to the impaired cognition and AD-like 
pathology 27–29. In the current study, we examined the early effects of the comorbidity on the 
inflammation in the white matter which is highly susceptible to pathological changes, particularly 
the key cellular components of inflammatory response, microglia and astrocytes.  
While there is a clear connection between metabolic diseases and AD, the exact underlying 
mechanisms regarding how metabolic diseases affect mental health and contribute to the existing 
neuropathology, especially at the very initial stages of their development, remain unclear. The gap 
in our understanding of this interaction appears to be a limiting factor in any success in finding 
effective therapeutic and preventive interventions. This highlights the importance of developing 
experimental models that combine prodromal phase AD-like pathology with risk factors such as 
MetS to investigate the potential of early intervention and prevention.  
The present study was undertaken to better understand the relation between metabolic 
abnormalities and prodromal AD dementia, particularly studying the impact on changes in white 
matter inflammatory pathology and coincident cognitive deficits. The comorbidity of prodromal 
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AD with MetS was examined in a novel APP21 transgenic (TG) rat model of prodromal AD 30,31 
created on a Fischer 344 background which carries a human APP (hAPP) gene with Swedish and 
Indiana mutations, implicated in early-onset AD. This rat has been previously shown to express 
high levels of human brain APP and serum β-amyloid (Aβ1-40 and 1-42) without spontaneous Aβ 
plaques deposition in brain tissue with age 32,33. Thus, it allows us to study the early interaction 
between MetS and prodromal AD-like processes in the brain in a model with AD-predisposing 
conditions.  
In this study we focused on the pathology of diet-induced MetS in relation to prodromal phase of 
AD, specifically examining the consequences of its chronic course on the white matter 
inflammation, one of the earliest and most critical events occurring in the brain in response to 
insult, particularly on its key cellular players, microglia and astrocytes. In addition, we examined 
the effects of diet in the prodromal AD model on behavior and cognitive function. The hypothesis 
is that there would be greater white matter inflammation and cognitive deficits in the combined 
model than in either condition alone.  
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2.2 Methods 
2.2.1 Animals 
All animal handling and experimental procedures were approved by Western University Animal 
Care Committee (AUP 2008-113) and were carried out in accordance with the guidelines of the 
Canadian Council on Animal Care and National Institute of Health Guides for the Care and Use 
of Laboratory Animals. A total of 24 male wildtype (WT) and 22 male APP21 TG Fischer 344 
rats were involved in this study, and rats were assigned to experimental groups at random. APP21 
TG rats overexpressed hAPP with Swedish and Indiana mutations driven by the ubiquitin-C 
promoter were created via lentiviral vector method. Rats were bred in house with original breeding 
pairs obtained from Drs. Yuksel Agca and Cansu Agca (University of Missouri, Colombia, MO, 
USA) 30 and confirmed to be homozygous. Animals were housed in pairs under standard conditions 
(12:12 light/dark cycle, at 22-24°C) and maintained on a standard rat diet provided ad libitum. At 
the age of 8.5-9.5 months, half of the rats of each genotype were randomly assigned to a high-
calorie Western type diet (HCD), while the other half continued on a standard diet (control diet, 
CD). Diets were provided ad libitum and rats were maintained on the diets for 12 weeks. A study 
timeline is shown in Figure 2-1. Body weight as well as food and drink consumption were 
measured twice a week throughout the experiment. Towards the end of the experiment, there were 
slight variations in the exact time for the physiological and metabolic measures since they would 
interfere with the acquisition of behavioral data. Animal numbers for each experimental dietary 
group were as follows: WT CD, n=12; TG CD, n=11; WT HCD, n=12; and TG HCD, n=11.  
 
2.2.2 Diets 
Rats maintained on a standard diet received chow with the following composition (in %kJ): 26 
protein, 59.7 carbohydrate, and 14.3 fat with 1.52 % of saturated fatty acid (Prolab RMH 3000 
5P00). The Western diet consisted of the following (in %kJ): 17 protein, 43 carbohydrate, and 40 
fat with 62.4% of saturated fatty acid (D12079B, Research Diets, Inc) which included 0.21% 
cholesterol. The metabolizable energy from standard and Western diet (in kJ/g) was 13.31 and 
19.66, respectively. The solid food was supplemented with water in the CD group and with 20% 
81 
 
corn syrup water solution in the HCD group as an additional source of calories (Bee Hive, ACH 
Food Companies, Inc, USA).  
 
2.2.3 Intraperitoneal Glucose Tolerance Test (IpGTT) and Insulin Measurement 
IpGTT was performed at two weeks prior, and 11 weeks following the change in diet (Figure 2-
1). Following a 12-h overnight fast, 100-150 microliters of blood was drawn from the saphenous 
vein for determination of glucose and insulin baseline levels. A 60% glucose solution of D-(+)-
glucose (G 8270, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) in 0.9% saline (2g/kg) was 
then injected intraperitoneally. Blood was collected from a tail vein repeatedly at 15, 30, 60, 90 
and 120 minutes after the glucose load. Glucose levels (mmol/l) were measured using Freestyle 
Light Blood Glucose Monitoring System (Abbott Diabetes Care Inc, Alameda, CA). Glucose 
responses over time were analyzed to determine the area-under-the-curve (AUC). Fasting insulin 
levels were determined in serum samples using an ELISA kit (Ultra-sensitive rat insulin ELISA 
kit, Crystal Chem. Inc) according to the manufacturer’s instructions. Homeostasis model 
assessment index of insulin resistance (HOMA-IR) was calculated to estimate insulin resistance 
using the following formula34: HOMA-IR=(fasting glucose (mmol/l) x fasting insulin 
(mmol/l)/22.5. 
 
2.2.4 Lipid Profile Analysis  
Triglycerides, total cholesterol  and high-density lipoprotein (HDL) cholesterol were measured in 
serum samples isolated from cardiac blood at time of euthanasia and analyzed at the Clinical 
Laboratory at University Hospital (London, ON, Canada). Non- HDL cholesterol was calculated 
as total cholesterol – HDL cholesterol . The cholesterol ratio (Chol:HDL ratio) was calculated by 
dividing total cholesterol value by HDL cholesterol number.  
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2.2.5 Blood Pressure Analysis 
Systolic and diastolic arterial blood pressure were assessed three weeks before and at week 6 and 
10 on the diet (Figure 2-1) via a non-invasive tail cuff method (CODA Blood Pressure System, 
Kent Scientific Corp., Connecticut, USA).  
 
2.2.6 Open Field Activity and Anxiety-like Behavior 
Locomotor activity and anxiety-like behavior were tested in a square open field arena (Med 
Associates Inc., St. Albans, VT, USA) over the course of 20 minutes on week 9 of the diet (Figure 
2-1). Ambulatory distance and time spent in central and peripheral zones were evaluated using 
Activity Monitor software, Med Associates Inc.  
 
2.2.7 Morris Water Maze  
Rats first encountered the Morris water maze test (MWM) 1 week prior to the diet onset. The 
second testing (relearning) was performed 12 weeks after the diet following the same protocol, but 
with a new platform location (Figure 2-1). Rats were trained to find a hidden escape platform in a 
circular pool (145 cm in diameter, 58 cm in depth) filled with water, dyed with black non-toxic 
acrylic paint, using extra-maze cues placed on the walls around the pool. The training protocol 
consisted of 16 trials over 4 consecutive days (4 trials/day). The duration of one trial was 60 sec 
with a 30-sec inter-trial period during which time the rats remained on the platform. The platform 
(12cm in diameter) was placed in the middle of one of 4 virtual quadrants the pool was divided 
into, and this location remained unchanged during the training phase. Start positions were 
presented in a randomized order for every day of spatial acquisition. Learning progress was 
assessed using time and distance required to reach the platform (actual path length) and path 
efficiency (ratio of direct path length to the platform to actual path length, 1 being most efficient) 
in the acquisition trials. The day after the last day of training the rats were subjected to a 30-sec 
probe trial where the platform was removed from the pool and the rats were released from a novel 
start position. At the end of the training and probe prior to the dietary manipulation two 
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reacquisition trials in which the platform was returned to the previous position were administered 
to prevent memory extinction. Performance was evaluated using such parameters as time and 
distance travelled in the quadrant of a previous platform location (target quadrant) and swimming 
speed. Performance was monitored using video-tracking software (ANY-maze®, Stoelting Co., 
Wood Dale, IL, USA). 
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Figure 2-1. Project timeline. Rat’s age (in months) at the start (day 0) and the end (week 13) of 
the study are shown in brackets. Diets were assigned on day 0 and all testing time points are in 
reference to this day. Baseline measurements were completed 3 weeks prior to the start of the diet. 
Morris water maze spatial training was completed on week -1 (4 days, 4 trials a day) with a probe 
trial (Pr1) following on the day after. A second probe trial (Pr2) was completed on week 12 on a 
diet. Learning of a new platform location started the next day following the same protocol with a 
probe trial (Pr3) at the end. BP = blood pressure measurement, IpGTT = intraperitoneal glucose 
tolerance test, MWM = Morris Water Maze, Pr = probe trial, OF = open field test, BC = blood 
collection, TC = tissue collection, W = week. 
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2.2.8 Euthanasia and Tissue Collection 
Following a 12-h fasting period the rats were weighed and euthanized by a pentobarbital overdose. 
Cardiac blood was collected immediately before perfusion. Epididymal fat pads were collected 
and weighed. Rats were then perfused transcardially with 0.01 M phosphate buffered saline (pH 
7.35) followed by 4% paraformaldehyde (PFA, pH 7.35). Brains were post-fixed in PFA overnight 
and then transferred to a 30% sucrose solution until saturated fully submerged. Brains were 
sectioned coronally on a cryostat into 35 μm thick sections approximately from bregma 4.70mm 
to bregma -5.20mm 35, sorted into 12 series and were stored in cryoprotectant at -20°C until used 
for immunohistochemistry. 
 
2.2.9 Immunohistochemistry  
Immunohistochemistry was performed on free-floating sections to visualize microglia, activated 
microglia, astrocytes, neurons and synapses using rabbit polyclonal antibody against the ionized 
calcium binding adaptor molecule-1 (anti-Iba-1; 1:1000; Wako Chemicals USA Inc., Richmond, 
VA, USA), mouse monoclonal antibodies directed against the MHC II receptor (OX-6; 1:1000; 
BD Pharmingen, Mississauga ON, Canada), glial acidic fibrillary protein (anti-GFAP; 1:2000; 
Sigma-Aldrich, St Louis MO, USA), neuronal nuclei (anti-NeuN; 1:1000; EMD Millipore Corp., 
USA) and synaptophysin, a major synaptic vesicle protein,  (anti- synaptophysin; 1:1000; Sigma-
Aldrich, St Louis MO, USA), respectively. Following an overnight an incubation with the primary 
antibody at 4ºC, sections were incubated with biotinylated anti-mouse or anti-rabbit secondary 
antibody (1:500, Vector Laboratories, Inc. Burlingame, CA, USA) followed by incubation with 
avidin-biotin complex (ABC kit, Vector Laboratories, Inc. Burlingame, CA, USA) reagent and 
then developed in 0.05% 3, 3’ diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis 
MO, USA). Sections were then mounted on glass slides, air-dried, dehydrated, cleared in xylene 
and coverslipped with DePex mounting media (DePex, BDH Chemicals, Poole, UK). Detection of 
changes in white matter fiber myelination was done in sections pre-washed in 0.01M PBS mounted 
on glass slides, dried overnight and stained with Luxol fast blue following the protocol described 
elsewhere36.  
86 
 
2.2.10 Imaging and Quantification of Immunohistochemistry 
Immunohistochemically and histochemically processed brain sections were imaged at 10x 
objective with a Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2 colour camera head 
using NIS-Elements Imaging Software Version 4.30.02 (Nikon Instruments Inc., Melville, NY). 
Brain sections stained for OX-6 and Luxol fast blue were scanned with Aperio digital entire-slide 
scanner, allowing 20x magnification (Department of Pathology, Western University, London, 
Ontario, Canada). Entire series of brain sections was screened for positive OX-6 signal to 
determine regions of interest (ROIs) for all further analysis. Analysis and quantification were 
carried out using 64-bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of 
Health, Bethesda, MD, USA). The investigator was blinded to the identity of rats included in the 
quantification analysis. Images were converted into a black-and-white 8-bit format, underwent 
thresholding and were calibrated prior to taking all the measurements. Based on the location of the 
positive OX-6 immunostaining being mainly in the white matter structures, the corpus callosum, 
internal capsule and fimbria of the dorsal hippocampi were chosen as ROIs. A total of six regions 
from three consecutive brain sections containing corpus callosum, internal capsule or fimbria were 
analyzed for each animal. For the assessment of activated microglia cells (OX-6 stained) in the 
corpus callosum and internal capsule, areas with positive signal were manually outlined using a 
free outline tool. Integrated density, defined as a sum of the values of the pixels in the selected 
area, was measured for each region and summarized into a single value per animal. To analyze 
changes in general microglia population (Iba-1stained), activation of astrocytes, activated 
microglia in the fimbria and myelin content, white matter tracts were manually outlined, and a 
measure of the area of coverage by positive signal (percent of the total area) was noted for each 
region and expressed as a weighted average. The neuronal population of the hippocampus, CA1 
subregion, was visualized with NeuN immunostaining and was assessed using the NIS Elements 
analysis software. In the ROI sampled from two to three coronal brain sections neuronal nuclei 
were automatically counted in a selected field of 0.2 mm2 area and an average number was 
generated for each animal. Synaptophysin staining was quantified in the CA1 and CA3 
hippocampal subregions in a total of 8 fields per subregion, sampled from two brain sections, per 
animal in the ImageJ. The area of coverage by positive signal was expressed as a weighted average. 
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2.2.11 Data Analysis 
Statistical analysis was performed using GraphPad Prism 6.0. Data were analyzed by performing 
t-test or One-way or Two-way analysis of variance (ANOVA), followed by Tukey’s multiple 
comparisons test. Data is expressed as mean ± standard error of the mean (SEM), and a p value of 
≤ 0.05 was considered statistically significant.  
 
2.3 Results 
First, we performed an extensive physiological characterization of the model by analyzing body 
weights, parameters of glucose and lipid metabolism and arterial blood pressure values. 
 
2.3.1 Body Weights, Diet, Fat Accumulation,  Lipid and Glucose Metabolism 
Both TG and WT rats on a HCD gained weight rapidly and weighed significantly more than CD 
groups as early as the first week on the diet (Figure 2-2A). Starting from week 6 on the diet, rats 
from the comorbid group weighed more than the WT HCD group and this weight difference 
remained significant until the end of the study. In addition, as shown in Figure 2-2B, epididymal 
fat pads mass was significantly increased with HCD consumption (F(1,42)=335.9; p<0.0001), with 
an even greater increase in the TG rats (genotype effect F(1,42)=11.26; p<0.0017, interaction 
F(1,42)=3.769; p<0.059). Analysis of diet consumption across the 12 weeks showed a decrease in 
amount of food consumed (WT CD 20±0.2, TG CD 21±0.3 vs WT HCD 9±0.2, TG HCD 11±0.4 
g/day), however there was a large increase in drink consumption by rats from both HCD groups 
(WT CD 23±0.7, TG CD 27±0.7 vs WT HCD 68±2.4, TG HCD 61±1.9 g/day). This resulted in a 
significantly higher total energy intake in the HCD groups during the entire period of 12 weeks 
(WT CD 264±3.0, TG CD 272±4.0 vs WT HCD 406±5.0, TG HCD 402±3.0 kJ/day). Based on 
genetic profiles, rats had different preferences for the source of calories; TG rats favored high-fat 
food, whereas WT rats had a stronger preference for carbohydrates from drink. Triglyceride levels 
were significantly elevated by HCD (Figure 2-2C).  
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Total cholesterol was increased in both groups on the HCD, but reached statistical significance 
only in the comorbid rats compared to controls. Both TG and WT rats on the HCD had an increased 
cholesterol content of atherogenic lipoprotein particles (non-HDL cholesterol; Figure 2-2D). HDL 
cholesterol levels, when analyzed separately, were not different for HCD rats in comparison to the 
control groups. However, the Chol:HDL ratio, a relevant clinical index, was significantly greater 
in both HCD groups, indicating that these rats had a decrease in HDL cholesterol and a significant 
shift towards the atherogenic Non-HDL fraction (Table 2-1). 
Rats maintained on HCD did not show signs of hyperglycemia based on the fasting blood levels 
of glucose (Table 2- 1). Surprisingly, a glucose intolerance pattern was observed only in WT rats 
maintained on a HCD, which was characterized by a greater increase in blood glucose levels at 30 
minutes after a glucose injection that remained significantly increased till the end of a 2-h period 
(Figure 2-2E). This also translated into a significantly greater AUC for blood glucose. There 
appeared to be no effect of diet on glucose tolerance in the TG rats and AUC was very similar to 
CD group values (Table 2- 1). Fasting insulin levels were significantly higher for both WT and 
TG rats from HCD groups (Figure 2-2F). Two-way ANOVA analysis revealed a significant effect 
of the diet (F(1,41)=21.20; p<0.0001) in both genotypes. HOMA-IR index was significantly greater 
for both WT and TG rats from hypercaloric diet groups compared to the control groups (Table 2- 
1). Nevertheless, these data suggest that HCD did not lead to the development of frank diabetes, 
yet led to the manifestation of a pre-diabetic state. In contrast, the HCD had a robust effect on lipid 
metabolism.  
 
2.3.2 Blood Pressure 
Systolic and diastolic blood pressure values obtained at 6 and 10 weeks of diet were not different 
between the experimental groups, indicating that no animal group showed signs of hypertension 
due to dietary intervention or genotype (Figure 2-3).  Additional analysis of the pressure changes 
with age and diet within individual groups indicated a decrease in systolic (week 6 p=0.0025; week 
10 p=0.0011) and diastolic (week 10 p=0.131) pressure levels of TG HCD rats from the baseline 
(week -3) levels. HCD WT group showed an increase in diastolic pressure from baseline level at 
week 6 (p=0.0065), which then dropped to initial values at week 10 (p=0.0004).  
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Figure 2-2.  Weight gain, visceral fat accumulation, lipid and glucose metabolism. (A) Body 
weight change over the course of the diets. (B) Post-mortem paired epididymal fat pad weight. (C) 
Fasting triglyceride levels measured at the end of week 12 on the diets. (D) Fasting levels of total 
cholesterol presented as the whole bar and its fractions: Non-HDL (upper part of a bar) and HDL 
cholesterol (lower part of a bar). (E) Blood glucose levels during 2-h intraperitoneal glucose 
tolerance test (IpGTT) after 11 weeks on the diets. Zero time point (0) represents fasting glucose 
value obtained immediately before glucose load. (F) Fasting insulin levels measured from a blood 
sample drawn at time point 0 during IpGTT.  Animal numbers are as follows: WT CD (n=12), TG 
CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are presented as mean ± SEM. Significance 
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is indicated by * between HCD and both CD groups (in d – for non-HDL cholesterol), † between 
HCD groups and ‡ between TG HCD and both CD groups for total cholesterol. RM Two - way 
ANOVA and One - way ANOVA, Tukey’s multiple comparisons test, p < 0.05. CD = control diet, 
HCD = hypercaloric diet, HDL = high density lipoprotein, TG = transgenic, WT = wildtype. 
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Table 2-1. Serum glucose-, insulin- and lipid-related measures  
 WT CD TG CD WT HCD TG HCD 
Glucose, 
mmol/l (initial) 
3.73±0.10 3.82±0.07   
Glucose, 
mmol/l (post) 
3.6±0.13 3.63±0.14 3.96±0.13  3.91±0.12 
AUC IpGTT 
(initial) 
929.98±45.91 786.08±53.51   
AUC IpGTT 
(post) 
891.08±82.09 907.25±79.11 1568.85±172.74*† 892.44±90.58 
Insulin, 
pmol/ml (post) 
243.1±28.60 237.9±29.16   
HOMA-IR  
(post) 
0.19±0.03 0.17±0.03 0.56±0.09* 0.58±0.13* 
Chol:HDL, 
mmol/l 
1.64±0.09 1.49±0.06 2.43±0.17* 2.44±0.17* 
 
Initial – data obtained prior to the diet assignment; rats used in the study were combined by 
genotype. Post – data collected after 11-12 weeks on the diets. Non-specified – data obtained at 
the end of the study. All measures (except AUC IpGTT) represent fasting state values. Values are 
presented as mean ± SEM. The symbols * and † indicate significance for HCD group vs both 
control groups and between HCD groups respectively. One - way ANOVA, Tukey’s multiple 
comparison test; p<0.05. Abbreviations: AUC – area-under-the-curve, CD – control diet, Chol – 
total cholesterol, HCD – hypercaloric diet, HDL – high density lipoprotein cholesterol, HOMA-
IR – homeostasis model assessment index of insulin resistance, IpGTT – intraperitoneal glucose 
tolerance test, TG – transgenic, WT – wildtype. 
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Figure 2-3. Arterial blood pressure measured three weeks prior to and 6 and 10 weeks on 
the diet. A) Systolic blood pressure levels prior to the diet onset (week -3), on week 6 and 10 on 
the diet. B) Diastolic blood pressure levels on week -3, week 6 and 10 on the diet.  Animal numbers 
are as follows: WT CD (n=12), TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are 
presented as mean ± SEM. The symbol * indicates significance at a timepoint compared to the 
baseline (week -3) within the group . Two - way ANOVA, Tukey’s multiple comparisons test, 
p<0.05. CD = control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. 
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2.3.3 Behavioral Assessment 
We monitored cognitive performance using a spatial navigation version of MWM task. First 
testing was done prior to the assignment of different dietary regimens to assess baseline learning 
abilities of rats. The testing at the end of the study evaluated effects of the HCD-induced metabolic 
dysregulation alone and in combination with AD predisposing conditions on learning and memory.  
 
2.3.3.1 MWM and Spatial Learning Preceding Diet  
At the end of the initial training period, one week prior to the start of the diet, all groups had learned 
the location of the platform to the same extent (Figure 2-4A). Distance travelled in the target 
quadrant during the probe trial 1 following the learning was indicative of a good memory of the 
platform location (Figure 2-4B).  
 
2.3.3.2 MWM and Spatial Relearning after Diet 
Following 12 weeks on the diet, the latency to platform, path length to platform and path efficiency 
were significantly improved in CD groups, but were not significantly improved in the HCD groups 
(Figure 2-5A,B,D). Comorbid rats had on average shorter path lengths compared to the WT CD 
and TG CD animals (p=0.0451 and p=0.0494, respectively) on day 1 of the training (Figure 2-5B). 
However, when performance on individual trials within day 1 was compared, there was no 
significant difference between the groups (Figure 2-5C). Furthermore, TG HCD rats started the 
day 2 at the same level as the rest of the rats and continued in a comparable manner. This suggests, 
that TG HCD rats encountered the platform on average faster than CD rats on the very first day of 
learning the new location which could contribute to the observed day1-day4 lack of difference. 
This could likely occur by chance, especially on the trial 1, or due to choosing a certain swim 
strategy such as chaining, rather than represent a true spatial learning. TG rats on the HCD showed 
an inconsistent learning pattern with a sudden drop in path efficiency and increase in latency and 
path length to platform on the second day of the task. However, by the end of the spatial acquisition 
phase all rats learned the task to the same extent as indicated by the absence of differences between 
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groups in any of these measurements at day 4 of training. Learning swim speed was comparable 
between the groups across days. During the probe trial (Probe 3), comorbid rats spent less time 
searching in the target quadrant, while the other groups had a preference for the quadrant where 
the platform was located during learning days. Tukey’s multiple comparisons test showed a 
significant decrease (p<0.01; one-way ANOVA; Figure 2-5E) in time spent in the target quadrant 
for the comorbid rats compared to WT control group. Swim speed did not differ between groups 
(Figure 2-5F). Two-way ANOVA analysis revealed a significant effect of dietary treatment 
(F(1,42)=7.384; p<0.01) and genotype (F(1,42)=4.462; p<0.05) for time travelled in the target 
quadrant with no significant interaction, but the TG HCD group was significantly different from 
WT CD group (p=0.0085). Altogether, these results demonstrate diet- and genotype-dependent 
impairment in memory consolidation with a negative outcome in the comorbid condition.  
 
2.3.3.3 Open Field Test 
Assessment of the effects of HCD alone and in conjunction with AD pathology on locomotion and 
anxiety level was done in the open field maze. Analysis of total ambulatory distance during a 20 
min task did not result in any significant changes in the locomotor activity between groups (Figure 
2-6A), however, there was a genotype-dependent decrease (F(1,43)=6.371; p=0.0154) in locomotor 
activity of TG rats. Time spent in the central zone of the open field arena as a measure of anxiety-
like behavior was not affected by the diet. In contrast, the transgene significantly decreased 
(F(1,42)=10.09; p<0.01) time spent in the central zone (Figure 2-6B), suggesting that TG rats were 
more anxious.  
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Figure 2-4. Morris water maze learning and memory test performed one week prior to the 
diet onset. A) Latency to reach the platform in the 4-day training phase. B) Time spent in the 
target quadrant during the probe trial following the learning phase (Pr1) expressed as percent of 
total time in probe trial. Animal numbers are as follows: WT CD (n=12), TG CD (n=11), WT HCD 
(n=12), TG HCD (n=11). Values are presented as mean ± SEM. Significance is indicated by * 
between days 1 and 4 in all experimental groups. RM Two - way ANOVA, One - way ANOVA, 
Tukey’s multiple comparisons test, p<0.05. Cd = control diet, HCD = hypercaloric diet, TG = 
transgenic, WT = wildtype. 
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Figure 2-5.  Morris water maze relearning and probe trial for memory test after 12 weeks 
on the diet. (A) Latency to platform in the 4-day training phase. (B) Mean path length to reach the 
platform in the 4-day training phase. (C) Path length to platform in individual trials of each training 
day. (D) Path efficiency to reach the platform during 4 days of training. (E) Time spent in the 
target quadrant during the probe trial (Pr3) following relearning expressed as percent of total 
distance in probe trial. (F) Swim speed in the Pr3. Animal numbers are as follows: WT CD (n=12), 
TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Values are presented as mean ± SEM. 
Significance is indicated by ‡ between days 1 and 4 in CD groups, by * in A – between TG CD 
and HCD groups, in B – between CD groups and TG HCD, in E - between TG HCD and WT CD. 
RM Two - way ANOVA, One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. CD = 
control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. 
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Figure 2-6. Locomotor activity and anxiety-like behavior in open filed test.  (A) Total 
ambulatory distance for 20 minutes and (B) percentage of time spent in central zone of an open 
field arena. Animal numbers are as follows: WT CD (n=12), TG CD (n=11), WT HCD (n=12), 
TG HCD (n=11). Values are presented as mean ± SEM. Significance is indicated by * for WT CD 
vs TG CD and TG HCD. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. CD = 
control group, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. 
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2.3.4 Neuroinflammation 
Neuroinflammation is one of the earliest and most critical events occurring in the brain in response 
to insult and plays an important role in pathogenesis of AD. Microglia are the key cellular 
component of the inflammatory processes occurring in the brain and are the first ones to become 
activated and proliferate in response to disturbances in cerebral homeostasis. Astrocytes play a 
major role in maintaining brain health and get readily involved in inflammatory reactions. These 
two types of glial cells were included in our analysis as the elements of particular interest and were 
visualized using immunohistochemistry technique.  
 
2.3.4.1 Microglia Activation  
We looked for signs of microglial inflammation by scanning the entire brain from all frontal to 
posterior levels. The pathology observed was located mainly in the white matter regions with very 
few activated microglia cells observed in the gray matter regions such as the cortex and 
hippocampus. There were no apparent differences among the groups. Microglia activation  in the 
white matter, detected with the OX-6 immunostaining, has been shown to undergo an age-related 
increase in the TG rats compared to WT rats31. The images of the OX-6 activated microglia in 
three white matter regions from the three-month-old TG animal demonstrate there is a low 
activation of microglia  in the young animal (Figure 2-7A), similar to that of the WT aged rat. 
These images were complemented with an Iba-1 positive microglia cells from the young TG 
animal (Figure 2-8A). 
A detailed immunohistochemical assessment of the brain sections indicated significant changes in 
white matter inflammation due to the combination of the diet and transgene. The comorbid 
condition of HCD in the TG group, resulted in a large increase in OX-6 positive activated ramified 
microglia in all subcortical white matter areas examined, including corpus callosum (starting as 
far anterior as the forceps minor), internal capsule, anterior commissure, optic tract and fimbria of 
the hippocampi. Representative images are shown in Figure 2-7A. TG HCD group had significant 
microgliosis in all white matter regions compared to all other groups (Figure 2-7B). For the TG 
HCD compared to the WT CD group the p value was less than 0.0001 for all regions.  Within the 
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TG groups the TG HCD was significant compared to the TG CD CD groups with p=0.0003 in the 
corpus callosum and p=0.0002 in the internal capsule and fimbria.    
This white matter microglial activation was also genotype-dependent, with APP21TG rats showing 
significantly higher OX-6-positive signal in comparison to WT rats in the corpus callosum (F1,40 
= 17.84; p =0.0001), internal capsule (F1,40 = 49.03; p<0.0001) and fimbria (F1,12 = 53.17; 
p<0.0001). In addition, two-way ANOVA analysis showed a significant effect of diet on 
microgliosis in the corpus callosum (F1,40 =22.88; p <0.0001), internal capsule (F1,40 = 22.89; 
p<0.0001) and fimbria (F1,12 = 29.73; p=0.0001). There was also a significant diet-genotype 
interaction on microgliosis in the internal capsule (F1,40 = 4.250; p=0.0458) and fimbria (F1,12= 
12.09, p=0.0046), and almost significant interaction in the corpus callosum (F1,40 = 3.809, 
p=0.0588). 
Comorbid impact on total microglia within the white matter tracts was also assessed (Figure 2-8). 
The comorbid TG HCD group had significantly more microglia than the WT CD group for both 
the corpus callosum (p=0.0195) and the internal capsule (p=0.0013), changes not seen in the 
fimbria. In the corpus callosum TG CD rats also had greater numbers of microglia than WT CD 
animals (p=0.0161). 
Iba-1 stained section analysis indicated a significant transgene–dependent increase in area 
coverage by Iba-1 positive microglia in the corpus callosum (F1,12 = 15.13; p=0.0021), internal 
capsule (F1,12 = 13.73; p=0.003) and fimbria (F1,12 = 7.684; p=0.0169; Figure 2-8B). There was an 
additional effect of the diet on the microgliosis in the internal capsule (F1,12 = 12.04; p=0.0046).  
Thus, comorbid rats demonstrated a large microglial activation in all white matter areas analyzed 
along with an increase in microglial proliferation in the corpus callosum and internal capsule. 
Additional analysis revealed transgene related effects on microglial activation and proliferation in 
all white matter regions. There was a diet induced activation in all regions and proliferation in the 
internal capsule.  
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2.3.4.2 Astrogliosis 
Area of coverage by GFAP-immunopositive astroglia expressed as a percentage of total area of 
ROI was taken as a measurement of astrocyte reactivity in subcortical white matter (Figure 2-
9A,B). For the comorbid TG HCD group the only observed increase in astrocytes was compared 
to the WT HCD group in the corpus callosum (p=0.0095). In the corpus callosum even the TG CD 
group had higher levels of astrocytes compared to the WT HCD (p=0.0188). 
 
There was a transgene effect in that TG rats showed a significant increase in astrocyte density in 
the corpus callosum (F1, 11=20.05, p=0.0009) and fimbria hippocampi (F1, 11=8.307, p=0.0149), 
compared to WT groups.  
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Figure 2-7. Activated microglia in white matter. (A) 10x photomicrographs of representative 
OX-6 immunolabelled activated microglial cells in the corpus callosum, internal capsule and 
fimbria hippocampi from the boxed regions indicated on the whole brain section insertion, right 
hemisphere. Photographs of the activated microglia in the three white matter regions of the three-
month-old TG rat are shown in the right column. Scale bar 200µm. (B) Integrated density as a 
measure of microgliosis for corpus callosum and internal capsule. Animal numbers are as follows: 
WT CD (n=12), TG CD (n=11), WT HCD (n=12), TG HCD (n=11). Area coverage by a positive 
signal (as a percentage of a total area of the region) as a measure of microgliosis for fimbria. 
Animal numbers are n=4 in each group. Values are presented as mean ± SEM. Significance is 
indicated by * between TG HCD and all other groups; by † between CD groups. One - way 
ANOVA and Tukey’s multiple comparisons test, p<0.05. 3M = three-month-old TG rat, CD = 
control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. 
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Figure 2-8. Total microglia in white matter. (A) 10x photomicrographs of representative Iba-1 
immunolabelled microglial cells in the corpus callosum, internal capsule and fimbria hippocampi 
from the boxed regions indicated on the whole brain section insertion, right hemisphere. 
Photographs of the microglia in the three white matter regions of the three-month-old TG rat are 
shown in the right column. Scale bar 100µm. (B) Area coverage by a positive signal (as percentage 
of a total area of a region) for corpus callosum, internal capsule and fimbria. Animal numbers are 
as follows: WT CD (n=4), TG CD (n=4), WT HCD (n=4), TG HCD (n=4). Values are presented 
as mean ± SEM. Significance is indicated by * for WT CD vs both TG groups in corpus callosum 
and WT CD vs TG HCD in internal capsule). One - way ANOVA and Tukey’s multiple 
comparisons test, p<0.05. 3M = three-month-old TG rat, CD = control diet, HCD = hypercaloric 
diet, TG = transgenic, WT = wildtype. 
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Figure 2-9. Reactive astrocytosis in white matter. (A) 10x photomicrographs of representative 
GFAP immunolabelled astrocytes in the corpus callosum, internal capsule and fimbria 
hippocampi. Scale bar 100µm. Magnified images of individual astrocytes are inserted at the 
bottom right corner of image panels in A. (B) Area coverage by a positive signal (as percentage of 
a total area of a region) for corpus callosum, internal capsule and fimbria. Animal numbers are as 
follows: WT CD (n=4), TG CD (n=4), WT HCD (n=3), TG HCD (n=4). Values are presented as 
mean ± SEM. Significance is indicated by * for WT HCD vs both TG groups in corpus callosum). 
One - way ANOVA and Tukey’s multiple comparisons test, p<0.05. CD = control group, HCD = 
hypercaloric diet, TG = transgenic, WT = wildtype. 
  
105 
 
2.3.5 Neuronal density 
Dorsal hippocampus, particularly the CA1 region, is a crucial structure for spatial learning and 
memory and is very susceptible to the pathological processes in AD37–40. We assessed whether 
there is a loss of neurons in the CA1 subregion of the hippocampus (Figure 2-10A).  Counts of 
NeuN positive pyramidal neurons revealed no differences in the neuronal density between 
experimental groups (WT HCD vs TG HCD p=0.0816; WT CD vs TG HCD p=0.1844; Figure 2-
10B).   
 
2.3.5 Synaptic density 
Synaptic density was analyzed in the CA1 and CA3 dorsal hippocampal subregions using 
synaptophysin immunostaining to detect synaptic vesicles (Figure 2-11A). The area of coverage 
by a positive signal was significantly decreased in the TG rats compared to the WT animals in both 
regions (CA1 p=0.0008, F(1,20) =15.38; CA3 p=0.0001, F(1,20) =22.60; Figure 2-11B). In the TG 
rats that were also on the HCD there was no additional effect of the comorbidity on the synaptic 
density in any of the regions (TG CD vs TG HCD in CA1 p>0.99; in CA3 p>0.98). Rats from the 
Control TG and HCD TG groups showed significantly lower synaptic density compared to the 
HCD WT (p=0.0126 and 0.0148, respectively) in the CA1 region, and to the HCD WT (p=0.0153 
and 0.0065, respectively) and Control WT (p=0.0342 and 0.0149, respectively) in the CA3 region.  
 
106 
 
 
 
 
Figure 2-10. Neuronal counts identified by neuronal nuclear antigen (NeuN) 
immunohistochemistry. (A) 20x photomicrographs of the dorsal hippocampus CA1 subregion 
pyramidal neurons. Scale bar 100 um. Boxed area corresponds to a field defined for cell counts. 
(B) NeuN positive cell counts in a field of area 0.2 mm2. Animal numbers are n=4 in each group. 
Values are presented as mean ± SEM. Cd = control diet, HCD = hypercaloric diet, TG = transgenic, 
WT = wildtype. 
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Figure 2-11. Synaptic density in the hippocampus identified by synaptophysin (SYN) 
immunohistochemistry. (A) 20x photomicrographs of the pyramidal neurons in the dorsal 
hippocampus CA1 (top row) and CA3 (bottom row) subregions. Scale bar 50 um. Boxed area 
corresponds to a field defined for quantification. (B) Synaptophysin area coverage (%) in CA1 and 
CA3 regions of the hippocampus. Animal numbers are n=6 in each group. Values are presented as 
mean ± SEM. Significance is indicated by * for HCD WT vs both TG groups in CA1 and for both 
TG groups vs both WT groups in CA3 region. HCD = hypercaloric diet, TG = transgenic, WT = 
wildtype. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. 
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2.3.6 Myelination 
Activated microglia were highly accumulated in the cerebral white matter of TG rats on HCD with 
some more minor transgene and diet effects. To assess if signs of demyelination of the white matter 
tracts were present at this level glial pathology, Luxol fast blue staining was performed (Figure 2-
12A,B). We quantified the percentage of area coverage by a positive signal for both corpus 
callosum (Figure 2-12C) and internal capsule (Figure 2-12D). There was no statistically significant 
difference in myelin content between the groups and no effect of genotype or diet was detected. 
Thus, increased microglial activation was not accompanied by loss of myelin at this stage.  
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Figure 2-12.   Myelination of white matter. 10x photomicrographs of representative brain 
sections stained with Luxol fast blue containing (A) corpus callosum and (B) internal capsule, right 
hemisphere. Scale bar 100µm. Area coverage by a positive signal (as percentage of a total area of 
a region) for (C) corpus callosum and (D) internal capsule. Animal numbers are as follows: WT 
CD (n=4), TG CD (n=4), WT HCD (n=4), TG HCD (n=4). Values are presented as mean ± SEM. 
CD = control diet, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. 
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2.4 Discussion 
The results of this investigation clearly show, for the first time, that APP21 TG predisposed to AD 
rats maintained on a high fat and high carbohydrate diet not only develop considerable metabolic 
perturbations, but they also exhibit marked widespread white matter microgliosis that was 
accompanied by impairment on a spatial memory task compared to the performance level of 
wildtype rats. However, there was no neuronal loss or decrease in synaptic density in the 
hippocampus of these comorbid rats. Although there were some behavioral, synaptic and 
inflammatory changes that could be attributed to the diet or the transgene alone, it was clear that 
the more significant neuroinflammation and memory and learning deficits were due to the 
combination of the energy-rich high fat, high carbohydrate diet and the TG condition. This is the 
first demonstration of the impact of hypercaloric diet on white matter in a vulnerable aging brain 
with increased levels of pathogenic hAPP. These TG rats have been previously characterized to 
have dense neuronal staining for hAPP, but no evidence of plaques 30,33. This differs from previous 
mouse models that assessed high-fat diet induced MetS on animals with established classical AD 
events including amyloid plaque and tau pathology. 
The hypercaloric diet approach was chosen to mimic a modern dietary pattern in the human 
population represented by a combination of food that is high in fat and simple sugars and 
carbohydrate-rich beverages 10,41. This study was not designed to examine the exact effects of the 
specific source of fat or type of fatty acids or specific carbohydrates ingested in a large amount. 
The intent was to examine a combined diet with a high content of both components to deliver an 
excess of calories associated with induction of MetS pathology in our rat model10,41,42. We 
therefore cannot extrapolate on the potential effects of high fat diet or high carbohydrate diet in 
isolation. 
Twelve weeks on the HCD were sufficient for the development of significant obesity and visceral 
adiposity in these rats. While rats in control groups had normal rat chow as the only source of 
energy, rats maintained on high-fat, high-sugar diet had an additional energy uptake from a corn 
syrup drink, which resulted in a reduction of food consumption in these animals, but nonetheless 
a greater total caloric intake per rat compared to rats on CD. 
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The ingestion of high fat and high carbohydrate calories had effects in the periphery and markedly 
altered lipid metabolism, increasing triglycerides, total cholesterol and atherogenic non-HDL 
fraction in rats of both genotypes. Rats TG for hAPP were more susceptible to these changes and 
had a greater degree of dyslipidemia. In contrast, WT rats were more prone to perturbations in 
glucose metabolism. Such sensitivity of lipid homeostasis to a long-term consumption of high fat 
diets has been shown previously 41 and has also been reported for the Fischer 344 rat strain 23,43. 
However, this is the first instance where the high-fat high-sugar diet has been tested in the APP21 
TG rat demonstrating a greater degree of dyslipidemia compared to the WT subjects. 
Although fasting glucose levels were within a normal range for both groups on HCD, the HCD led 
to the increase of fasting insulin levels suggesting the development of hyperinsulinemia and insulin 
resistance in rats of both genotypes.  
During a 2-h glucose tolerance test, WT rats had sustained high blood glucose levels indicating a 
decreased tolerance for glucose in this group. Interestingly, HCD did not appear to induce 
pronounced glucose intolerance in TG rats, at least not after the 12-week long intervention. This 
physiological difference in response to excessive caloric intake could implicate mutated hAPP 
gene inserted in the genome of rats and overexpressed in tissues other than brain (i.e. liver, kidney, 
lung) and its possible interaction with mechanisms of metabolism. Similar to our observation, 
5xFAD mice bearing 5 human familial AD mutations including APPSwe placed on a high-fat diet 
for 10 weeks did not show signs of glucose intolerance in the oral version of the test compared to 
WT control group 44. The presence of carbohydrate metabolism alterations has been reported in 
patients with symptomatic AD, in which there are lower rates of fasting blood glucose as well as 
lower glucose values in the oral glucose tolerance test 45. However, this unique phenomenon would 
need further separate investigation using more sensitive methods to find out whether there is a 
difference in glucose metabolism and in the role of compensatory mechanisms to overcome dietary 
effects between the two genotypes, which could account for this diverse response to a glucose load 
and was not in the focus of the present study.   
There was no dietary effect on the blood pressure, demonstrating that a 12-week exposure to the 
HCD was not long enough to develop hypertension in this rat strain. However, the non-invasive 
method to measure blood pressure used in this study falls short of the accuracy of invasive 
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techniques, and might be insensitivity to subtle early changes in blood pressure possibly present 
at this stage. 
Behavioral analysis at the end of the diet indicated an impact of the diet-induced metabolic 
alterations on memory consolidation in rats with AD predisposition, however only compared to 
the WT CD rats. This observation clearly has implications for human populations with a high 
prevalence of obesity due to a hypercaloric Western style diet with advancing age and increasing 
levels of brain amyloid 18,46. Studies using TG AD mouse models have shown similar effects of 
high-fat diet on the spatial memory domain and noted the link of these effects to the inflammatory 
events44,47–49. One study showed increased microglia activation detected in vivo using positron 
emission tomography, and a greater amyloid plaque load in APP/PS1 TG mouse which received a 
high-fat diet and a streptozocin treatment 49. Interestingly, a triple-transgenic AD mouse on a high-
fat diet did not exhibit increase in amyloid plaque deposition or tau-pathology, rather a 
significantly increased number of activated microglia associated with plaques in the hippocampal 
region that was suggested to be the primary mediating pathology to an observed cognitive 
impairment 47. Another study using a APPswe/PS1 TG mouse of AD similarly showed no effect 
of the Western diet on the brain parenchymal amyloid burden, however the diet resulted in 
decreased synaptic plasticity and blood brain barrier dysfunction which could contribute to the 
behavioral deficits48. These changes were attributed to the systemic inflammation promoted by the 
Western diet48. This is in line with studies of human brain showing a lack of correlation between 
amyloid plaque burden and presence or severity of dementia symptoms50,51. This suggests that 
other events contribute to manifestation and progression of cognitive decline and that 
neuroinflammation including white matter microgliosis and astrogliosis can be among them52.  
As the field of AD research has started to move away from the amyloid causal hypothesis, the 
white matter inflammation and other white matter changes concepts have been gaining attention 
and recognition as important players in cognitive impairment 3,7,53,54. White matter abnormalities 
visualized as hyperintensities on MRI scans are common findings among the elderly population. 
These signals increase with aging, are often present in mild cognitive impairment (MCI), AD and 
patients with metabolic disorders, and have been shown to highly correlate with cognitive decline 
8,55,56. Of great interest is the clinical finding that white matter lesions tend to be present well before 
symptoms of cognitive deterioration start to appear 7,8,54. This has opened a new avenue to explore 
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the potential of cerebral white matter lesions as a new biomarker of cognitive impairment such as 
MCI and AD dementia and a possible target for prevention and therapy. 
Our results clearly indicate an increased microgliosis and microglial proliferation in the white 
matter tracts of TG rats expressing pathogenic hAPP markedly aggravated by diet-induced 
metabolic dysregulations in the comorbid rats. Analysis of the brain tissue has shown a widespread 
inflammation of the white matter, including the corpus callosum, fimbria, internal capsule, 
cingulum, anterior commissure and optic tract. This finding is of considerable interest as it 
replicates the white matter pathology associated with advanced age, MCI, early AD and metabolic 
disorders in the human population 3,5,6. Intriguingly, the white matter inflammation appeared to be 
an early pathological event as there was no apparent loss of CA1 hippocampal neurons or 
additional to the TG background decrease in synapses in the CA1 and CA3 subregions of the 
hippocampus in the comorbid animals at this stage of the disease.  
In the present study we also assessed myelination of two major white matter tracts, the corpus 
callosum and internal capsule, which appeared to be unchanged in APP21 TG rats on the HCD. 
Further analysis confirmed that the white matter microgliosis was not accompanied by signs of 
myelin loss at this stage. Nevertheless, axonal damage or perturbation to oligodendrocyte health 
could begin to develop and should be examined in the future studies to enhance understanding of 
the white matter pathological changes.  
Additional brain tissue analysis should be carried out in order to identify the nature and magnitude 
of the inflammatory events as well as determine if these inflammatory events are precursors to or 
consequences of potential vascular changes and other processes that might take place at this early 
stage of dietary intervention and contribute to the cognitive dysfunction.  However, these elements 
of interest were not in the focus of the present study which aimed to address the effects of HCD 
superimposed on the high amyloid background on the major glial cells, microglia and astrocyte, 
activation as an indicator of neuroinflammatory process. 
Clinical data, points towards an association of cerebral white matter pathology with perturbations 
in executive function, processing speed and general cognition57. Widespread neuroinflammatory 
responses to the HCD, primarily denoted by microgliosis and increased microglia cell activation, 
seen in the white matter of TG rats may interfere with functioning of multiple cognitive domains 
114 
 
leading to a general decline and may contribute to the observed impairment in the behavioral task 
performance. However, to establish a clear connection between the white matter inflammation and 
cognitive impairment, more studies including neuronal health assessment, should be performed. 
The spatial navigation version of the MWM used in the present study was chosen to assess learning 
and memory dependent on hippocampal formation that is highly vulnerable to AD pathology. 
However, it is not the most sensitive for specific testing of executive function components that 
might be affected at the prodromal stage of the disease in our TG rat model. It will be necessary 
to perform more sensitive tests (e.g. operant conditioning based set-shifting task) to clarify the 
cognitive deficits that may be related to the observed brain white matter pathology.  
The sex-dependent differences in the effect of MetS on neuroinflammation and other early 
pathology of pre - AD and cognition were not tested in the current study using only male rats. 
Future projects should consider including experiments conducted on female animals to address the 
potential role of biological sex and endocrinological differences in the interaction of these 
conditions.  
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2.5 Conclusions 
Our study using a TG APP21 rat on HCD,  suggests the role of diet-induced metabolic alterations 
as a risk factor for white matter inflammation, which is an early brain pathology in MCI and AD, 
as a possible point of interaction with prodromal phase AD. Results further suggest that white 
matter inflammation may lead to accelerated development of cognitive symptoms, since the white 
matter microglial activation  was accompanied by cognitive impairment in comorbidity condition 
compared to normal rats from WT population. The other 2 groups, TG rats on the CD and WT on 
the HCD did not demonstrate this significant cognitive change from the WT CD animals. Activated 
inflammatory cells were mainly located in the white matter which raises a number of important 
questions on the nature of events and mechanisms that trigger this specific response. The intense 
white matter inflammatory response provoked by the dietary intervention in the TG rats also 
suggests specific anti-inflammatory agents may be a potential treatment and preventative strategy. 
Several approaches could be taken in this therapeutic direction including targeting inflammatory 
cytokines or components of the arachidonic acid pathway that mediate the inflammation.   
116 
 
2.6 References  
1. Querfurth, H.W. LaFerla, F. M. Mechanisms of disease. Alzheimer’s disease. N Engl J Med 
362, 329–344 (2010). 
2. Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in 
Alzheimer disease. Nat. Rev. Neurosci. 16, 358–372 (2015). 
3. Simpson, J. E. et al. White matter lesions in an unselected cohort of the elderly: astrocytic, 
microglial and oligodendrocyte precursor cell responses. Neuropathol. Appl. Neurobiol. 33, 
410–419 (2007). 
4. Simpson, J. E. et al. Microglial activation in white matter lesions and nonlesional white 
matter of ageing brains. Neuropathol. Appl. Neurobiol. 33, 670–683 (2007). 
5. Englund, E. & Brun, A. White matter changes in dementia of Alzheimer’s type: the 
difference in vulnerability between cell compartments. Histopathology 16, 433–439 (1990). 
6. Raj, D. et al. Increased white matter inflammation in aging- and Alzheimer’s disease brain. 
Front. Mol. Neurosci. 10, 1–18 (2017). 
7. Lee, S. et al. White matter hyperintensities are a core feature of Alzheimer’s disease: 
Evidence from the Dominantly Inherited Alzheimer Network. Annu. Neurol. 79, 929–939 
(2016). 
8. Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and 
dementia: an update. Nat. Rev. Neurol. 11, 157–165 (2015). 
9. Cechetto, D. F., Hachinski, V. C. & Whitehead, S. N. Vascular risk factors and Alzheimer 
’s disease. Expert Rev. Neurother. 8, 743–750 (2008). 
10. Cordain, L. et al. Origins and evolution of the Western diet : health implications for the 21st 
century. Am. J. Clincal Nutr. 81, 341–54 (2005). 
11. Tappy, L. & Le, K.-A. Metabolic Effects of Fructose and the Worldwide Increase in 
Obesity. Physiol. Rev. 90, 23–46 (2010). 
12. Saklayen, M. G. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep. 
20, 1–8 (2018). 
13. Kivipelto, M. et al. Obesity and vascular risk factors at midlife and the risk of dementia and 
Alzheimer disease. Arch Neurol 62, 1556–1560 (2005). 
14. Tsai, C.-K. et al. Increased risk of cognitive impairment in patients with components of 
metabolic syndrome. Medicine (Baltimore). 95, e4791 (2016). 
15. Vanhanen, M. et al. Association of metabolic syndrome with Alzheimer disease. Neurology 
843–847 (2009). doi:10.1212/01.wnl.0000234037.91185.99 
16. Razay, G., Vreugdenhil, A. & Wilcock, G. K. The metabolic syndrome and Alzheimer 
disease. Metab. Syndr. Obes. 64, 93–96 (2007). 
17. Tolppanen, A.-M., Solomon, A., Soininen, H. & Kivipelto, M. Midlife vascular risk fctors 
and Alzheimer’s disease: evidence from epidemiological studies. J. Alzheimer’s Dis. 32, 
531–540 (2012). 
117 
 
18. Whitmer, R. A., Gunderson, E. P., Barrett-Connor, E., Quesenberry, C. P. & Yaffe, K. 
Obesity in middle age and future risk of dementia: A 27 year longitudinal population based 
study. Br. Med. J. 330, 1360–1362 (2005). 
19. Panza, F. et al. Metabolic syndrome, mild cognitive impairment and dementia. Curr. 
Alzheimer Res. 8, 492–509 (2011). 
20. Frisardi, V. et al. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome 
and Alzheimer’s disease. Ageing Res. Rev. 9, 399–417 (2010). 
21. Viticchi, G. et al. Metabolic syndrome and cerebrovascular impairment in Alzheimer’s 
disease. Int. J. Geriatr. Psychiatry 30, 1164–1170 (2015). 
22. Freeman, L. R., Hayley-Zitlin, V. & Granholm, A.-C. Diet-induced effects on neuronal and 
glial elements in the middle-aged rat hippocampus. Nutr Neurosci 14, 32–44 (2011). 
23. Granholm, A.-C. et al. Effects of a saturated fat and high cholesterol diet on memory and 
hippocampal morphology in the middle-aged rat. J. Alzheimer’s Dis. 14, 133–45 (2008). 
24. Kanoski, S. E., Zhang, Y., Zheng, W. & Davidson, T. L. The effects of a high-energy diet 
on hippocampal function and blood-brain barrier integrity in the rat. J. Alzheimer’s Dis. 21, 
207–219 (2010). 
25. Molteni, R., Barnard, R. J., Ying, Z., Roberts, C. K. & Gómez-Pinilla, F. A high-fat, refined 
sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and 
learning. Neuroscience 112, 803–814 (2002). 
26. Soares, E. et al. Spatial memory impairments in a prediabetic rat model. Neuroscience 250, 
565–577 (2013). 
27. Bhat, N. R. Linking cardiometabolic disorders to sporadic Alzheimer’s disease: A 
perspective on potential mechanisms and mediators. J. Neurochem. 115, 551–562 (2010). 
28. Jayaraman, A. & Pike, C. J. Alzheimer’s disease and type 2 diabetes: multiple mechanisms 
contribute to interactions. Curr. Diab. Rep. 14, 476 (2014). 
29. Misiak, B., Leszek, J. & Kiejna, A. Metabolic syndrome, mild cognitive impairment and 
Alzheimer’s disease-The emerging role of systemic low-grade inflammation and adiposity. 
Brain Res. Bull. 89, 144–149 (2012). 
30. Agca, C. et al. Development of transgenic rats producing human β-amyloid precursor 
protein as a model for Alzheimer’s disease: transgene and endogenous APP genes are 
regulated tissue-specifically. BMC Neurosci. 9, 1–13 (2008). 
31. Weishaupt, N. et al. APP21 transgenic rats develop age-dependent cognitive impairment 
and microglia accumulation within white matter tracts. J. Neuroinflammation 15, 1–12 
(2018). 
32. Rosen, R. F. et al. Exogenous seeding of cerebral β-amyloid in βAPP -transgenic rats. J 
Neurochem 120, 660–666 (2012). 
33. Klakotskaia, D. et al. Memory deficiency, cerebral amyloid angiopathy, and amyloid-β 
plaques in APP+PS1 double transgenic rat model of Alzheimer’s disease. PLoS One 13, 1–
16 (2018). 
34. Antunes, L. C., Elkfury, J. L., Jornada, M. N., Foletto, K. C. & Bertoluci, M. C. Validation 
118 
 
of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats. Arch. 
Endocrinol. Metab. 60, 138–142 (2016). 
35. Watson, C. & Paxinos, G. The rat brain in stereotaxic coordinates. (Elsevier Inc. 
Burlington, MA, USA Academic press, 2007). 
36. Carriel, V., Campos, A., Alaminos, M., Riamondo, S. & Geuna, S. Staining methods for 
normal and regenerative myelin in the nervous system. (Methods Molecular Biology, 2017). 
37. Pothuizen, H. H. J., Zhang, W.-N., Jongen-re, A. L., Feldon, Ã. J. & Yee, B. K. Dissociation 
of function between the dorsal and the ventral hippocampus in spatial learning abilities of 
the rat : a within-subject , within-task comparison of reference and working spatial memory. 
Eur. J. Neurosci. 19, 705–7012 (2004). 
38. Moser, M. & Moser, E. I. Functional Differentiation in the Hippocampus. Hippocampus 
619, 608–619 (1998). 
39. Tsien, J. Z., Huerta, P. T. & Tonegawa, S. The essential role of hippocampal CA1 NMDA 
receptor – dependent synaptic plasticity in spatial memory. Cell 87, 1327–1338 (1996). 
40. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol. 82, 239–259 (1991). 
41. Gomez-Smith, M. et al. A physiological characterization of the Cafeteria diet model of 
metabolic syndrome in the rat. Physiol. Behav. 167, 382–391 (2016). 
42. Pasinetti, G. M. & Eberstein, J. A. Metabolic syndrome and the role of dietary lifestyles in 
Alzheimer’s disease. J. Neurochem. 106, 1503–1514 (2008). 
43. Pancani, T. et al. Effect of high-fat diet on metabolic indices, cognition, and neuronal 
physiology in aging F344 rats. Neurobiol. Aging 34, 1977–1987 (2013). 
44. Lin, B. et al. High-fat-diet intake enhances cerebral amyloid angiopathy and cognitive 
impairment in a mouse model of alzheimer’s disease, independently of metabolic disorders. 
J. Am. Heart Assoc. 5, 1–17 (2016). 
45. Adolfsson, R., Bucht, G., Lithner, F. & Winblad, B. Hypoglycemia in Alzheimer’s disease. 
Acta Med Scand 208, 387–388 (1980). 
46. Nguyen, J. C. D., Killcross, A. S. & Jenkins, T. A. Obesity and cognitive decline: Role of 
inflammation and vascular changes. Front. Neurosci. 8, 1–9 (2014). 
47. Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M. & Lawrence, C. B. High-fat 
diet-induced memory impairment in triple-transgenic Alzheimer’s disease (3xTgAD) mice 
is independent of changes in amyloid and tau pathology. Neurobiol. Aging 35, 1821–1832 
(2014). 
48. Thériault, P., ElAli, A. & Rivest, S. High fat diet exacerbates Alzheimers disease-related 
pathology in APPswe/PS1 mice. Oncotarget 7, 67808–67827 (2016). 
49. Yeh, H.-H. et al. Neuroimaging of inflammaion: high fat-induced exacerbation of 
Alzheimer disease. J Nucl Med 58, 273 (2017). 
50. Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive 
impairment among the elderly. Arch Neurol 65, 1509–1517 (2008). 
119 
 
51. Davis, D. G., Schmitt, R. A., Wekstein, D. R. & Markesbery, W. R. Alzheimer 
neuropathologic alterations in aged cognitively normal subjeets. J Neuropathol. exp neurol 
58, 376–388 (1999). 
52. Xiang, Z., Haroutunian, V., Ho, L., Purohit, D. & Pasinetti, G. M. Microglia activation in 
the brain as inflammatory biomarker of Alzheimer’s disease neuropathology and clinical 
dementia. Dis. Markers 22, 95–102 (2006). 
53. Bilello, M. et al. Correlating cognitive decline with white matter lesion and brain atrophy 
MRI measurements in Alzheimer’s disease. J. Alzheimer’s Dis. 48, 987–994 (2015). 
54. Brickman, A. M. et al. Reconsidering harbingers of dementia: Progression of parietal lobe 
white matter hyperintensities predicts Alzheimer’s disease incidence. Neurobiol. Aging 36, 
27–32 (2015). 
55. Reijmer, Y. D., Leemans, A., Brundel, M., Kappelle, L. J. & Biessels, G. J. Disruption of 
the cerebral white matter network is related to slowing of information processing speed in 
patients with type 2 diabetes. Diabetes 62, 2112–2115 (2013). 
56. Wang, M., Norman, J. E., Srinivasan, V. J. & Rutledge, J. C. Metabolic, inflammatory, and 
microvascular determinants of white matter disease and cognitive decline. Am. J. 
Neurodegener. Dis. 5, 171–177 (2016). 
57. Filley, C. M. White matter dementia. Ther. Adv. Neurol. Disord. 5, 267–277 (2012). 
 
  
120 
 
Chapter 3: Effect of the Novel Anti-inflammatory Prodrug Ketoprofen -
lysine in Comorbid APP21 Transgenic Rat and Diet-induced Metabolic 
Syndrome 
This experiments in this chapter were designed to examine the effects of a novel brain targeted 
NSAID prodrug Ketoprofen-lysine on the increased white matter microgliosis and cognitive 
deficits in the comorbid model of prodromal AD and MetS (Objective 2). This manuscript has 
been reviewed by all authors and is ready to be submitted for publication.  
 
3.1 Introduction 
Dementia and mild cognitive impairment (MCI), which is associated with an increased risk of 
converting to dementia, represent a serious public health challenge. The progressive and incurable 
characteristic of these age-related disorders is of considerable concern given their prevalence in 
the human population. Alzheimer's disease (AD), the most common form of dementia, is a 
neurodegenerative disease that leads to severe mental health decline. The major hallmark of the 
disease is an accumulation of amyloid-β peptide (Aβ), produced through cleavage of amyloid 
precursor protein (APP) and formation of neurofibrillary tangles 1. However, white matter 
abnormalities and neuroinflammation are thought to be implicated in the early stages of AD 
development and contribute to its progression 2–6. Analysis of brain and serum specimens of AD 
patients have shown elevation of pro-inflammatory chemokines and cytokines such as IL-6, IL-
1β, TNF-α, TGF-β, increased expression of inflammatory genes and activation of signaling 
pathways associated with inflammation (e.g. TNF-α, NF-κB, COX1, COX2), and reactive glial 
activation in both grey and white matter structures6–8.  
In the human elderly population MCI and AD very often co-exist with metabolic disorders such 
as diabetes and metabolic syndrome (MetS). MetS can include a combination of abdominal 
obesity, dyslipidemia, insulin resistance and hypertension. A chronic inflammatory state is also a 
characteristic feature of the MetS 9–11. Inflammation appears to be a shared pathology with AD and 
is suggested to be a point of their interaction12–14. This interaction between prodromal AD and 
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MetS was recently demonstrated in our previous study of a novel human APP21 transgenic (TG) 
rat model of early AD15–17 and a hypercaloric diet (HCD) designed to induce obesity and MetS. 
This combination of MetS in a prodromal model of AD resulted in a larger increase in 
neuroinflammation in the white matter of the comorbid animals compared to either condition 
alone.  
Recognition of neuroinflammation as one of the key processes in the etiopathogenesis of the 
disease has opened a potential new avenue for the early treatment of dementia. Promising 
candidate agents for treatment belong to the class of non-steroidal anti-inflammatory drugs 
(NSAIDs)18–22, that primarily block pro-inflammatory mediators production via cyclooxygenase 
(COX) enzyme inhibition23. Both COX-1 and COX-2 enzymes are thought to be involved in the 
inflammatory processes24,25, and it is possible that agents from this pharmacological group with 
various selectivity have the potential to modulate pathological changes and be considered for a 
treatment or prevention of AD. 
Several epidemiological studies have shown an associated reduced risk of AD with a long-term 
treatment with NSAIDs26–30. In addition, studies using these agents for treatment in animal models 
of AD have shown beneficial effects on amyloid pathology, neuronal health and cognitive 
function31–36. However, clinical trials on prevention and treatment of mild cognitive impairment 
and AD, have produced controversial results for NSAIDs of both selective and non-selective COX 
inhibitor subclasses37. Cases describing beneficial outcome of a trial were linked to the use of non-
selective NSAIDs, especially with prolonged intake20,37–40. The majority of animal studies 
reporting a positive effect of the treatment have also used conventional non-selective drugs40. 
Although there have been many failures in clinical trials to treat or delay the progression of 
cognitive decline40–47, analysis of clinical data has indicated that the timing of the treatment 
appears to be critical for any positive outcome. The studies suggest that the desired beneficial 
effect can be achieved by early intervention, before symptomatic onset and at the start of or likely 
before cerebral pathological changes37,48.  
Thus, there appears to be strong epidemiological support for NSAIDs in the prevention of AD, 
although more studies are necessary to characterize potential therapeutic effects of these agents as 
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well as to investigate the exact conditions and define the best regimen of treatment taking into 
consideration some of the lessons learned from clinical trials. 
In the present study we examine therapeutic potential of a novel non-steroid anti-inflammatory 
prodrug, ketoprofen-lysine (KL), that was designed to specifically target the brain. This study 
analyzed the effect of KL prodrug on neuroinflammation and cognitive function in the comorbid 
APP21 TG rat model of prodromal AD combined with diet-induced MetS. The prodrug was 
synthetized via conjugation of a non-selective NSAID ketoprofen to an amino acid l-lysine that 
allows large neutral amino acid transporter (LAT1) - mediated drug transport through the blood 
brain barrier. This manipulation of the drug should  provide a major advantage of improved drug 
delivery to the central nervous system49. Thus, the prodrug has a rapid uptake from the bloodstream 
minimizing undesired systemic side effects, good brain tissue distribution and a high cell uptake 
providing a targeted action.  
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3.2 Methods 
3.2.1 Animals 
All animal handling and experimental procedures were carried out in accordance with the 
guidelines of the Canadian Council on Animal Care and were approved by Western University 
Animal Use Subcommittee (AUP 2014-016).  
Breeding pairs of the homozygous APP21 TG Fischer 344 rat model of AD were obtained from 
Drs. Cansu and Yuksel Agca (University of Missouri, Colombia, MO, USA) and were bred in 
house alongside wildtype Fischer 344 rats15. We have previously characterized the combination of 
this TG rat and HCD diet for the effects on cognitive function and neuroinflammation.  
A total of 80 male wildtype (WT) and male APP21 TG rats were involved in this study. Single and 
paired rats were housed under standard conditions (12:12 light/dark cycle, at 22-24°C) and 
maintained on a standard rat diet. At the age of 10-10.5 months half of the rats of each genotype 
were randomly assigned to a Western type high-caloric diet (HCD), while the other half continued 
on a standard control diet (CD). Diets were provided ad libitum during the 15-week duration of 
the study. A subset of animals of each genotype and each dietary group was assigned to the non-
steroidal anti-inflammatory KL prodrug treatment protocol. Animal numbers for each 
experimental group were the following:  
 WT TG 
CD 11 9 
CD-KL 10 8 
HCD 11 10 
HCD-KL 11 10 
For histological analysis, lipid and visceral fat measurements animal numbers in non-KL groups 
were the following: WT CD n=9, TG CD n=5, WT HCD n=6 and TG HCD n=6. One rat from TG 
CD-KL and one from WT CD-KL group died after 1 month of drug administration. 
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3.2.2 Diets 
A study timeline is shown in Figure 3-1. The CD contained (in % Kcal): 26 protein, 59.7 
carbohydrate, and 14.3 fat with 1.52 % of saturated fatty acid (Prolab RMH 3000 5P00). The HCD 
consisted of the following (in % Kcal): 17 protein, 43 carbohydrate, 40 fat with 62.4% of saturated 
fatty acid and 0.21% cholesterol (D12079B, Research Diets, Inc). The metabolizable energy 
content of CD and HCD (in kcal/g) was 3.18 and 4.7, respectively. Rats were given free access to 
water in CD groups and 20% corn syrup water solution in HCD groups (Bee Hive, ACH Food 
Companies, Inc, USA).  
 
3.2.3 Chronic Prodrug Treatment  
KL prodrug was synthesized by Dr. Jukka Leppänen (School of Pharmacy, University of Eastern 
Finland). Treatment was initiated 2 days after the dietary regimens were assigned. 
The prodrug was dissolved in saline to a concentration of 30 mg/ml. This dilution allowed a single 
dose to be less than 0.1 ml to make it suitable for continuous daily subcutaneous administration 
for an extensive period of study (15 weeks). The treatment dose used in this study was 4.1 mg/kg 
body weight, which corresponds to 2.5 mg/kg of free ketoprofen. Rodent studies on NSAIDs (e.g. 
ibuprofen) treatment in AD models with detected plaque pathology commonly use a dose of 5 
mg/kg. However, we were using a model of early stage AD and the treatment was prophylactic 
and initiated simultaneously with metabolic disease induction. Furthermore, ketoprofen, that is 
mainly used for surgical pain management in rodents, has a higher rate of adverse effects and has 
been shown to produce gastrointestinal damage in rats in a commonly used therapeutic dose 50. 
Finally, the prodrug has been engineered to easily cross the blood brain barrier. For these reasons, 
we chose a dose half of what has been used for other NSAIDs.  
 
125 
 
3.2.4 Physiological and Metabolic Assessment 
3.2.4.1 Caloric Intake 
Body weight, food and drink consumption were measured twice a week throughout the experiment 
and caloric intake for each category was determined. 
 
3.2.4.2 Intravenous Glucose Tolerance Test (IvGTT) 
IvGTT was performed one week before the study initiation and at week 12 of the study (Figure 3-
1). Following a 10-12-h overnight fast, a needle was inserted into the saphenous vein to draw 
approximately 100-150 µl of blood for the determination of baseline glucose levels. A 50% 
D(+)glucose (G 8270, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) solution in sterile water 
(1g/kg body weight) was then injected in a lateral tail vein. Blood was collected from the 
saphenous vein repeatedly at 5, 10, 20, 30, 40 and 50 min after the glucose load. Glucose levels 
were immediately measured using Freestyle Light Blood Glucose Monitoring System (Abbott 
Diabetes Care Inc, Alameda, CA).  
 
3.2.4.3 Lipid Profile Analysis  
After euthanasia cardiac whole blood samples were collected and transported to the CORE 
Laboratory (University hospital, London, ON, Canada) for serum analysis of lipid metabolism that 
included triglycerides, total cholesterol and high-density lipoprotein cholesterol (HDL) 
measurements. Non- HDL was calculated as total cholesterol – HDL. The cholesterol ratio 
(Chol:HDL ratio) was calculated by dividing total cholesterol value by HDL cholesterol number.  
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3.2.4.4 Blood Pressure Analysis 
Systolic and diastolic arterial blood pressure was measured using the non-invasive tail cuff method 
(CODA Blood Pressure System, Kent Scientific Corp., Connecticut, USA). Rats underwent an 
acclimation procedure followed by baseline level measurements two weeks before the experiment 
started. Assessment of blood pressure was repeated at week 11 of the study (Figure 3-1).  
 
3.2.5 Open Field Task 
Locomotor activity and anxiety-like behavior were tested in an open field arena (45.7x45.7cm) 
over the course of 20 min on week 12 of the experiment (Figure 3-1). Ambulatory time and 
distance and time spent in the central zone (27.5x27.5cm) were evaluated using video-tracking 
software (ANY-maze®, Stoelting Co., Wood Dale, IL, USA).  
 
3.2.6 Morris Water Maze Task 
3.2.6.1 Spatial Navigation Protocol  
Rats were trained to find an escape platform submerged in a circular pool (145 cm in diameter, 58 
cm in depth) using visual extra-maze cues positioned on the surrounding walls. The platform 
(12cm in diameter) was placed in the middle of one of 4 quadrants the pool was conceptually 
divided into and its location remained unchanged during the training phase. The training protocol 
started in week 13 (Figure 3-1) consisted of 16 trials over 4 consecutive days (4 trials/day). The 
duration of one trial was 60 sec with a 30-sec inter-trial period during which rats were allowed to 
remain on the platform. Release positions were different for each trial of the day and their order 
alternated for every other day of spatial acquisition.  
At the end of the training, the rats were subjected to two 30-sec probe trials 7 days apart where the 
platform was removed from the pool and the rats were released from a novel start position. Probe 
1 was introduced on day 5, the day after the training. Probe 2 was performed on day 12 after the 
start of the training. All sessions were monitored and recorded using video-tracking software 
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(ANY-maze®, Stoelting Co., Wood Dale, IL, USA). Learning progress was assessed using latency 
and path length to reach the platform for each day of training. Probe performance was evaluated 
using such parameters as time and distance travelled in the quadrant where the platform had 
previously been located (target zone). Swim speed was monitored at all stages of the test. 
 
3.2.6.2 Shifting Strategy Protocol  
A cognitive flexibility (strategy shifting) protocol was adapted for use in this study51–55 to assess 
components of the executive function such as working memory and behavioral flexibility that were 
shown to be affected in early stages of AD56–61. Immediately after Probe 2 the platform was 
returned to the pool to the previous location and new rules were introduced. For this paradigm rats 
received 8 trials grouped in 2 blocks of 4 trials each with a 30-sec inter-trial period within the 
block and a 1 h gap in between the blocks. Rats remained on a platform during the inter-trial period. 
After being familiarized with the novel protocol rats were given a 3 day shifting challenge (Figure 
3-1). Platform position was fixed for each day and then changed every day, thus placing a high 
demand on spatial working memory.  
The first trial of each day presented information about the platform position specific for each given 
day. The second trial was a retention trial where rats needed to recall the information learned in 
the first trial which is required to escape the water. The following trials were used to solidify 
information making the shift to a new escape location on the next day more challenging. The 
difference in time and path length to platform between trials 1 and 2 were analyzed as a criterion 
of working memory efficiency and flexibility. The difference in time and distance between trials 
1 and 4 as well as trials 1 and 8 were used to evaluate learning ability in the new task setting. Old 
platform location preference was used for assessment of the ability to abandon previously used 
and now irrelevant information, i.e. persistent behaviour. For this analysis, time and distance spent 
searching in the platform zone (designated a 9.5 cm proximity to the platform) of the previous day 
during trial 1 were measured. 
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3.2.6.3 Cued Trials 
Upon the completion of the cognitive flexibility protocol, the rats were subjected to a series of 4 
cued trials in the same pool (Figure 3-1). Extra-maze cues were removed to exclude their use for 
spatial navigation. Instead a cue was directly mounted on top of the submerged platform that could 
be seen above the water surface to indicate the platform location. The platform was placed in a 
novel position each time and the start position was switched for every trial to interfere with the 
spatial learning. These trials served as a control procedure to determine if there were any visual or 
motivational impairments that could account for differences in learning and memory between 
groups. Quantification of the path length and latency to reach the platform assessed cued learning. 
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Figure 3-1. Project timeline. The age of the rats (in months) at the start (day 0) and the end of the 
study (week 16) are shown in brackets. Diets were assigned and began on day 0 and all testing 
time points are in reference to this day. Baseline measurements of blood pressure and glucose 
tolerance were completed in the 2 weeks before the start of the diets. Morris water maze (MWM) 
navigation training was completed within 4 days on week 13, with a probe trial 1 (Pr1) on the day 
after training. The second probe trial (Pr2) was 7 days later, on week 14 on the diet. Immediately 
after the Pr2, the cognitive flexibility (shifting) protocol was initiated, and was completed in 3 
days. MWM cued trials were performed the next day after the shifting paradigm test. Ketoprofen-
lysine prodrug was administered subcutaneously once daily at a dose of 4.1 mg/kg starting 2 days 
after day 0 and continuing to the end of the experiment. BP = blood pressure measurement, IvGTT 
= intravenous glucose tolerance test, mo = month, MWM = Morris Water Maze, Pr = probe trial, 
OF = open field test, BC = blood collection, TC = tissue collection, w = week. 
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3.2.7 Euthanasia and Tissue Collection 
At the beginning of week 16 animals were weighed and then euthanized with pentobarbital 
overdose following a 12-h fasting period. Cardiac blood was collected immediately before 
perfusion. Epidydimal fat pads were collected and weighed. Rats were then perfused transcardially 
with 0.01M phosphate buffered saline (pH 7.35) followed by 4% paraformaldehyde (PFA, pH 
7.35). The brains were post-fixed in 4% PFA overnight and then transferred to a 30% sucrose until 
fully submerged. The brains were sectioned coronally on a cryostat into 30μm thick sections and 
were stored in cryoprotecting solution at -20°C until they were used for immunohistochemical 
procedures. 
 
3.2.8 Immunohistochemistry  
Immunohistochemical analysis was performed on free-floating sections to visualize total microglia 
and activated microglia using rabbit polyclonal antibody against the ionized calcium binding 
adaptor molecule-1 (anti-Iba-1; 1:1000; Wako Chemicals USA Inc., Richmond, VA, USA) and 
mouse monoclonal antibody against the MHC II receptor (OX-6; 1:1000; BD Pharmingen, 
Mississauga ON, Canada) respectively. After an overnight incubation with the primary antibody 
at 4oC, sections were incubated with biotinylated anti-mouse secondary antibody (1:500; Vector 
Laboratories, Inc. Burlingame, CA, USA) followed by incubation with avidin-biotin complex 
(ABC kit, Vector Laboratories, Inc. Burlingame, CA, USA) and then developed in 0.05% 3, 3’ 
diaminobenzidine tetrahydrochloride (Sigma-Aldrich, St. Louis MO, USA). Sections were then 
mounted on glass slides, air-dried, dehydrated, cleared in xylene and coverslipped with DePex 
mounting media (DePex, BDH Chemicals, Poole, UK). 
 
3.2.9 Imaging and Quantification of Immunohistochemistry 
Immunohistochemically processed brain sections were imaged with a Nikon Eclipse Ni-E 
microscope using NIS-Elements Imaging Software Version 4.30.02 (Nikon Instruments Inc., 
Melville, NY), allowing 10x magnification. Analysis and quantification were carried out using 64-
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bit ImageJ software (Version 1.48u4, Wayne Rasband, National Institutes of Health, Bethesda, 
MD, USA). A total of three brain sections containing anterior, mid-anterior and central-to-
posterior regions of the corpus callosum and three sections from the ventral hippocampal level for 
the internal capsule were chosen and scanned for each animal.  
Images were converted into a black-and-white 8-bit format, underwent background subtraction, 
thresholding and were calibrated prior to taking measurements. Based on the white matter 
pathology observed in our model previously, regions of interest (ROIs) included the entire body 
(BCC) and periventricular regions (PVCC) of the corpus callosum and internal capsule in both 
hemispheres and were manually outlined using a free outline tool. For the assessment of activated 
microglia population total area, the area covered by a positive signal (area%) was measured for 
each region and then expressed as a weighted average.  
 
3.2.10 Data Analysis 
Statistical analysis was performed using GraphPad Prism 6.0. The data was analyzed by 
performing t-test, one-way or two-way analysis of variance (ANOVA), Tukey’s multiple 
comparison post hoc test. Data are expressed as mean ± standard error of the mean (SEM), and a 
p value of ≤0.05 was considered statistically significant.  
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3.3 Results 
We first performed a comprehensive physiological assessment. 
 
3.3.1 Body Weight, Visceral Fat Accumulation and Diet Consumption  
At the end of 15 weeks of dietary treatment, body weight gain from baseline was significantly 
greater in all HCD groups compared to the CD groups (Figure 3-2A) as a result of a greater total 
caloric intake in these animals (Figure 3-2B). Both TG and WT rats on the HCD with or without 
KL prodrug treatment started to gain weight rapidly and weighed significantly more than CD 
groups as early as the beginning of the 3rd week on the diet and remained significantly heavier to 
the end of study. Epididymal fat pad weights, representative of visceral fat accumulation, were 
significantly increased in the HCD groups compared to the control diets (F(1,62)=193.4; p<0.0001) 
(Figure 3-2C). Fat accumulation also had a genotypic difference with fat deposits being larger in 
the TG rats (genotype effect F(1,62)=9.606; p=0.0029).  
 
3.3.2 Lipid and Glucose Metabolism 
The HCD had a robust effect on lipid metabolism resulting in dyslipidemia (Figure 3-2D, E). Total 
cholesterol was significantly increased in the comorbid animals with or without the KL prodrug 
and also in WT HCD rats receiving the KL prodrug (diet effect F(1,61)=46.52; p<0.0001). A similar 
pattern was seen for the non-HDL cholesterol (cholesterol content of atherogenic lipoprotein 
particles). The non-HDL cholesterol was increased in the WT HCD and comorbid rats, with and 
without the prodrug (F(1,60)=89.49; p<0.0001; Figure 3-2D). However, the WT HCD on the 
prodrug had higher levels than the WT HCD without the drug. The Chol:HDL ratio, a relevant 
clinical index, was significantly elevated by HCD (F(1,61)=65.97; p<0.0001; Table 3-1). 
Triglyceride levels were significantly elevated by HCD in all groups (F(1,61)=115.1; p<0.0001; 
Figure 3-2E). There was no apparent effect of KL prodrug administration on lipid metabolism with 
an exception of effect on total and non-HDL cholesterol levels in WT HCD rats.  
133 
 
The IvGTT results demonstrated a glucose intolerance in WT and TG groups on the HCD (Figure 
3-3). This was characterized by a significantly greater blood glucose levels at individual time 
points during the GTT (two-way ANOVA analysis, Tukey’s MC test). HCD groups started to 
deviate significantly from the control group values as early as at 5 min after the glucose injection 
(for WT HCD) and maintained high glucose levels up to 40 min post-load for WT rats and 20 min 
post-load for TG rats (Figure 3-3). Interestingly, glucose levels of TG HCD rats normalized earlier 
than those of the WT rats, as their glucose levels were comparable to control groups already at the 
30 min time point, whereas WT HCD rats remained significantly elevated and returned to normal 
only by the end of the test. The glucose intolerance was also characterized by a significantly greater 
AUC for HCD experimental groups compared to the appropriate control diet groups (diet effect 
F(1,76)=103.2; p<0.0001),  except the TG HCD group which was only statistically different from 
WT CD, but not from TG CD rats (Figure 3-2F). TG animals had a lower AUC compared to the 
WT rats (genotype effect F(1,76)=12.95; p=0.0006), suggesting a better glucose uptake from the 
blood stream in transgene carriers (Figure 3-2F). Rats maintained on the HCD had comparable 
fasting blood glucose levels compared to CD groups that remained within the normal range (Table 
3-1). This data suggests that HCD led to the development of glucose intolerance in both genotypes, 
however, TG rats were significantly less prone to perturbations in glucose metabolism than WT 
animals. Prodrug administration has shown no effect on glucose metabolism. 
 
3.3.3 Blood Pressure  
Systolic and diastolic blood pressure values obtained at week 11 of diets were not significantly 
different between the experimental groups. Neither HCD, nor transgene presence or KL prodrug 
treatment had an effect on either the systolic or diastolic pressure (Table 3-1). 
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Figure 3-2.  Physiological characteristics. A) Body weight gain expressed as a percentage of 
baseline value. B) Average caloric intake during the 15 weeks on the diets. Drink in the HCD 
groups represents energy derived from the corn syrup solution. C) Post-mortem paired epididymal 
fat pad weight. D) Total serum cholesterol is presented by entire bar. High density lipoprotein 
fraction (HDL) and the remaining combined non-high-density lipoproteins (non-HDL) are also 
shown in each bar.  E) Blood triglyceride levels. F) Area under the curve (AUC) from the IvGTT 
after 12 weeks on the diets. Animal numbers for C-E are as follows: WT CD, n=9; TG CD, n=5; 
WT HCD, n=6; TG HCD, n=6; WT CD-KL, n=12; TG CD-KL, n=11; WT HCD-KL, n=12; TG 
HCD-KL, n=11. Animal numbers for A,B,F are as follows: WT CD, n=11; TG CD, n=9; WT 
HCD, n=11; TG HCD, n=10; WT CD-KL, n=12; TG CD-KL, n=11; WT HCD-KL, n=12; TG 
HCD-KL, n=11. Values are presented as mean ± SEM.  * in A, B (total caloric intake), C, D (total 
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cholesterol), E, F, indicates significance between HCD and CD groups. † in D, indicates 
significance between individual HCD and all CD groups for the Non-HDL. † in F, indicates 
significance between the TG HCD groups and the WT HCD group. ‡ in F, indicates significance 
between TG HCD group and WT CD, TG CD-KL groups. One-way ANOVA and Tukey’s 
multiple comparisons test p < 0.05. CD = control diet, HCD = hypercaloric diet, HDL = high 
density lipoprotein, IvGTT = intravenous glucose tolerance test, KL=ketoprofen-lysine prodrug, 
TG = transgenic, WT = wildtype. 
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Figure 3-3. Intravenous glucose tolerance test on week 12 on the diet. Glucose curves during 
the IvGTT are shown for 4 experimental groups without the Ketoprofen-lysine prodrug treatment. 
* indicates significance between WT HCD and both CD groups, † between TG HCD and both CD 
groups, ‡ between TG HCD and WT HCD.  Animal numbers are as follows: WT CD, n=11; TG 
CD, n=9; WT HCD, n=11; TG HCD, n=10. Values are presented as mean ± SEM. Two-way 
ANOVA Tukey’s multiple comparisons test, p<0.05. CD = control diet, HCD = hypercaloric diet, 
IvGTT=intravenous glucose tolerance test, TG = transgenic, WT = wildtype. 
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Table 3-1. Physiological and metabolic characteristics obtained at the end of the study 
 WT CD WT CD-KL TG CD TG CD-KL WT HCD WT HCD-KL TG HCD 
TG HCD-
KL 
Chol:HDL, 
mmol/l 
1.19±0.25 1.27±0.13 1.32±0.05 1.26±0.05 2.05±0.31* 3.14±0.22#* 2.53±0.27* 2.34±0.22* 
Fasting 
glucose,  
mmol/l  
4.44±0.10 4.47±0.12 4.27±0.15 4.19±0.10 4.56±0.15 4.55±0.11 4.47±0.13 4.62±0.13 
Systolic 
pressure, 
mmHg 
136.79±2.72 145.43 ±2.17 
 
137.47±2.20 136.12±1.94 138.19±3.56 137.16 ±3.19 
 
136.37±2.97 133.03±3.12 
Diastolic 
pressure, 
mmHg 
90.55± 2.02 
 
98.16± 2.61 
 
96.17±1.97 95.47±2.44 91.52±3.16 94.05645 ±4.18 
 
95.61±2.78 93.11±2.91 
Values are presented as mean ± SEM. The symbols * indicate significance for HCD groups vs appropriate CD groups, # -between WT HCD 
and WT HCD - KL groups. One - way ANOVA, Tukey’s multiple comparisons test, p<0.05. Abbreviations: CD – control diet, HCD – 
hypercaloric diet, TG – transgenic rats, WT – wild type, KL – ketoprofen-lysine prodrug recipients, Chol – total cholesterol, HDL – high 
density lipoprotein cholesterol. 
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3.3.4 Behavioral Assessment 
We used two different MWM protocols to evaluate effects of comorbidity of HCD-induced MetS 
with genetic predisposition to early AD and the effect of the KL prodrug treatment. These were 
designed to asses spatial learning and reference memory, as well cognitive flexibility and working 
memory.  
 
3.3.4.1 MWM Spatial Learning and Memory 
During the training phase, all animals significantly improved in both latency and path length to the 
platform when day 1 vs day 4 performances were compared, indicating there was good learning of 
the spatial version of the task in all experimental groups (Figure 3-4A). In addition, neither of these 
measurements were significantly different between the groups at the end of acquisition phase (day 
4). No significant difference was observed in the time or distance travelled in the quadrant of the 
previous platform location (Target zone), during both probe trials (Figure 3-4B). Swim speed was 
not different between the groups (Figure 3-4C). Thus, these spatial learning and memory results 
demonstrate an absence of diet, genotype and drug effects on the spatial navigation ability and 
reference memory of the rats.   
 
3.3.4.2 MWM Cognitive Flexibility and Working Memory  
Working memory efficiency and flexibility is demonstrated by a significant reduction in path 
length and latency to reach the platform between trials 1 and 2. This can be seen in the WT and 
TG CD groups. However, in comorbid rats, with or without KL prodrug treatment, this significant 
reduction in path length and latency from trial 1 to 2 averaged for 3 shifting days was not present 
(Figure 3-5A,C). The lack of reduction in path length from trial 1 to 2 on each day, suggests that 
the combined TG HCD rats were not using working memory as efficiently as the other groups and 
that the KL prodrug administration had no effect on this deficit. There was no effect of the KL 
prodrug treatment as no change in the pattern was seen in any of the 4 experimental group pairs. 
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TG CD-KL and both TG HCD groups on average had a significantly shorter swims (p=0.0011 TG 
HCD, p=0.0001 TG HCD-KL, p=0.0053 TG HCD-KL) and were faster (p=0.0069 TG HCD, 
p<0.0001 TG HCD-KL, p=0.0083 TG HCD-KL) in locating the platform on trial 1 compared to 
the WT CD rats (Figure 3-5A,C). However, further analysis of the trial 1 performance in each 
separate day showed no differences between the groups. This behavior could likely occur by 
chance since rats did not know the location yet or represent potential differences in swimming 
strategies (i.e. chaining, scanning etc) between groups and may contribute to the smaller intertrial 
differences in these groups. 
The lack of improvement in the performance on the second trial in the comorbid groups could 
suggest they are using a random swim strategy instead of learning the location in the first and 
following trials using the spatial cues. However, when the performance in trial 1 was compared to 
that of trials 4 and 8, all groups without exception achieved a significant improvement in distance 
and latency even by trial 4 and all were comparable on the last trial of the day, trial 8 (Figure 3-
5A,C). Thus, all rat groups including the comorbid rats were able to learn the location of the 
platform throughout the day using rules of spatial navigation and the earlier assumption of a 
random swimming strategy choice by comorbid groups is not accurate.  
A potential reason for the lack of significance between trial 1 and 2 in the comorbid rats could be 
a delayed learning of new task rules. Rats from comorbid groups may have more strongly adhered 
to the previously learned location of the platform from the previous day and were ineffective in 
switching strategies that would affect progression on the novel task. In trial 1 of each day, the 
distance travelled in the platform zone of the previous day is an indicator of the domination of an 
“old rule” of spatial navigation. However, all groups exhibited no difference in swimming distance 
searching for the escape platform in the previous days platform zone (Figure 3-5B). Thus, 
comorbid rats were able to adapt to the new protocol as well as the other groups, but not as efficient 
or flexible in learning the new information presented on each day.  
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3.3.4.3 MWM Cued Trial Performance 
All measurements were averaged over the 4 trials of a cued test day. There were no significant 
differences in latency and path length to reach the platform (Figure 3-4D) or swim speed across 
all experimental groups. This suggests that all groups were able to see the cue to locate the 
platform, were equally motivated and had the motor capability to escape the pool.  
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Figure 3-4. Morris water maze spatial navigation task and cued trials. A) Path length to the 
hidden platform during 4 days of training. B) Distance travelled in the quadrant of the previous 
platform location (Target Zone) as a percentage of the total distance in the probe trials 1 and 2, 
one week apart. C) Swim speed in probe trials. D) Average path length to the platform during 4 
cued trials. Animal numbers are as follows: WT CD, n=11; TG CD, n=9; WT HCD, n=11; TG 
HCD, n=10; WT CD-KL, n=10; TG CD-KL, n=8; WT HCD-KL, n=11; TG HCD-KL, n=10. 
Values are presented as mean ± SEM. Significance is indicated by * between days 1 and 4 in all 
experimental groups. One-way and two-way ANOVA, Tukey’s multiple comparisons test, p<0.05. 
CD = control diet, HCD = hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT 
= wildtype. 
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Figure 3-5. Morris water maze shifting strategy task. All results are presented as an average 
of 3 days of testing. A) Path length to the hidden platform in trials 1, 2 and 8. B) Distance travelled 
in the previous day’s platform location for trial 1, expressed as a percentage of the total distance 
travelled in the first trial. C) Latency to find the hidden platform in trials 1, 2 and 8. Animal 
numbers are as follows: WT CD, n=11; TG CD, n=9; WT HCD, n=11; TG HCD, n=10; WT CD-
KL, n=10; TG CD-KL, n=8; WT HCD-KL, n=11; TG HCD-KL, n=10. Values are presented as 
mean ± SEM. # indicates significance for trial 1 with WT CD, * indicates significance from trial 
1, NS indicates not significant from trial 1. One-way ANOVA or two-way ANOVA (repeated 
measurement) and Tukey’s multiple comparisons test, p<0.05. CD = control diet, HCD = 
hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype. 
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3.3.4.4 Open Field Exploratory Activity and Anxiety-like Behavior 
Analysis of the total ambulatory distance during the 20 min arena exploration indicated that TG 
rats had a significantly shorter ambulatory distance than the comparable WT rats (F(1,75)=48.63; 
p<0.0001; Figure 3-6A). A reduction in total ambulatory distance is an indication of decreased 
spontaneous physical and exploratory activity in these animals. Furthermore, there was an overall 
significant impact of the KL prodrug resulting in an increase in locomotor activity in groups 
receiving the prodrug (F(1,75)=8.259; p=0.005; Figure 3-6B).  
Time spent in the central zone of the open field arena expressed as a percentage of total testing 
time and decrease in the central zone is a measure of anxiety-like behavior. There was no 
significant group difference in the time in the arena center during the full 20 min test duration 
(Figure 3-6C).  
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Figure 3-6. Locomotor activity and anxiety-like behavior in the open field test on week 12 on 
the diet.  Total ambulatory distance A) combined in 4 groups by genotype and diet irrespective of 
the prodrug treatment and B) combined by genotype and prodrug assignment. C) Percentage of 
time spent in the central zone during 20 min in an open field arena for all 8 experimental groups. 
Values are presented as mean ± SEM. Animal numbers are as follows: WT CD (n=11), TG CD 
(n=9), WT HCD (n=11), TG HCD (n=10), WT CD-KL (n=10), TG CD-KL (n=8), WT HCD-KL 
(n=11), TG HCD-KL (n=10). *  in A and B, indicates significance between TG groups and WT 
groups. † in B, indicates significance between WT-KL and WT-ND groups. One - way ANOVA 
and Tukey’s multiple comparisons test or t-test, p<0.05. CD = control diet, HCD = hypercaloric 
diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype. 
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3.3.5 Microglia Activation  
We have examined and quantified OX-6 positive activated microglia cells primarily located in 
white matter tracts throughout the brain, including the body of the corpus callosum (BCC), the 
periventricular region of the corpus callosum (PVCC) and the internal capsule (Figure 3-7A). For 
all groups of animals, WT and TG with either CD or HCD, there was no effect of the KL prodrug 
on the activated microglia in any of the 3 regions measured (Figure 3-7B). 
In both areas of the corpus callosum, BCC and PVCC, there was an increase in activated microglia 
in the TG compared to the WT rats, irrespective of diet (F(1,17)=84.87, BCC; F(1,17)=74.13, PVCC; 
p<0.0001; Figure 3-7C). For the internal capsule, the TG HCD rats had more activated microglia 
than the WT CD (p=0.0024) and WT HCD (p=0.0130) (Figure 3-7C). Furthermore, in both areas 
of the corpus callosum, the TG HCD had significantly more activated microglia than the TG CD, 
indicating a more pronounced effect of the comorbid condition (p=0.0116, BCC; p=0.0118, 
PVCC; Figures 3-7A,C).  
An assessment of the total microglia proliferation within the white matter tracts using anti-Iba-1 
immunohistochemistry indicated that there was no apparent change in the total microglia in the 
white matter of either the corpus callosum or the internal capsule regions (Figure 3-8). 
We have also observed a marked increase in the activated microglia in multiple brain regions of a 
total 6 rats from all 4 experimental groups which all received a KL prodrug treatment. This 
indicated a potential serious negative effect of the prodrug which was studied in a more detail in 
these 6 cases and described in the Chapter 4 of this thesis. 
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Figure 3-7. Activated microglia in white matter. A) The schematics show the coronal sections 
at one of the levels used for analysis: Bregma 0.6 mm for the corpus callosum (on the left) and 
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Bregma -2.92 mm for the internal capsule (on the right). Photomicrographs (10X) of representative 
OX-6 immunolabelled activated microglial cells in the body of the corpus callosum (all 
experimental groups) and internal capsule (only HCD groups on and off the prodrug treatment) 
were sampled from the regions in the right hemisphere indicated by the black box on schematics. 
Scale bar 100µm. B,C) Bars represent the density of the OX-6 positive microglia coverage 
expressed as the percentage of a total area of the region: the body of the corpus callosum, 
periventricular regions of the corpus callosum and internal capsule. B) All experimental groups 
are shown; C) data presented only for 4 groups not receiving the prodrug treatment. Values are 
presented as mean ± SEM. Animal numbers are as follows: WT CD (n=6), TG CD (n=5), WT 
HCD (n=5), TG HCD (n=6), WT CD-KL (n=5), TG CD-KL (n=5), WT HCD-KL (n=4), TG HCD-
KL (n=6). * indicates significance between the TG and WT groups. † between TG HCD and TG 
CD. One - way ANOVA, Tukey’s multiple comparisons test p<0.05. CD = control diet, HCD = 
hypercaloric diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype. 
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Figure 3-8. Total microglia in white matter. A) The schematics show the coronal sections at one 
of the levels used for analysis: Bregma 0.6 mm for the corpus callosum (on the left) and Bregma -
2.92 mm for the internal capsule (on the right). 10x photomicrographs of representative Iba-1 
immunolabelled microglial cells in the body of the corpus callosum and internal capsule (control 
WT CD, all TG groups) were sampled from the regions in the right hemisphere indicated by the 
black box on schematics. Scale bar 100µm. B) Area coverage by a positive signal (as percentage 
of a total area of a region) for corpus callosum and internal capsule. Animal numbers are as 
follows: WT CD (n=6), TG CD (n=5), TG HCD (n=6), WT CD-KL (n=5), TG CD-KL (n=5), TG 
HCD-KL (n=6). Values are presented as mean ± SEM. CD = control diet, HCD = hypercaloric 
diet, KL=ketoprofen-lysine prodrug, TG = transgenic, WT = wildtype. 
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3.4 Discussion 
Targeting neuroinflammation appears to be one of the most promising approaches to slowing or 
preventing some forms of dementia, including AD, since it has been shown to be one of the earliest 
processes related to the disease pathogenesis. Furthermore, neuroinflammation is persistent over 
time and contributes to disease progression5,62. A previous study using the APP21 TG rat model of 
prodromal AD in combination with diet-induced MetS supported the concept of the role of 
neuroinflammation in the early onset of the disease and mild cognitive impairment. In particular, 
we previously demonstrated that white matter microgliosis, in particular, may be one of the key 
elements in prodromal AD-related pathology and that increased white matter inflammation may 
be point of interaction between specific AD and metabolic disease.  
A consideration of previous results along with accumulated evidence from epidemiology and 
supportive data from clinical and other animal research, suggests that anti-inflammatory agents 
may be potential treatment candidates to interrupt this neuroinflammatory interaction caused by a 
combination of amyloid and high fat, high sugar diet. In the present study we investigated the 
potential therapeutic effect of a novel non-steroidal anti-inflammatory prodrug, Ketoprofen-lysine, 
in the APP21 TG rat model of prodromal AD with HCD–induced MetS. As in our previous 
investigation, we did observe changes to metabolism characteristic of the MetS syndrome 
development (obesity, increased adiposity, dyslipidemia, glucose intolerance). We also observed 
again increased white matter microglial activation that was accompanied by working memory 
impairment, based on the MWM cognitive flexibility test, in the comorbid TG HCD group after 
15 weeks of the HCD consumption. However, the results of this investigation did not demonstrate 
any obvious beneficial effect on the white matter inflammation and cognitive deficits associated 
with the chronic KL prodrug treatment.  
The metabolic and physiological profile in the current investigation was consistent with our 
previous study. Chronic HCD consumption in WT and TG led to the development of obesity and 
markedly altered lipid metabolism. Previously, using an intraperitoneal GTT (IpGTT), we 
observed a genotypic difference in the response of glucose metabolism. Even with HCD exposure 
the TG rats were able to maintain glucose tolerance, while WT rats had greatly elevated glucose 
levels that did not normalize even at the end of the 2h of testing. In the present investigation, we 
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used an intravenous glucose challenge demonstrating that both TG HCD and WT HCD rats 
developed glucose intolerance.  
Interestingly, the WT HCD rats again showed the highest blood glucose concentration at each time 
point during the test resulting in a greater AUC compared to the TG HCD rats in the present study. 
The lack of development of glucose intolerance in the previous study in which TG HCD rats did 
not show an increase in AUC compared to the control groups when using an IpGTT may, in fact, 
be an artefact of the different route of glucose delivery between two versions of the test. In the 
IpGTT, the glucose passes from the peritoneal cavity to the systemic circulation entering the liver 
first. In the intravenous administration it bypasses the liver allowing a direct assessment of the 
glucose disposal and effects of acute insulin release.  
Alternatively, the mutated hAPP in our APP21 TG rats is overexpressed in several peripheral 
tissues including liver and this APP might interact with the mechanisms of glucose metabolism 
leading to the observed differences between the WT and TG animals. Similarly,  the absence of 
glucose intolerance with the oral GTT have been reported in a transgenic 5xFAD mice also 
expressing a mutant APPSwe, compared to the WT group
63. Clinically, both lower oral GTT and 
fasting glucose values were observed in an AD patient cohort64. These data suggest a potential 
implication of APP in the glucose metabolism regulation, findings that require additional 
investigation.  
The KL prodrug administration did not affect any of the metabolic outcomes measured. There is 
evidence in the literature of beneficial effects of NSAIDs on glucose and lipid metabolism that 
could provide an advantage for their use in a patient population with metabolic disorders65. 
However, these effects are thought to be dose-dependent. In the present investigation, the treatment 
of the ketoprofen was administered at a relatively low dose since the ketoprofen was delivered in 
a prodrug form which allows faster delivery to and greater fraction entered in the brain. This low 
dose with a direct action in the brain would minimize the systemic exposure and effects observed 
by others.  
We have previously shown the comorbid rats had impaired memory consolidation on the MWM 
re-learning task. In the present study, we aimed to assess working memory and cognitive 
flexibility, the processes that show an early decline in AD. The comorbid, TG HCD, rats 
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demonstrated preserved spatial learning ability and they did not maintain a preference for the 
previous days escape location during the first trial of shifting strategy version of the MWM task. 
However, the comorbid animals showed no improvement from trial 1 to 2 in the shifting strategy 
testing. These results suggest the comorbid groups may have a slower information processing 
speed and working memory impairment, leading to the slower switch to the changed escape 
location, i.e. cognitive inflexibility.  
Executive behavioral deficits have been observed in these APP21 TG rats with advanced age (19 
month old) compared to the WT rats when tested on a strategy shifting MWM task similar to that 
of the present investigation 55. Furthermore, another study investigated behavioral flexibility in 
comorbid stroke and early AD in 13 month old APP21 TG rat model and have shown impairments 
in strategy change efficiency. This impairment in the comorbid stroke and APP TG rats was based 
on an operant set-shifting task which allows for a more specific and broad assessment of the 
executive function66. The testing in our study was done in 13.5 month old animals and we did not 
detect impairments in the APP21 TG rats in the control diet group using the MWM adapted 
protocol. This MWM protocol lacks sensitivity comparing to the operant-based set-shifting task. 
Nevertheless, the animals with metabolic disturbances due to the HCD in the TG animals resulted 
in working memory dysfunction even with the MWM protocol. Thus, our results support our 
previous demonstration of cognitive impairment in HCD and APP TG comorbid animals. 
However, as indicated, above, the KL prodrug administration did not prevent this behavioral 
deficit in the comorbid rats (TG on the HCD).  
In the present experiments, locomotor activity tested in the open field was lower in the transgene 
carriers. This result is consistent with previously observed behavioral differences in this animal 
model55 and in APP transgenic mouse models of AD67,68. Interestingly, KL prodrug treatment 
appeared to increase exploratory activity overall among all experimental groups, with a more 
pronounced effect in the WT rats. This could be due to peripheral pain-relieving action of 
ketoprofen which could alleviate the discomfort associated with obesity and increased load on 
joints in HCD groups, however, this effect was observed in all diet groups, including rats on 
CD69,70. Furthermore, a rapid delivery of active ketoprofen in the prodrug form to the brain likely 
minimized ketoprofen systemic effects including analgesic effect. This further suggests there 
might be a direct central analgesic effect of the drug that is not attributable to prevention of any 
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increases in neuroinflammation due to the transgene or the HCD70,71. How the ketoprofen effects 
the brain to produce this increase in exploratory behavior requires further exploration. 
In the present study, microglial activation in the white matter indicated increased 
neuroinflammation in TG animals compared to WT and in comorbid animals with MetS and hAPP 
compared to TG animals alone. A previous investigation has shown that the APP21 TG rats 
demonstrate a significant increase in the OX-6 positive microglia in the corpus callosum compared 
to the WT from 12 and 15 months of age55. Thus, the present investigation indicates that the HCD 
can markedly aggravate the age-related white matter pathology in the TG rats. These results are 
consistent with our previous study characterizing this combined disease model in which the 
comorbid group (TG HCD) had a significant increase in microglial activation in white matter 
tracts, including the corpus callosum and internal capsule. However, the present results indicate 
that the anti-inflammatory KL prodrug treatment was not able to reduce the microglial activation 
in the white matter in the comorbid group. Furthermore, 2 lethal cases and 6 cases of pronounced 
microgliosis indicated a potential serious negative prodrug effects questioning safety of this agent. 
One limitation to this study that needs be mentioned is that there was no vehicle-treated group to 
control for the effects of chronic injections as a stress factor. This study was primarily aimed to 
investigate the potential of the prodrug treatment to decrease white matter microglial activation, 
thus, only KL treatment was done. However, it is necessary to perform a follow-up saline-
controlled experiments as well as dose-response studies to fully assess the treatment potential. 
The hypothesis for this study was that the KL prodrug would ameliorate the white matter 
inflammation and the cognitive deficits in the comorbid animals. The results are very clear that 
there is no significant impact of the drug on these measures. Factors potentially influencing the 
effect of the drug in our model could include timing of the treatment initiation, duration, dosage 
and properties of the active compound ketoprofen 72. Potential changes in expression or function 
of the LAT-1 transporter in our transgenic prodromal AD model and/or HCD consumption and the 
establishment of metabolic dysregulation could also affect pharmacokinetics of the prodrug and 
its potency. Clinical trials have also indicated that NSAIDs might be ineffective when sufficient 
pathology already exists at the start leading eventually to disease progression and establishment of 
symptoms without regard to the treatment. Therefore, clinical studies suggest that an early 
intervention occurring prior to overt pathological changes35,37,48 or at the very early stages of the 
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disease is necessary for beneficial effects48,73. It may be that in or study, the rats by 10 months of 
age have already developed pathologies driving or contributing to white matter inflammation that 
could not be rescued or reversed by the KL prodrug administered in the current dose and timeframe 
for delivery. The inherent pathologies in our animals may be progressing with increasing age that 
by itself could  contribute to the previously described phenomenon of decreased protection of 
drugs37 through dyshomeostasis in immune and vascular systems. In addition, these pathological 
processes can be further aggravated by transgene presence in our prodromal AD rat model and 
even more by the altered metabolic condition, and both of these conditions that can further sustain 
inflammatory process and affect treatment results. Therefore, further experimentation should be 
done to establish the timeframe of the development of neuropathological changes to determine the 
earliest point for successful intervention. Moreover, these studies should be accompanied by the 
safety testing of the treating agents. 
Our model of prodromal AD has demonstrated inflammation primarily affecting white matter. 
White matter is a structure that is highly susceptible to damage and white matter pathology appears 
to be one of the earliest signs in diseases including AD and MetS and precedes cognitive 
decline2,3,6,74–76. Thus, it might be important to consider potential re-directing of the treatment 
strategy towards targeted protection of the white matter rather than focusing simply on general 
suppression of inflammation. This would require a detailed analysis of underlying white matter 
lesions and the timeline of their development. Furthermore, it might not be effective, and in fact it 
is likely insufficient, to target only one out of many processes of the complex pathogenesis in the 
progression of MCI and AD. Therefore, future research directions might also include an integration 
of anti-inflammatory treatment into a combined therapy that accounts for multiple key players in 
the disease development to increase success of the treatment and obtain the maximal beneficial 
effect.
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Chapter 4: Negative Impact of Ketoprofen-lysine Treatment on Cerebral 
Pathology and Cognition in a Comorbid APP21 Transgenic Rat and Diet -
induced Metabolic Syndrome  
This chapter presents the analysis of a subset of animals from the previous investigation that 
received the prodrug that developed a large amount of neuroinflammation (Objective 3). The 
negative effects on neuropathology and behavior associated with the long-term prophylactic 
prodrug treatment in a subset of rats are described. Full description of the  methodology of this 
study is presented in Chapter 3 and the current chapter includes only highlights and additional 
methods used for the extended pathological examination. This manuscript has been reviewed by 
all authors and is ready to be submitted for publication. 
4.1 Introduction 
Alzheimer's disease (AD), a common cause of dementia, is a progressive incurable 
neurodegenerative disease that leads to a severe mental health decline. Neuroinflammatory 
processes occupy an important place in the pathogenesis of AD, developing at the very early stages 
of the disease and contributing to the progression1–5. Obesity and metabolic syndrome (MetS), 
whose development is greatly associated with the intake of high-fat, -sugar hypercaloric diet 
(HCD), represent risk factors for dementia including AD later in life. A chronic inflammatory state 
is also a characteristic feature of these disorders6–8 and has been suggested to be a point of 
interaction between AD and metabolic diseases9–12.  
Epidemiological studies have shown a long-term treatment with non-steroidal anti-inflammatory 
drugs (NSAIDs) is associated with reduced risk of AD14,15,24,25,16–23. Particularly, this association 
is thought to be mediated through the inhibition of cyclooxygenase (COX) enzymes COX-1 and 
COX-2 and blockage of downstream pro-inflammatory mediators production13, which are 
involved in the inflammatory processes critical to the AD development and progression1,26–29. 
However, clinical trials on NSAIDs have produced controversial results30, leading to the need for 
further studies investigating treatment potential of this class of agents.  
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We previously conducted a 12-week study on the effects of diet-induced metabolic disturbances 
on neuroinflammation and cognition in a novel human APP21 transgenic (TG) rat model of early 
AD48–50. The results demonstrated an intense white matter inflammatory response accompanied by 
a poor cognitive performance in the comorbid condition, suggesting inflammation might be one of 
the key players in early AD and highlighting a potential for an anti-inflammatory treatment 
strategy.  
We subsequently conducted another study designed to examine the therapeutic effect of a novel 
prodrug ketoprofen-lysine (KL)51, a conjugate of NSAID ketoprofen and amino acid lysine, 
specifically targeting the brain. This study examined the impact of KL on white matter microgliosis 
and cognition in the comorbid model of early stage AD and diet-induced MetS. We hypothesized 
that chronic prophylactic treatment with a novel KL prodrug which was initiated at the prodromal 
AD stage simultaneously with the dietary switch for MetS induction and therefore administered at 
a half-treatment for this drug class dose, will prevent increased white matter inflammation and the 
concomitant cognitive impairment in the comorbid AD and MetS. Long-term prophylactic 
treatment failed to stop accumulation of white matter microglia activation induced by comorbidity.  
However, there was an additional phenomenon that needs to be reported since it has considerable 
implications for the potential use of brain targeted NSAIDs. In all groups receiving the prodrug 
there was a subset of rats that demonstrated a dramatic increase in pathologic neuroinflammation 
in the neocortex and subcortical structures accompanied by a negative impact on spatial working 
memory and cognitive flexibility.  
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4.2 Methods  
The complete study design with detailed methods section is described elsewhere.  
Male Fischer 344 wildtype (WT) and TG carrying human amyloid-β precursor protein gene 
(hAPP) with Swedish and Indiana mutations (APP21)48 rats 10-10.5 months of age were 
maintained on either a control diet (CD; Prolab RMH 3000 5P00) or the hypercaloric diet (HCD; 
D12079B, Research Diets, Inc) supplemented with 20% corn syrup water solution. A total of 21 
WT and 18 APP21 TG rats received the KL prodrug in once daily subcutaneous injections in a 
dose of 4.1 mg/kg body weight, which corresponds to 2.5mg/kg of free ketoprofen, for a full 
duration of the study (15 weeks).  
Tissue processing and immunohistochemistry were performed to visualize total, activated 
microglia and astrocytes as described previously. Additional staining was done to visualize 
neurons using mouse monoclonal primary antibody against neuronal nuclei protein (anti-NeuN; 
1:1000; Millipore Corp; USA). Systolic and diastolic arterial blood pressure was measured using 
the non-invasive tail cuff method (CODA Blood Pressure System, Kent Scientific Corp., 
Connecticut, USA) at week 11 of the study. Spatial learning abilities, working memory and 
cognitive flexibility were evaluated using the Morris water maze task (MWM) at weeks 13-15 on 
the diet as described in the original study. Data is reported as mean with the standard error of the 
mean (SEM). Differences in the 2-way ANOVA followed by Tukey MC test or t-test were 
considered statistically significant where p≤0.05.  
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4.3 Results 
In total there were 39 animals receiving the KL prodrug. These animals included 10 WT CD, 8 
TG CD, 11 WT HCD and 10 TG HCD. The first indication that there may be a problem with the 
drug treatment was the death of two rats receiving the KL prodrug, one each from the WT CD and 
TG CD group. These animals were found dead in their home cages after one month of drug 
administration. Previously, in these MetS studies alone, we have used a total 126 rats in these types 
of experiments that do not involve any kind of surgery or invasive treatment and we have not had 
any animals succumb. Unfortunately, the brains were not saved for histological analysis due to 
undetermined time after spontaneous death. 
 
4.3.1 Neuroinflammation 
One of the hypotheses for the overall experiment was that there would be increased white matter 
inflammation in the TG rats on the HCD and that the KL prodrug would ameliorate this 
inflammation. When we performed immunohistochemical analysis of OX-6 activated microglia, 
it revealed the expected white matter inflammation in the comorbid AD and MetS animals, 
however there was also a widespread microgliosis in 6 animals on the KL prodrug (Figures 4-1,2). 
Areas of OX-6 microgliosis have also shown an increase in the Iba-1 reactivity of microglial cell 
population (Figures 4-1,2). These animals were not localized to any one group, but were in all 4 
experimental groups irrespective of the presence of the transgene or the HCD (Figures 4-1,2).  
The only common element is that all of these animals with extensive neuroinflammation were 
exclusively from animals receiving the KL prodrug and included both genotypes and dietary 
regimens: WT CD, n=1; TG CD, n=1; WT HCD, n=2; TG HCD, n=2. In all animals, there were 
highly activated OX-6 positive microglia cells clustered together in large areas spreading across 
both gray and white matter. Images of the activated microglia are shown for representative animals 
from each group in Figures 4-1,2. This was a striking finding since this type of neuroinflammation 
had never been observed in any (126 rats) of the previous animals in these studies. We particularly 
did not expect this in those that are part of the control groups. We previously observed only 
localized white matter inflammation increase in comorbid animals that were TG and on the HCD.  
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The areas of neuroinflammation included the neocortex, thalamus, hippocampus, striatum, 
amygdala, septal nuclei, hypothalamus, spreading into the adjacent white matter (Figures 4-1,2). 
Morphologically, the microglia cells exhibited enlarged irregular soma with shortened thickened 
processes and an increase in the number of processes (Figure 4-1).  
These brains were also stained for GFAP. Analysis of the brain sections has shown an increase in 
GFAP-immunoreactivity of cells in the areas of microgliosis (Figures 4-1,2). These hypertrophic 
GFAP+ astrocytes exhibited thickening of their processes as well as an increase in the number and 
length of the processes (Figure 4-1).  
Staining for NeuN was done to obtain an indication of the numbers of neurons in these areas (boxed 
fields on Figures 4-1,2). Neuronal density expressed as NeuN positive cell automated counts, 
indicated there was a consistent relative decrease in the numbers of neurons in the regions of 
microglial activation compared to corresponding areas of a control brain from a rat not receiving 
the drug (Figure 4-3).  
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Figure 4-1. Widespread microgliosis and reactive astrocytosis in Ketoprofen-lysine prodrug 
recipients in groups on the control diet. 2x photomicrographs of representative brain regions 
from coronal sections at the levels indicated by the Bregma (mm) with immunolabelled OX-6, Iba-
1 activated microglia and GFAP astroglia. Scale bar 500µm. Boxed regions refer to areas selected 
for neuronal cell counting. Magnified images obtained at 10x magnification show morphology of 
microglia and astrocytes in the core of the affected region. Scale bar 100 µm. CC = corpus 
callosum, CD = control diet, fmiCC = forceps minor of  corpus callosum, KL = ketoprofen-lysine 
prodrug, LH = left hemisphere, LV = lateral ventricle, M = motor cortex, RH = right hemisphere, 
TG = transgenic, WT = wildtype. 
  
165 
 
 
 
Figure 4-2. Widespread microgliosis and reactive astrocytosis in Ketoprofen-lysine prodrug 
recipients in groups on the hypercaloric diet. 2x photomicrographs of representative brain 
regions from coronal sections at the levels indicated by the Bregma (mm) with immunolabelled 
OX-6, Iba-1 activated microglia and GFAP astroglia. Scale bar 500µm. Boxed regions refer to 
areas selected for neuronal cell counting. 3V = 3rd ventricle, CD = control diet, IC = internal 
capsule, KL = ketoprofen-lysine prodrug, LH = left hemisphere, LV = lateral ventricle, RH = right 
hemisphere, TG = transgenic, WT = wildtype. 
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Figure 4-3. Neuronal density in areas of extensive neuroinflammation in Ketoprofen-lysine 
prodrug recipients. Neuronal counts (NeuN+ cells) in affected brain areas of representatives from 
WT CD, TG CD, WT HCD and TG HCD animals in comparison to control brain of untreated WT 
animal on CD. Amyg = amygdala, CD = control diet, CPu = caudate putamen, HCD = hypercaloric 
diet, KL = ketoprofen-lysine prodrug, Prim SS Cortex = primary somatosensory cortex, SeptNu = 
septal nuclei, TG = transgenic, WT = wildtype. 
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4.3.2 Behavioral deficits  
To assess the impact of KL prodrug induced neuroinflammation on cognitive performance we 
performed an additional analysis of behavioural data dividing rats in two groups: a group that was 
not receiving the prodrug (ND, n=41) and group receiving the KL prodrug that exhibited 
widespread neuroinflammation (DI, n=6). Both of these groups contained rats from the 
combination of dietary protocols and genotypes.  
The analysis of spatial learning in the MWM demonstrated that both ND and DI rats had significant 
improvement in the time to reach the hidden platform by the end of the training (Figure 4-4A), 
indicating that spatial learning ability was not compromised in the DI animals. In addition, these 
two groups were similar in motor ability since swim speed did not differ between groups in any of 
the probe trials (Figure 4-4B).  
In the 3-day MWM shifting strategy protocol with the platform location changing every day the 
average time to find the hidden platform in the first trial of the day was not different between the 
groups. However, the time to recall the newly learned platform location and reach the platform in 
trial 2 was significantly longer in DI group compared to the ND group (p=0.027; Figure 4-4C). 
Thus, the improvement in the time on trial 2 compared to trial 1 was only significant in ND group 
indicating the KL prodrug reduced cognitive flexibility due to working memory impairments.  
Furthermore, analysis of the performance in trials 2-4 showed that DI rats were significantly slower 
in learning the platform position within each day (p=0.02; Figure 4-4D). Finally, the latency to 
reach the platform in trial 5, after a one-hour break, was significantly longer in DI rats (Figure 4-
4E), suggesting there are difficulties in retaining information during the break. Altogether, these 
results demonstrate negative effects of detrimental neuroinflammatory pathology on the spatial 
reference and working memory and cognitive flexibility of the rats.   
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Figure 4-4. Behavioral performance of Ketoprofen-lysine prodrug recipients with extensive 
neuroinflammation. Rats divided in two groups: those not receiving prodrug (ND) and those with 
prodrug and with extensive gray matter inflammation (DI). Each group combines both dietary 
protocols and genotypes. Spatial navigation MWM. A) Latency to the hidden platform as a 
measure of learning progress over 4 days of training. B) Swim speed during probe trials one week 
apart performed right after the spatial training. Shifting strategy MWM protocol for spatial working 
memory and cognitive flexibility assessment. C) Average time to find the platform in trials 1 and 
2 of the day as working memory efficiency criteria. D) Average latency during trials 2-4 within 
the day as working memory and cognitive flexibility measure. E) Latency to reach the platform in 
trial 5, after a one-hour break in testing day, as a measure of spatial reference memory. Trial bar 
in C-E) represents an average of trial time across 3 days of shifting strategy MWM task. Values 
are presented as mean ± SEM. Significance is indicated by * between different time points within 
the group and by # - between groups. t- test, 2-way ANOVA Tukey post-hoc test (in A), p≤0.05. 
CD = control diet, HC = hypercaloric diet, KL = ketoprofen-lysine prodrug, MWM = Morris water 
maze, TG = transgenic, WT = wildtype. 
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4.3.3 Blood pressure 
Systolic and diastolic arterial blood pressure levels assessed at week 11 of diets were not different 
between the rats on the prodrug treatment that developed extensive neuroinflammation and non-
treated rats, DI and ND experimental groups respectively (Figure 4-5).  
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Figure 4-5. Systolic and diastolic arterial blood pressure of Ketoprofen-lysine prodrug 
recipients with extensive neuroinflammation. Rats divided in two groups: those not receiving 
prodrug (ND) and those with prodrug and extensive inflammation (DI) Each group includes those 
rats both dietary protocols and genotypes. Values are presented as mean ± SEM. 
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4.4 Discussion 
The original study aimed to investigate therapeutic effect of a novel non-steroidal anti-
inflammatory KL prodrug to treat the negative effects of the combination of early AD-like 
pathology and a high fat, high sugar hypercaloric diet. In two separate studies this combination 
has been demonstrated to induce localized white matter inflammation and cognitive deficits. The 
investigation that included the impact of the KL prodrug on the activated microglia in the white 
matter and the behavior indicated no significant reduction in the white matter pathology or the 
cognitive deficits. However, of the 39 animals receiving the KL prodrug 2 died unexpectedly, and 
6 developed widespread neuroinflammation and neuronal degeneration, irrespective of the 
experimental group. This widespread pathology also impacted behavioral performance when 
compared to untreated rats. Although this phenomenon was observed in a relatively small number 
or animals (total of 8 out of 39), the magnitude of the pathology and that fact this did not show up 
in any other animals (41 rats) not receiving the KL prodrug in this study or a previous study, such 
a pronounced deleterious effect that appears to be KL prodrug dependent, is important to report in 
light of the clinical push to use NSAIDs to treat early symptoms of AD.  
The rats receiving the KL prodrug developed massive cerebral inflammation, including both 
microgliosis and astrocytosis that affected large regions of the cerebral cortex, basal ganglia, 
thalamus, hippocampus, hypothalamus and adjacent white matter. Analysis of cells positive for a 
neuronal marker showed neuronal loss in areas corresponding to the regions of neuroinflammation. 
Treatment has also appeared to lead to a lethal outcome in two cases after one month of KL prodrug 
treatment. 
Spatial learning tested in the MWM navigation task, in which the hidden platform remained in the 
same position over 4 days, remained intact. However, the MWM shifting strategy, or cognitive 
flexibility task, adapted for use in this study52–56 to assess the executive function components, in 
which the platform was moved to a novel position for each of the 3 testing days, revealed 
significant deficits in spatial working memory and challenged learning ability under the novel task 
rules and changing environment indicating a cognitive inflexibility in these rats.  
To our knowledge such negative effects of NSAIDs have not been reported by other animal studies 
in the literature to date. However, there are clinical reports with evidence of adverse cardiovascular 
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and cerebrovascular effects using this group of drugs57–65. These effects include fatal and non-fatal 
heart failure, myocardial infarction, ischemic and hemorrhagic stroke, and transitory ischemic 
attack. An increased risk for serious vascular complications with the NSAIDs treatment has been 
registered for the general population63,66 and specifically for NSAID use in osteoarthritis65 and 
rheumatoid arthritis62 patient cohorts as well as individuals with a family history of AD63. The 
adverse effects depended on dose and duration factors and were especially worse for long 
treatments at high doses.  
Potential underlying mechanisms leading to the development of the adverse effects with  NSAID 
use include vascular damage including due to oxidative stress, a shift towards a prothrombotic 
state due to lack of or insufficient blockage of COX-1 dependent platelet aggregation and elevation 
of blood pressure that might result into cerebrovascular event42,58,59,62. There are 3 characteristics 
of ketoprofen that suggest the treatment agent in our study might have a prothrombotic effect and 
result in the adverse cardio- and cerebrovascular events. First, ketoprofen exerts a reversible 
inhibition of COX-1 pathway compared to other NSAIDs that have a more permanent COX-1 
inhibition67. Secondly, it has a relatively weak affinity for COX-2 expression59,64. COX-2 is 
increased in the vasculature and is associated with vasoconstriction in an inflammatory 
environment such as that seen in metabolic disorders68. Thirdly, ketoprofen has a half-life less than 
12h69,70. The treatment protocol of a once daily injection that we used and this dosage chosen could 
produce insufficient antithrombotic action in the long term.  
Ketoprofen itself may have a tendency for a higher degree of adverse effects. Blood pressure levels 
measured via tail-cuff method were not different in the KL treated rats and does not appear to add 
to the pathological events observed in the present study. However, aging, AD and MetS are 
associated with the vascular pathology and it is, therefore, possible that cerebrovascular 
derangements are present in our model and the actions of the KL prodrug could intersect with or 
even further aggravate preexisting pathologies, resulting in cerebral insults seen in our animals. 
Further investigation of the vascular status in our model would be needed to make conclusions on 
this assumption. 
In light of this, of great importance is a question of the safety of these agents in a population with 
concurrent chronic diseases such as diabetes and MetS as studied in our model. These are 
173 
 
individuals who are in a high-risk group for vascular complications and may already have 
cardiovascular diagnoses and/or cerebrovascular history. Presence of these conditions can 
potentially increase the risk of these side effects even more, leading to recurrent cardio- or 
cerebrovascular insults57,71.  
What is most critical about the KL prodrug we used in this investigation is the alteration in the 
molecular structure, adding the amino acid lysine, to enhance uptake by the brain via LAT1-
mediated transport. Although this may seem like a logical approach to generate more efficacious 
anti-inflammatory agents to combat the earliest neuroinflammatory pathological events, it may, in 
fact be very counterproductive if other NSAIDs manipulated in a similar manner to ketoprofen 
also generate this type of brain pathology. The toxicity could result from particular NSAIDs itself, 
i.e. ketoprofen in our study, or could be attributed specifically to the lysine addition. Additional 
experimental studies need to be done to understand the clinical risks associated with the use of 
NSAIDs for the treatment of mild cognitive impairment and the slowing or prevention of dementia.  
 
One of the limitations to this study is that there were no vehicle control groups in the current 
experimentation. Our primary goal was to assess whether the novel prodrug could reduce the white 
matter inflammation in our comorbid model. However, saline control experiment should be carried 
out to examine possible effects of chronic injection stress and their contribution to the 
neuropathology and behavioral performance. 
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Chapter 5: Relationship between White Matter Inflammation and 
Metabolic and Physiological Parameters in a Comorbid APP21 Rat Model 
of Prodromal Alzheimer’s Disease and Metabolic Syndrome  
This chapter describes the relationships between the white matter inflammation and systemic 
metabolic and physiological parameters using the combined data from the two studies described 
in the Chapters 2 and 3 of this thesis. The relationships between behavioral performance and white 
matter inflammation are also described. The methods section of this chapter contains only 
highlights of the tests used for metabolic and behavioral measurements described in detail in the 
previous chapters.  This aim of this study is to identify potential biomarkers of white matter 
inflammation (Objective 4). This manuscript has not yet been submitted for publication.  
 
5.1 Introduction 
Dementia represents one of the biggest global public health challenges these days. Alzheimer's 
disease (AD) is the most commonly diagnosed type of dementia and is a progressive, irreversible, 
and currently, incurable disease1. Extensive search for the treatment of AD has not yet yielded the 
desired results and research from both pre-clinical and clinical fields is continued. In addition to 
the search for treatment of AD, there has been an increase in studies examining biomarkers of the 
disease that would aid in early identification of the disease pathology2–5. Timely and accurate 
diagnosis of AD is essential for early intervention and better prognosis and remains a great 
challenge and most likely one of the major contributors accounting for the failure of clinical trials 
for potential treatments. However, identified biomarkers have a limited use in the clinical 
examination yet and bear significance primarily for research purposes6–9. Current biomarkers 
proposed for the diagnosis of AD include changes in brain inflammatory cells, changes in 
perfusion and metabolism on positron emission tomography, structural changes using MRI, 
changes in cytokine, tau and amyloid protein levels in blood and cerebrospinal fluid2,10–12. Most 
of these parameters are not easily obtained and the techniques are not widely available in hospitals 
and clinics. In addition, they are expensive and require complex technical set up. 
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Markers of neuroinflammation, or the inflammatory process in the brain, are of special interest. 
Neuroinflammation, mainly regulated by microglia and astrocytes, is one of the features of 
pathological processes that occur in metabolic disorders in the elderly, including obesity and 
metabolic syndrome (MetS) 13,14. Neuroinflammation  is also a common process in 
neurodegenerative diseases, including AD in which it is thought to be implicated at early stages of 
the development and progression of the disease 15–18.  
White matter pathology, including inflammatory changes, appears to be a promising candidate for 
early treatment and prevention. White matter abnormalities are often visualized as hyperintensities 
(WMH) on MRI scans in individuals from the elderly population and are thought to be 
characterized by excessive neuroinflammation and glial activation as well as by loss of myelin and 
axonal fibers, however, the particular pathology and chronological events might differ with the 
specific disease19–21. These abnormalities increase with aging, are often present in the prodromal 
phase of AD 22,23, mild cognitive impairment (MCI)24 and in patients with MetS 25, and have been 
shown to highly correlate with cognitive decline and, moreover, occur well before symptoms of 
cognitive deterioration become evident 22,26.  
Potential biomarkers of these WMH include increased blood insulin levels and hypertension, 
which represent individual components of MetS27. Blood IL-8 levels were found to be associated 
with the WMH particularly in AD pointing to a potential inflammatory basis of this pathology28. 
The presence of WMH, however, might indicate more advanced changes to the white matter, thus, 
investigation into the early pathological events, such as white matter inflammation, and their 
markers is needed. 
Neuroinflammation, as a feature of both AD and MetS, and represents a risk factor for MCI and 
AD, and also appears to be a shared pathology between these disorders. AD and MetS are often 
coexisting in human population and neuroinflammation is suggested to be a point of their 
interaction 29,30. This interaction between pre-AD and MetS was recently demonstrated in our study 
of a novel human amyloid precursor protein (hAPP) transgenic (TG) rat model of early AD 
(APP21) and a hypercaloric diet (HCD) induced obesity and MetS. The combination of prodromal 
AD and MetS resulted in a larger increase in neuroinflammation, specifically in the white matter 
throughout the entire brain primarily driven by OX-6+ activated microglia of the comorbid animals 
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compared to either condition alone. This increase in white matter neuroinflammation was 
accompanied by spatial reference memory impairment in the comorbid group compared to the 
control animals and occurred in the absence of neuronal loss in the hippocampus suggesting that 
white matter neuroinflammation in particular could be one of the early brain pathologies 
contributing to cognitive deficits observed in MCI and dementia, including AD cases. 
The results summarized above suggest the importance of finding potential biomarkers of the 
neuroinflammatory process, including those specific to the white matter, to identify a population 
at risk for dementia and to be able to intervene and prevent further development of cognitive 
decline. Thus, an examination of the relationship between changes in metabolism and/or 
physiological markers associated with MetS and early signs of white matter inflammation in a 
prodromal AD model could be an important first step in developing an understanding of potential 
biomarkers for AD pathology at specific stages.  
In this study, we performed an analysis of the relationships between systemic blood based 
metabolic changes and physiological parameters with activation markers of the key brain 
inflammatory cells, microglia and astrocytes, in the white matter. This would enable the 
identification of potential measurable indicators, biomarkers or precursors to brain pathogenic 
white matter inflammatory processes. Using the measures collected from our pre-clinical model, 
we focused on those which are easy to obtain in the clinical setting. We also analyzed the 
relationship between behavioral performance and white matter inflammation. 
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5.2 Methods 
5.2.1 Animals and Diets 
All animal handling and experimental procedures were approved by Western University Animal 
Care Committee (AUP 2008-113, 2014-016) and were carried out in accordance with the 
guidelines of the Canadian Council on Animal Care and National Institute of Health Guides for 
the Care and Use of Laboratory Animals.  
These results were drawn from 2 cohorts of animals. The first comprised a total of 24 male 
wildtype (WT) and 22 APP21 TG Fischer 344 rats 8.5-9 months old at the start of experiment 
involved in a study of the characterization of the comorbid model of pre-AD and MetS. Additional 
animals were included in the analysis from a second study investigating the therapeutic effect of 
the anti-inflammatory prodrug using the same model of Mets and pre-AD and involved a total of 
15 male WT and 11 TG rats 10-10.5 months of age. Rats were bred in house with original breeding 
pairs obtained from Drs. Yuksel Agca and Cansu Agca (University of Missouri, Colombia, MO, 
USA) and confirmed to be homozygous 31,32. Animals were housed in pairs under standard 
conditions (12:12 light/dark cycle, at 22-24°C). A subset of rats of each genotype was randomly 
assigned to a high-calorie Western type diet (D12079B, Research Diets, Inc) supplemented with 
20% corn syrup drink (HCD), while the other half continued on a standard diet (control diet, CD; 
Prolab RMH 3000 5P00). Diets were provided ad libitum and rats were maintained on the diets 
for 12 - 15 weeks.  
For this correlational analysis, rats from both studies were combined for the same parameter with 
an exception of glucose and insulin metabolism measures with the following numbers for each 
experimental group: WT CD n=21, TG CD n=16, WT HCD n=18, TG HCD n=17. 
 
5.2.2 Physiological and Metabolic Measurements  
Detailed methodology can be found in the original studies. Briefly, the body weight at the end of 
the experiment was recorded and epididymal fat pads were collected and weighed at the time of 
euthanasia. The latter was used as a measure of visceral adiposity. Glucose metabolism was 
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assessed using the glucose tolerance test (GTT) at 11-12 week following the change in diets, with 
either the intraperitoneal (Ip; IpGTT) or intravenous (Iv; IvGTT) version of the test. Fasting serum 
insulin levels were determined and the homeostasis model assessment index (HOMA-IR) of 
insulin resistance was calculated for a subset of rats 33. Fasting serum lipid profile analysis included 
measurements of triglycerides, total cholesterol, calculations of non - high density lipoprotein 
(non-HDL) cholesterol and cholesterol ratio (Chol:HDL ratio; total cholesterol/ HDL cholesterol) 
which is an “atherogenic” index used clinically to assess cardiovascular risks34.  
 
5.2.3 Behavioral Testing 
The Morris Water Maze test (MWM), in which rats were trained over 4 days to find a hidden 
escape platform in a circular pool using extra-maze cues and then tested in a probe trial with no 
platform, was used to assess spatial navigation and reference memory. In the first study, rats were 
exposed to initial training before the dietary assignment, then underwent re-learning of the novel 
platform location at the end of experiment with a probe trial following a day after. In the second 
study rats received training only at the end of dietary treatment which was again followed by a 
probe trial. Spatial reference memory was evaluated during the probe trial using time and distance 
spent searching for a platform in the target zone where it used to be located expressed as a 
percentage of the total probe swim. Rats from the second study were then challenged with a 
modified 3-day shifting strategy task in which platform location was changed every other day and 
spatial working memory (cognitive flexibility) was assessed using differences in time and distance  
(i.e. path length) to reach the platform in trials 1 and 2 of the task 35,36. 
 
5.2.4 Immunohistochemistry 
Following a 12-h fasting period all the rats were euthanized by a pentobarbital overdose and 
sequentially perfused with phosphate buffered saline and 4% paraformaldehyde (PFA). Coronal 
sections of 30-35 μm thickness were immunohistochemically processed to visualize activated 
microglia and astrocytes using monoclonal antibodies directed against the MHC II receptor (OX-
6; 1:1000; BD Pharmingen, Mississauga ON, Canada) and glial acidic fibrillary protein (anti-
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GFAP; 1:2000; Sigma-Aldrich, St Louis MO, USA), respectively. Areas of interest included the 
entire body (BCC) and periventricular regions (PVCC) of the corpus callosum as well as the 
internal capsule (IC) in both hemispheres. Area coverage by a positive signal (area%) was 
measured for each region in the Image J software and expressed as a weighted average. Detailed 
protocols are described elsewhere. 
 
5.2.5 Data Analysis 
Statistical analysis was performed using IBM SPSS software. Statistical analysis was done on the 
entire set of data including all rats, on the data sets separated based on either genotype or diet and 
on individual experimental groups. Data for each measured parameter was first screened for 
outliers using 2SD±mean rule. All measures were checked for normality using the Shapiro-Wilk 
test. For the interregional white matter inflammation correlation, a partial correlation analysis was 
performed on the entire dataset controlling for diet and genotype. Statistical significance was set 
at a p value of ≤ 0.05. 
Firstly, correlations were computed for each behavioral outcome and white matter inflammatory 
marker to assess the relationship between the cognitive performance and cerebral pathology. 
Bivariate correlation matrix was created next to define potential predictors (independent variables) 
of the white matter inflammatory cellular pathology (dependent variable) from the measured 
peripheral outcomes to be included in the regression model. Independent variables that were 
making significant contributions to the explanation of the variance of the dependent variable were 
selected based on the correlation coefficient significance. Individual linear regressions were 
performed with each independent variable to model its relationship with dependent variable, the 
white matter inflammatory parameter. Single input models were compared between each other to 
identify a better model. Multiple linear regression analysis was next performed with low or non-
correlated independent variables to establish whether any model including more than one 
independent variable explains the variance of the dependent variable better and improves over 
models with a single entered component. Assumptions for linear regression were checked for each 
model: linearity of relationship between independent variable and dependent variable using 
scatterplots; independence, normality of distribution, linearity and homoscedasticity of residuals 
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using normal probability plot, standardized predicted values over standardized residuals 
scatterplot, Durbin-Watson test; multicollinearity using VIF, tolerance values, coefficients from 
bivariate correlation matrix. Models were compared by number of parameters including F statistics 
of overall significance of the model (p value), standard error estimate, t value, standardized 
coefficients (β) and adjusted R2. 
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5.3 Results 
5.3.1 White matter inflammation relationships 
Microglia activation throughout the brain of individual rats assessed using OX-6 immunomarker 
was highly positively correlated across examined white matter regions: BCC and PVCC 
Spearman’s rho=0.982, p<0.0001; BCC and IC rho=0.813, p<0.0001; IC and PVCC rho=0.810, 
p<0.0001. This relationship held true while controlling for genotype and diet (Table 5-1). In the 
individual groups, the BCC region activated microglia coverage was highly correlated with PVCC 
(r>0.9, p<0.0001) and IC (r>0.78) for all groups except WT CD, that did not show any significant 
relationship with the IC region inflammation. All groups with an exception of control rats on the 
CD had a PVCC-IC significant positive correlation (r>0.65, p<0.009).  
Astrocyte reactivity in the BCC measured by GFAP(+) signal area coverage (%) of the region 
positively correlated with the OX-6 activated microglia coverage in the BCC in the entire dataset 
(rho=0.36, p=0.004). When genotype and diet were entered as controlling factors, the correlation 
lost significance. Thus, this relationship was due to both inflammation makers correlated with the 
particular genotype and diet. Individual experimental group analysis revealed that the correlation 
between these two inflammatory markers in the BCC region was significant only in the comorbid, 
TG HCD, group (r=0.517, p=0.04). 
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Table 5-1. Correlation of microglia activation in the cerebral white matter 
 BCC PVCC Internal capsule 
 BCC - 0.974 
<1.2e-38 
0.835 
3.067e-018 
PVCC  - 0.819 
2.064e-016 
 
Strong positive correlation suggests that activation of white matter microglia increased globally 
throughout individual rat brains for both wildtype and transgenic rats on either control or 
hypercaloric diet. Pearson’s coefficient (r) and corresponding p values are shown for correlations 
of OX-6+ microglia (area%) between ROIs. Partial correlation was performed controlling for 
genotype and diet; n=66. BCC − corpus callosum body, PVCC − corpus callosum periventricular 
sub-regions, ROI − region of interest.  
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5.3.2 Behavioral performance and white matter inflammation relationships 
Linear regression analysis was performed to test whether the spatial reference memory probed in 
the MWM at the end of study in each of the protocols was related to the white matter microglial 
activation level.  The relationships with the target zone swim parameters were analyzed. The 
combined dataset showed a negative relationship between OX-6 microglia coverage in IC and the 
distance travelled in the target zone out of the total probe swim path (r=-0.368, p=0.015, 
F(1.42)=6.427, R
2=0.114) in the re-learning paradigm. This suggests a better behavioral 
performance (i.e. better spatial memory), as represented by the greater distance travelled searching 
in the target zone of the pool, is associated with a lower white matter microglial activation in the 
IC region. This relationship was not observed within either individual genotype subsets or 
individual experimental groups, however it appeared in the HCD subset and maintained the 
directionality and strength of significance (r=-0.53, F(1.19)=7.427, p=0.013, R
2=0.281). Astrocyte 
reactivity in the white matter was not associated with any parameter of the cognitive function. 
Analysis of the groups also indicated specific relationships between behavior and 
neuroinflammation. Time spent searching in the target zone, expressed as a percentage of the total 
probe trial time, was strongly inversely correlated with microglial activation in the BCC for TG 
HCD. This suggests there is a poorer cognitive performance on the test with increase in microglial 
activation in the BCC (Table 5-2). This was observed in the second study subgroup (n=6) of rats 
for which this was a first ever encounter with the maze. In this rat group, a significant negative 
linear relationship was also found between OX6-positive microglia area coverage in the BCC and 
shifting strategy task performance. Thus, comorbid rats tended to have a smaller intertrial 
difference in the swim path, a smaller improvement, that suggested they were less cognitively 
flexible, when the activation level of the microglia in the BCC was higher (Table 5-2). In contrast 
to these results, TG CD rats (n=4) showed a very strong positive correlation (r=0.96, F(1.)=35.193, 
p=0.01, R2=0.895), suggesting a greater performance associated with the greater inflammation in 
the white matter of the corpus callosum.  
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Table 5-2. Relationship of the behavioral performance in the MWM of TG HCD rats with OX-
6 microglial activation in the BCC 
 Pearson’s r Adjusted R2 p F 
MWM shifting Δ distance*  -0.836  0.624 0.038 9.315  
MWM target zone time (%,s)* -0.897 0.756 0.015 16.467 
 
MWM − Morris water maze; TG HCD − transgenic rats on the hypercaloric diet (comorbid group); 
* results of the second study only (n=6); shifting Δ distance – 3- day average difference in distance 
(path length) to reach the hidden platform between trials 2 and 1 with a greater value indicating a 
better cognitive performance.
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5.3.3 Metabolic, physiological parameters and white matter microgliosis relationships  
Correlations and linearity of the relationship of OX-6 positive activated microglia coverage in each 
of the three different white matter regions (BCC, PVCC, IC) were done individually for each 
measurement and included an examination of the whole dataset as well as genotype, diet and 
specific group analyses (Table 5-3).  
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Table 5-3. Metabolic measures and white matter microgliosis correlations 
 Genotype Diet  Body weight Visceral Fat Total 
Cholesterol 
Triglycerides Non-HDL 
Cholesterol 
Chol:HDL AUC GTT Fasting 
Insulin; 
HOMA-IR 
Entire Dataset 
BCC β=0.513 
F(1,64)=22.839  
p<.0001 
R2=0.263 
β=0.341 
F(1,64)=5.711 
p=0.005 
R2=0.102 
β=0.376 
F(1,64)=10.558 
p<0.0001 
R2=0.244 
β=0.494 
F(1,64)=22.701 
p=0.002 
R2=0.128 
β=0.293 
F(1,62)=5.824 
p=0.019 
R2=0.071 
 
     
PVCC β=0.543 
F(1,64)=26.695 
p<0.0001 
R2=0.294 
β=0.363 
F(1,64)=9.708 
p=0.003 
R2=0.132 
β=0.398 
F(1,64)=12.045 
p=0.001 
R2=0.158 
β=0.516 
F(1,64)=23.184 
p<0.0001 
R2=0.266 
β=0.334 
F(1,62)=7.803 
p=0.007 
R2=0.112 
 
 β=0.31 
F(1,62)=6.579 
p=0.013 
R2=0.096 
   
IC β=0.352 
F(1,63)=34.227 
p<0.0001 
R2=0.352 
 β=0.004 
F(1,63)=8.38 
p=0.005 
R2=0.117 
β=0.436 
F(1,63)=14.78 
p<0.0001 
R2=0.19 
β=0.282 
F(1,61)=5.279 
p=0.025 
R2=0.08 
 β=0.256 
F(1,61)=4.266 
p=0.043 
R2=0.05 
   
Presence of Transgene (TG rat dataset) 
BCC  β=0.396 
F(1,30)=5.58 
p=0.025 
R2 =0.129 
 
 β=0.482 
F(1,30)=9.072 
p=0.005 
R2 =0.207 
      
PVCC  β=0.463 
F(1,30)=8.166 
p=0.008 
R2=0.188 
 
 β=0.534 
F(1,30)=11.937 
p=0.002 
R2 =0.261 
      
IC    β=0.37 
F(1,29)=4.59 
p=0.041 
R2 =0.107 
      
HCD Dataset 
BCC β=0.547 
F(1,31)=13.255, 
  β=0.109 
F(1,31)=6.038 
    (Iv) β=-0.802 
F(1,9)=16.192 
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p=0.001 
R2=0.3 
p=0.02 
R2=0.136 
 
p=0.003 
R2=0.603  
 Genotype Diet  Body weight Visceral Fat Total 
Cholesterol 
Triglycerides Non-HDL 
Cholesterol 
Chol:HDL AUC GTT Fasting 
Insulin; 
HOMA-IR 
PVCC β=0.611 
F(1,32)=19.06 
p=0.008 
R2=0.373 
  β=0.506 
F(1,32)=11.038 
p=0.002 
R2=0.233 
 
    (Ip) β= -0.442 
F(1,21)=5.088 
p=0.035 
R2=0.157 
 
IC β=0.588 
F(1,31)=16.391 
p<0.0001 
R2=0.325 
  β=0.105 
F(1,31)=7.553 
p=0.002 
R2=0.233 
    (Iv) β=-0.726 
F(1,9)=10.049 
p=0.011 
R2=0.475  
(Ip) β=-0.464 
F(1,20)=5.491 
p=0.03 
R2=0.176  
 
Co-morbid TG HCD Dataset 
BCC   β= -0.522 
F(1,13)=5.711 
p=0.033, 
R2=0.252 
 
 β= -0.623 
F(1,13)=8.226 
p=0.013 
R2=0.34 
β= -0.637 
F(1,13)=8.895 
p=0.011 
R2=0.361 
β= -0.64 
F(1,13)=9.015 
p=0.01 
R2=0.364 
β= -0.639 
F(1,14)=9.679 
p=0.008 
R2=0.367 
 β= -0.671 
F(1,7)=5.718 
p=0.048 
R2 =0.371 
 
HOMA-IR 
β= -0.681 
F(1,7)=6.069 
p=0.043 
R2=0.388 
 
PVCC     β= -0.638 
F(1,14)=9.604 
p=0.008 
R2=0.365 
β= -0.635 
F(1,14)=9.47 
p=0.008 
R2=0.361 
 β= -0.658 
F(1,15)=11.465 
p=0.004 
R2=0.396 
 β= -0.744 
F(1,8)=9.911 
p=0.014 
R2 =0.198 
 
HOMA-IR 
β= -0.743 
F(1,8)=9.87 
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p=0.014 
R2=0.496 
 
 Genotype Diet  Body weight Visceral Fat Total 
Cholesterol 
Triglycerides Non-HDL 
Cholesterol 
Chol:HDL AUC GTT Fasting 
Insulin; 
HOMA-IR 
TG CD Dataset 
IC 
 
 
    
  (Iv) β= -0.619 
F(1,3)=14.315 
p=0.032 
R2=0.306 
β= -0.814 
F(1,8)=15.722 
p=0.004 
R2 =0.621 
  
HOMA-IR 
β= -0.76 
F(1,8)=10.92 
p=0.011 
R2=0.524 
 WT rat Dataset 
BCC  β=0.559 
F(1,30)=13.651 
p=0.001 
R2=0.29 
β=0.516 
F(1,30)=10.87 
p=0.003 
R2=0.242 
β=0.561 
F(1,30)=13.791 
p=0.001 
R2=0.292 
 β=0.425 
F(1,30)=6.605 
p=0.015 
R2=0.153 
β=0.439 
F(1,30)=7.177 
p=0.012 
R2=0.166 
β=0.544 
F(1,30)=13.302 
p=0.001 
R2=0.284 
(Ip) β=0.531 
F(1,30)=7.462 
p=0.013 
R2=0.244 
 
 
PVCC  β=0.517 
F(1,30)=10.922 
p=0.002 
R2=0.242 
 
β=0.479 
F(1,30)=8.955 
p=0.005 
R2=0.204 
β=0.523 
F(1,30)=11.279 
p=0.002 
R2=0.249 
 β=0.544 
F(1,30)=5.548 
p=0.025 
R2=0.128 
β=0.43 
F(1,30)=6.816 
p=0.014 
R2=0.158 
β=0.544 
F(1,30)=12.587 
p=0.001 
R2=0.272 
  
IC  β=0.585 
F(1,30)=15.648 
p<0.0001 
R2=0.321 
β=0.493 
F(1,30)=9.612 
p=0.004 
R2=0.243 
β=0.502 
F(1,30)=10.104 
p=0.003 
R2=0.227 
 β=0.439 
F(1,30)=7.147 
p=0.012 
R2=0.165 
β=0.377 
F(1,30)=4.974 
p=0.033 
R2=0.114 
β=0.382 
F(1,30)=5.122 
p=0.031 
R2=0.117 
  
 
Only significant correlations at a significance level of <0.05 are shown for OX-6+ activated microglia (area% coverage of the white matter region) in the 
corpus callosum (BCC, PVCC) and IC. Transgene in this context is human amyloid precursor protein with Swedish and Indiana mutations. β − 
standardized coefficient (Pearson’s R), R2 − adjusted R2. BCC − corpus callosum body, CD − control diet, PVCC − corpus callosum periventricular sub-
regions, HCD − hypercaloric diet, HOMA-IR − homeostasis model assessment index of insulin resistance, IC − internal capsule, Ip − intraperitoneal 
glucose tolerance test, Iv − intravenous glucose tolerance test, TG − transgenic rat, WT − wildtype. 
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5.3.3.1 Corpus callosum  
When the entire dataset was used, there were several factors that were significant predictors of the 
BCC microglial activation. These included genotype (β=0.513, R2=0.263); visceral fat 
accumulation (β=0.494, R2=0.128; 5-1A); and diet (β=0.341, R2=0.102). Final body weight was a 
less strong predictor (β=0.376, R2=0.244). Total cholesterol levels had a weak, yet significant 
positive association and the lowest prediction power (β=0.293, R2=0.071). When visceral fat mass 
and genotype were considered together, both genotype and visceral fat were significant predictors 
of microglial activation in the BCC (β=0.401 fat and β=0.425 genotype) and together they 
strengthened the regression model (F(2,62)=22.452, p<0.0001, R
2=0.398). 
The data set was then split in two groups based the presence of transgene (WT or TG) for one set 
and based on the diet (CD and HCD) for another analysis. The regression analysis indicated 
visceral fat accumulation was the strongest significant predictor in both genotypes (Figure 5-1B) 
and correlated in a positive manner in the HCD rat subset (Figure 5-1C). Genotype remained a 
significant predictor of BCC neuroinflammation in both dietary datasets. Additionally, weaker 
correlations that were also significant were detected for body weight, non-HDL cholesterol, 
triglycerides and for the GTT, including area under the curve (AUC) for glucose levels using the 
IpGTT in the WT subset and AUC using the IvGTT method in the HCD group.  
Thus, genotype was strongly associated with the microglia activation in the BCC in every dataset. 
Among the measured parameters, visceral fat mass was associated with a greater BCC microglia 
activation irrespective of the genotypic characteristics, however was predictive of it only in the 
HCD environment.  
Analysis of the entire dataset indicated significant predictors of the PVCC microglial activation 
included genotype (β=0.543, R2=0.294); visceral fat mass (β=0.516, R2=0.266; Figure 5-1D); body 
weight (β=0.398, R2=0.158); and diet (β=0.363, R2=0.132). Weaker, but significant, relationships 
were also seen with total cholesterol and non-HDL cholesterol levels. When visceral fat mass and 
genotype were both included in the regression model, it improved and both genotype and fat were 
still significant individual predictors (β=0.417 fat and β=0.451 genotype, F(2,62)=26.787, p<0.0001, 
R2 =0.442).  
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In the WT data sample, cholesterol ratio, visceral fat (Figure 5-1E), body weight, diet as well as 
non-HDL cholesterol and triglycerides each had a significant contribution to the variance of the 
microglial neuroinflammation.  The strongest association with microglial activation was with the 
Chol:HDL ratio, which had a better prediction capacity (β=0.544, R2=0.272) than body fat 
(β=0.523, R2=0.249). The strongest relationship with the OX-6 microglial activation in the PVCC 
region in the TG rat sample was found with the body fat mass (β=0.534, R2=0.261; Figure 5-1E). 
In both HCD and CD environments genotype was the strongest factor significantly related to the 
inflammation in the PVCC. In addition, the amount of visceral fat was the next strong predictor 
after the genotype in the HCD subset mass (β=0.506, R2=0.233; Figure 5-1F), followed by the 
AUC in the IpGTT.  
 
5.3.3.2 Internal capsule  
Microglia activation in the IC region was associated with the genotype as the strongest factor for 
the entire rat dataset (β=0.352, R2=0.352) as well as both dietary subgroups (CD β=0.681, 
F(1,31)=24.433, p<0.0001, R
2=0.463; HCD β=0.588, R2=0.325). For metabolic measures visceral 
fat showed the strongest relationship with neuroinflammation in the entire dataset (β=0.436, 
R2=0.19; Figure 5-1G) and HCD subset (β=0.105, R2=0.233; Figure 5-1I). Body weight and diet 
showed much weaker, yet significant correlation in the whole sample regression analysis. Total 
cholesterol and non-HDL fraction were also positively but weakly correlated to the inflammation.  
Multiple regression model which included both genotype and fat mass showed an increased 
precision with both variables contributing significantly to the variation in the inflammation 
(R2=0.45; β=0.321 fat and 0.523 genotype, F(2,62)=25.383, p<0.0001). Visceral fat was 
significantly correlated with the IC activated microglial coverage in both genotypes with a stronger 
relationship of the fat amount in WT rats (Figure 5-1F). Additional correlations indicated that diet 
was the strongest predictor (β=0.585, R2=0.32), while Chol:HDL ratio, body weight, non-HDL 
cholesterol and triglycerides which were the weakest and poorly explained the variance of 
inflammatory outcome in the WT rat subset. In the HCD subset the measure of AUC in IvGTT or 
AUC in IpGTT were identified as having a negative correlation with IC microgliosis (AUC IvGTT, 
β=-0.726, R2=0.475; AUC IpGTT, β=-0.464, R2=0.176).  
195 
 
Thus, transgene presence and HCD was associated with the greater microglia activation in the 
corpus callosum, both in the body and periventricular regions, and the IC. Greater visceral fat mass 
was associated with a greater microglia activation in all three white matter regions analysed 
irrespective of the genotypic characteristics, however was predictive of it only in the HCD 
environment. 
 
5.3.3.3 Relationships in individual experimental groups 
Group-wise linear regressions on the BCC activated microglia coverage identified candidate 
parameters only in the comorbid (TG HCD) group.  
Figure 5-2 indicates there was a strong negative correlation with final body weight (β=-0.522, 
p=0.033); fasting total cholesterol  levels (β=-0.623, p=0.013); triglycerides (β=-0.637, p=0.011); 
non-HDL cholesterol (β=-0.64, p=0.01); Chol:HDL (β=-0.639, p=0.008) and fasting insulin levels 
(β=-0.671, p=0.048). 
Linear regression analysis indicated that a lower Chol:HDL ratio was the best predictor of 
increases in the BCC microglial activation level in the comorbid rats (β=-0.639, R2=0.367). This 
was also true for the PVCC brain region for which Chol:HDL ratio model produced a strong 
negative relationship (β=-0.658, R2=0.396).  
For inflammation in the IC, group-wise linear regressions indicated a relationship with fasting 
insulin (β=-0.814, R2=0.621); HOMA-IR (β=-0.76, R2=0.524); and AUC IvGTT (β=-0.619, 
R2=0.306) in the TG CD group.  
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Figure 5-1. Relationships between visceral fat accumulation and white matter activated 
microglia. Visceral fat pads mass indicated as fat pad weight and OX-6+ activated microglia 
coverage expressed as percent of the total area of the white matter structure in A-C) BCC; D-F) 
PVCC; G-I) IC regions. Significant linear relationships were found for the datasets: A) entire set 
(R2=0.128, p=0.002); B) TG (R2=0.207, p=0.005) and WT (R2=0.292, p=0.001); C) HCD 
(R2=0.136, p=0.02); D) entire set (R2=0.266, p<0.0001); E) TG (R2=0.261, p=0.002) and WT 
(R2=0.249, p=0.002); F) HCD (R2=0.233, p=0.002); G) entire set (R2=0.19, p<0.0001); H) TG 
(R2=0.107, p=0.041)  and WT (R2=0.227, p=0.003); I) HCD (R2=0.233, p=0.002). Black and 
colored solid lines on each graph show linear regression line. Dotted lines indicate 95% confidence 
interval of linear regression. BCC = body of the corpus callosum, PVCC = periventricular regions 
of the corpus callosum, IC = internal capsule regions. 
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Figure 5-2. Relationships in the comorbid group between metabolic measures and microglia 
activation in the corpus callosum. Significant relationships between BCC OX-6 activated 
microglia coverage expressed as percent of the total region’s area and A) end of experiment body 
weight (R2=0.252, p=0.033), B) serum fasting total cholesterol (R2=0.34, p=0.013), C) non-HDL 
cholesterol (R2=0.364, p=0.01), D) Chol:HDL ratio (total cholesterol/HDL cholesterol); 
(R2=0.367, p=0.008), E) triglycerides (R2=0.361, p=0.011), F) fasting insulin levels (R2=0.371, 
p=0.048). The results are from the co-morbid model of transgenic rats on the hypercaloric diet (TG 
HCD). BCC = body of the corpus callosum, Chol = cholesterol, HDL = high density lipoprotein 
cholesterol. R2 = adjusted R2. 
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5.3.4 Metabolic, physiological measures and white matter astrocyte reactivity relationships 
Correlations and linearity of relationship of the GFAP activated astrocytes in the BCC and IC 
regions were done individually for each measurement and included whole dataset, genotype, diet 
and individual group analyses.  
Astrocyte reactivity in the BCC was related to the genotype when analyzing the entire dataset 
(β=0.292, F(1,60)=5.591, p=0.021, R2=0.085). Astrocytosis in the corpus callosum was inversely 
related only to the glucose metabolism, AUC IvGTT, in the data subsets from CD (β=-0.743, 
F(1,9)=11.101, p=0.009, R
2=0.503) and TG (β=-0.754, F(1,9)=11.852, p=0.007, R2=0.520) rat groups 
(Figure 5-3A). 
Reactive astrocytosis in the IC was inversely associated with the glucose metabolism, AUC Ip 
GTT, in the entire group of all rats (β =-0.625, F(1,13)=8.351, p=0.013, R2=0.391), WT (β=-0.813, 
F(1,5)=9.750, p=0.026, R
2=0.593) and HCD subsets (β=-0.792, F(1,5)=8.343, p=0.034, R2=0.628); 
(Figure 5-3B). The WT rat subset had negative significant, but weak relationships with body 
weight, visceral fat and Chol:HDL ratio.  
The TG CD group showed a strong inverse association between the AUC IvGTT and GFAP BCC 
coverage (β =-0.976, F(1,2)=40.682, p=0.024, R2=0.93). 
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Figure 5-3. Relationships between glucose tolerance and reactive astrocytes in the body of 
the corpus callosum and internal capsule. Glucose tolerance presented as glucose AUC in the 
GTT with greater AUC numbers corresponding to low glucose tolerance. GFAP+ reactive 
astrocyte coverage expressed as percent of the total area of A-C) body of the corpus callosum and 
D-F) internal capsule regions. Significant relationships between glucose intolerance and astrocyte 
reactivity are shown for the datasets: A) TG CD individual group (β =-0.976, p=0.024, R2=0.93); 
B) TG combined set (β=-0.754, p=0.007, R2=0.520); C) CD combined set (β=-0.743, p=0.009, 
R2=0.503); D) entire set (β =-0.625, p=0.013, R2=0.391); E) WT combined set (β=-0.813, 
p=0.026, R2=0.593); F) HCD combined set (β=-0.792, p=0.034, R2=0.628). AUC = area under 
the curve, CD = control diet, GTT = glucose tolerance test using intravenous (IvGTT) or 
intraperitoneal (IpGTT) method, HCD = hypercaloric diet, TG = transgenic, WT = wildtype. Solid 
lines on each graph represent linear regression lines. Dotted lines indicate 95% confidence interval 
of linear regression. R2 = adjusted R2. 
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5.4 Discussion 
This investigation was directed toward identifying potential markers of the cerebral white matter 
inflammation in prodromal AD by studying associations between metabolic parameters and 
cerebral white matter activated microglia and astrocytosis in APP21 TG and MetS rat models, 
alone or in combination.  
First it was determined whether there is any association between the neuroinflammatory markers 
and outcomes of behavioral tests utilized to assess spatial reference and working memory. White 
matter activated microglia, but not astrocyte reactivity, showed correlations with the cognitive 
performance. The general trend was indicative of an inverse correlation, i.e. a better cognitive task 
performance was associated with a lower white matter microglial activation. Interestingly, specific 
group analysis revealed differences in directionality of the relationship. The comorbid rats, TG on 
the HCD, followed the general trend. Unlike the general trend of an inverse correlation, the TG 
CD group had a very strong positive correlation, suggesting a greater performance associated with 
the greater neuroinflammation. These observations, however, should be treated with caution as the 
analysis was limited by the low sample size since the behavioral protocols were different for the 
two cohorts of animals.  
Linear regression examined the relationship of metabolic measures with microgliosis and 
astrocytosis in the corpus callosum and internal capsule. Microgliosis was strongly associated with 
the amount of visceral fat and lipid metabolism, whereas astrocytes reactivity was correlated with 
glucose metabolism. In addition, genotype appeared to be the leading predictor in the degree of 
neuroinflammation in every region, in this case the transgene was the hAPP with Swedish and 
Indiana mutations associated with early familial AD (APP21). These animals have high APP and 
amyloid beta proteins in the brain31,37 and develop increased white matter microglial activation 
with aging and with the HCD in our studies36. 
The most profound metabolic predictor of an increase in microglia activation in both white matter 
regions was greater visceral fat mass. The association between visceral adiposity and WMH have 
also been observed in humans 38–40. This seems to be in line with the notion of obesity as a systemic 
low-grade inflammatory condition and increased visceral fat accumulation as an active pro-
inflammatory secreting tissue influencing inflammatory status in the brain41,42. The amount of 
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visceral fat together with the transgene demonstrated the greatest contribution to the white matter 
microglial activation.  
Correlations with lipid profile parameters, including total cholesterol, atherogenic fraction and 
triglycerides levels indicated these parameters were also possible contributors to the amount of 
microgliosis, although not to the same extent as visceral fat, body weight or genotype. In the 
combined datasets, hyperlipidemia was significantly associated with higher levels of microglia 
activation in the white matter, a phenomenon which is associated with AD pathogenesis. This data 
fits one of the existing patterns observed in epidemiological studies which related high levels of 
total cholesterol, LDL-cholesterol and triglycerides, low HDL levels in mid-life with the greater 
risk of AD development43–45.  
There appeared to be different associations when the individual set of comorbid rats was compared 
to the combined dataset. This relationship was inversed in the TG HCD group, suggesting a 
negative association between blood lipids and white matter microgliosis in comorbidity condition. 
Such negative relationship between lipid profile and WMH load, although not significant, was 
noted in a sample of cognitively normal middle-aged subjects with a family history of AD, the 
majority of whom also had MetS 27.  
The strongest predictor of the OX-6 activated microglia accumulation in the corpus callosum for 
the comorbid rat sample was Chol:HDL ratio, which represents the ratio of two main cholesterol 
fractions, HDL and atherogenic non-HDL. A higher lipid ratio, which is observed in metabolic 
disorders, and is generally related to a greater risk for cardiovascular disease and dementia, was 
associated with lower levels of white matter microgliosis in comorbid group. Analysis of the lipid 
profile of our comorbid rats have indicated that these rats had blood levels of the HDL cholesterol, 
similar to that of CD rats. However, total cholesterol and the Chol:HDL ratio was significantly 
greater compared to controls, which suggests that the increase in the ratio was due to the greater 
non-HDL fraction. 
The literature provides evidence of the cholesterol paradox in the AD relationship46–50. The 
inconsistency of results regarding cholesterol association with AD points to a differential 
association with respect to the age of subjects and possibly even the stage of the disease. High 
blood total cholesterol and non-HDL cholesterol fractions are associated with decreased risk of 
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AD, particularly in the subjects of a greater age, whereas the opposite relationship is seen in middle 
age51–53. This could be due to observed declines in cholesterol along with higher energy demands 
of the brain with increased age54. Moreover, lower serum cholesterol levels were observed in AD 
patients a decade prior to the clinical onset, suggesting lower cholesterol levels are associated with 
the prodromal stage of the disease55.  
With respect to the white matter, axonal myelin sheaths are highly enriched by lipids and loss of 
membrane cholesterol and gangliosides along with myelin degradation and low biosynthesis all 
have been associated with aging and AD pathology56–59. It is possible, that increased cholesterol 
levels might counterbalance these effects. Thus, the analysis of the association between MRI-
detected white matter lesions and cardiovascular risk factors in the elderly participants of the 
Cardiovascular Health Study, showed a significant progression of the white matter lesions over 
time in participants with high HDL and low LDL blood cholesterol levels as well as with the use 
of statins60. In another study dyslipidemia (high triglycerides and low HDL cholesterol levels) 
were found to be positively associated with healthy white matter microstructure in generally 
healthy adults61.  
Furthermore, animal studies have shown the dual role of high dietary cholesterol pointing to anti-
inflammatory effects, including promotion of M2 “anti-inflammatory” microglia phenotype and 
higher IL-4 and IL-6 levels, of higher lipid levels in the aging brain62. This could relate the higher 
total cholesterol and non-HDL levels with the lower white matter microglial activation in the 
prodromal AD model in our study.  
The genetic background of our TG rats, specifically hAPP with Swedish and Indiana mutations, 
could also contribute to the observed relationship with lipid metabolites in our model since APP 
plays a role in cholesterol metabolism63,64. One study have shown that human astrocytes 
homozygous for APP Swedish mutation lead to disrupted cholesterol metabolism in the brain, in 
particular low intracellular cholesterol levels, impaired lipoprotein endocytosis and LDL receptor 
function were seen65. These changes might contribute to AD pathology such as white matter 
degeneration. APP is widely expressed as in the brain so in peripheral tissues. It is possible that 
mutated forms might also have effects on peripheral lipid homeostasis, which are yet to be 
investigated.  
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The effects of the mid-life hypercholesterolemia, dyslipidemia and associated increased levels of 
oxidized cholesterol forms (oxysterols) might be particularly detrimental to the white matter 
health, including myelin synthesis and breakdown regulated by glia, and thus predispose to AD 
pathology later in life. Oxysterols which are able to cross the blood-brain barrier were determined 
as a potential links between diet and obesity-related dyslipidemia and AD pathogenesis including 
via their contribution to neuroinflammatory and amyloidogenic events 66–78. Treatments that lower 
cholesterol, i.e. statins, may help protect vulnerable white matter during the mid-life period, but 
can be detrimental in advanced aging and fully developed AD and thus have no effect on the 
slowing down the progression of the disease in the clinical trials54.  
Interestingly, lower astrocyte reactivity, corresponding to a lower inflammation, was observed 
with a greater glucose AUC in the GTT, i.e. glucose intolerance likely related to insulin resistance. 
This is somewhat contradictory to what is usually expected since a greater insulin resistance is 
associated with poorer brain health. However, in our study the TG rats did not develop pronounced 
glucose intolerance compared to WT rats on the HCD. Similarly, patients with AD have been 
shown to have lower rates of fasting blood glucose as well as lower glucose values in the oral 
glucose tolerance test 79.  
There are some limitations to be considered for this investigation. Firstly, the data samples 
obtained from the two animal studies were not large. This factor could decrease the precision and 
power some of the relationships, such as related to the glucose and insulin metabolism parameters 
and in specific subsets. Secondly, we have considered only a limited number of factors that could 
contribute to the brain inflammatory pathology. There might be other measures that better explain 
the variation in the white matter inflammation and which could greatly improve the prediction of 
the defined models. Thirdly, there were only two cellular markers of the neuroinflammation 
analysed in the current study based on the data derived from our initial experiments. However, 
other white matter pathological processes, including for example oligodendrocyte health, axonal 
degeneration, myelination level and vascular status that could occur at the prodromal stage of the 
disease, could have a better correlation with systemic metabolic parameters and provide a better 
explanation of the cognitive performance. Finally, microglia and astrocyte immunohistochemical 
detection was limited to examination of a single marker of each type of cell. Other markers of 
activation of these cells should be considered. 
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In summary this study highlights the potential of visceral fat accumulation and lipid metabolism 
components such as cholesterol ratio, to be markers of activation of microglia in the white matter 
in a prodromal AD model. Astrocyte reactivity, another inflammatory factor, was associated with 
the glucose metabolism and insulin resistance. More studies investigating the association between 
metabolic measures found in the blood and specific brain pathology associated with the prodromal 
stage of AD and MCI should be pursued to clarify potential relationships and their usefulness as 
minimally invasive biomarkers in various age groups. Comorbid conditions including chronic 
metabolic and vascular diseases, gender, genetic variations and attributes of certain ethnic groups 
may modulate these relationships, thus requiring even more extensive investigations in this area. 
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Chapter 6: Discussion 
6.1 Summary of Results 
The studies constituting this thesis were undertaken to enhance our understanding of the interaction 
between metabolic vascular condition and pathogenic environment of the early prodromal stage of 
AD. Specifically, the studies aimed to investigate the effects of such interaction on the white matter 
inflammation and the impact on the cognitive outcome, and to determine the potential of 
manipulating inflammation with a novel brain-targeted NSAID to prevent pathological and 
cognitive changes. A high calorie high-fat, high-sugar diet-induced MetS in the APP21 TG rat 
model of prodromal AD was used to test the research hypothesis that the comorbid condition will 
result in increased white matter inflammation and cognitive dysfunction which can be prevented 
by anti-inflammatory treatment. The following objectives were addressed:  
1) To determine the impact of comorbid MetS and increased pathogenic APP environment on 
white matter inflammation, specifically on microglia and astrocytes, and the effect on cognitive 
function; thus, defining possible targets for early therapeutic intervention (Chapter 2) 
2) To examine the therapeutic potential of a novel anti-inflammatory agent by analyzing its 
effect on white matter inflammation and cognition in the comorbid model of prodromal AD and 
MetS (Chapter 3) 
3) To analyze the possible negative effects of a brain targeted anti-inflammatory agent tested 
as a potential therapeutic strategy to target increased white matter inflammation (Chapter 4). 
4) To identify potential biomarkers of white matter inflammation by characterizing the 
relationship between white matter inflammation and systemic metabolic and physiological 
parameters (Chapter 5). 
In support of the hypothesis, the comorbid rats demonstrated increased white matter microglia, but 
not astrocyte, activation, which was accompanied by spatial reference and working memory 
deficits and cognitive inflexibility (Chapters 2 and 3). TG rats on the HCD were the only group 
demonstrating spatial reference memory consolidation deficit compared to control group of the 
wild type rats suggesting that intense white matter inflammatory response to the presence of 
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metabolic alterations could be promoting and accelerating the development of this type of 
cognitive decline (Chapter 2). These results highlighted that white matter inflammation could be 
a potential treatment target.  
Experiments to demonstrate that an anti-inflammatory agent is a potential therapeutic approach, 
did not find support in our studies. The chronic treatment with a novel NSAID KL prodrug did not 
prevent the potentiating effect of the MetS on the white matter inflammation and cognitive 
dysfunction at the prodromal AD phase (Chapter 3). Moreover, the use of this particular prodrug 
was associated with detrimental effects in several animals on cognition and cerebral homeostasis 
expressed as substantial inflammatory pathology involving both microgliosis and reactive 
astrocytosis in large regions of gray and white matter of the cerebral cortex and subcortical 
structures (Chapter 4). Additional analysis indicated that white matter inflammation, specifically 
white matter activated microglia, is found to negatively correlate with cognitive performance. A 
general trend of a better cognitive task performance was associated with a lower white matter 
microglial activation (Chapter 5).  
The data overall supports the need for further studies to clarify the potential of an anti-
inflammatory treatment. However, this research should carefully choose the types of agents and 
consider timing as well as determine the best therapeutic window. In the meantime, identifying 
biomarkers for white matter inflammation is important as it could have implications for diagnosis, 
treatment and prevention.  
The attempt to find potential biomarkers of this pathology indicated that the presence of the 
mutated form of APP and amount of fat accumulated around internal organs is highly positively 
correlated with white matter microgliosis. Blood lipid metabolism components including total 
cholesterol, atherogenic fraction, triglycerides levels and Chol:HDL  ratio were also contributors 
to the amount of microgliosis. In particular, the comorbid condition has shown a negative 
association of white matter inflammation with the lipid profile, while the entire rat sample and WT 
dataset had a positive relation. These results indicate there are complex relationships between 
blood and physiological parameters and white matter microglial activation, which are complicated 
by the coincidence of metabolic and early AD pathologies. Thus, biomarker research should 
consider the presence of comorbidities that might affect the relationship between metabolic 
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measures and cerebral pathologies and therefore have an effect on interpretation and subsequent 
clinical application of the biomarker.   
6.2 Comorbid Model of Prodromal Alzheimer’s Disease and Metabolic Syndrome 
MetS is a chronic disorder highly prevalent among the elderly which is associated with increased 
risk for and is a common comorbidity of MCI and AD1–6. It is thought that these diseases interact 
with each other and might have synergistic effect on cerebral homeostasis and cognitive 
function7,8. The exact basis of such interaction has not been conclusively defined yet. Analysis of 
pathogenetic commonalities indicates that inflammation and white matter lesions might be the 
events linking the two conditions, specifically at the early prodromal stages of AD.  
To investigate this idea we developed a preclinical model of this comorbidity in the TG rat 
overexpressing pathogenic hAPP, implicated in human FAD, which shows increased production 
of APP and Aβ levels and yet no plaque and NFT pathology9,10. Thus, these TG rats model the 
early stage of disease pathology.  
Obesity and MetS in rodents are often induced via dietary manipulation and include high-fat or 
high-carbohydrate hypercaloric diets with a various composition and macronutrient percent 
content11–13. In our studies we combined high fat, rich in saturated fat and cholesterol, food with a 
corn syrup drink, rich in simple carbohydrates, that together resulted in increased caloric value to 
closely mimic the genesis of obesity in human populations with unhealthy dietary habits11,14. 
Twelve to fifteen weeks on this HCD led to successful development of MetS in our rats. In 
particular, the following components developed: obesity, hypertriglyceridemia, increase in levels 
of total and atherogenic non-HDL cholesterol, shift towards greater Chol:HDL ratio, insulin 
resistance, hyperinsulinemia and glucose intolerance15. Comorbid rats showed greater 
dyslipidemia and only modest glucose intolerance compared to the WT rats. This smaller reduction 
in glucose tolerance compared to the WT rats is similar to observed in AD patients and could be 
related to peripheral pathogenic hAPP effects on regulation of glucose metabolism16,17. Rats of 
both genotype on the HCD also had increased visceral adiposity which was greater in TG rats, 
suggesting establishment of pro-inflammatory environment in these animals18–22. In our animals, 
HCD did not induce hypertension, a parameter that is important component of the syndrome.  
Behavioral analysis using MWM variations showed modest cognitive changes in spatial reference 
memory consolidation, spatial working memory and ability to rapidly adjust to the environmental 
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changes (i.e. cognitive flexibility) driven exclusively by HCD consumption in the TG rats with 
AD predisposition. This suggests there is a potentiating effect of comorbidity on cognitive deficits. 
This  cognitive profile demonstrated by MWM closely resembles executive dysfunction, 
processing speed and general cognition deficits seen in humans with white matter lesions who are 
obese, have MetS or are in the initial phase of AD23–34.  
Other investigations have shown that the APP21 TG rats used in our studies develop executive 
dysfunction with increased age compared to WT animals supporting the clinical relevance of this 
model35,36. In our studies, a non-specific and less rigorous MWM protocol to test executive domain 
was used and the TG rats alone did not develop executive dysfunction. However, executive 
dysfunction was shown in the comorbid animals there is a potentiating effect on behavioral 
deficits.  
Brain analysis identified predominant widespread white matter microgliosis and reactive 
astrocytosis in TG rats, which was not accompanied by evident demyelination. MetS combined 
with the prodromal AD environment significantly increased the white matter microgliosis 
compared to TG condition alone, although there was no additional increase in astrocyte reactivity 
or change to myelination level. In addition, the numbers of neurons in the hippocampus were not 
found to be affected in TG rats compared to WTs35. There was also no apparent hippocampal 
neuronal loss in the comorbid animals. While there was a decrease in hippocampal synaptic density 
in TG rats compared to WTs, it was not further aggravated by the presence of metabolic syndrome 
in the comorbid rats. Thus, the HCD was efficient in modeling MetS traits similar to that observed 
in humans and indicated possible effects of comorbidity on physiology and metabolism which 
might be relevant and important for clinical consideration. Moreover, the combined model 
indicated synergistic effects of comorbidity on neuroinflammation, specifically white matter 
inflammation demonstrated by increased microglia activation, and behavioral deficits suggesting 
a potential link between the AD and MetS and white matter inflammation might be underlying 
mechanism potentiating the effect of comorbidity on cognitive deficits.   
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6.3 White Matter Inflammation  
The Fischer 344 rat strain used in these studies have shown to be especially prone to white matter 
alterations, specifically development and progression of widespread inflammation, with increased 
aging, similar to what is seen in humans as they age 35,37–42. APP21 TG rats created on the Fischer 
344 background have previously been shown to develop accelerated microglia activation in white 
matter compared to the WT rats of this strain35. This phenomenon was also observed in our animals 
as described in this thesis.  
The regions of microglial activation included the corpus callosum, particularly the anterior part 
starting at the forceps minor and more found in the periventricular areas, fimbria, internal capsule, 
cingulum, anterior commissure, hippocampal commissure and optic tract. The predominance of 
white matter changes in the anterior region of the corpus callosum is similar to the pattern seen in 
human aging and the early phase of AD, changes that support the retrogenesis hypothesis of white 
matter disruption due to local events prior to neurodegenerative changes43–47.  
Significantly more activated microglial cells were observed in the corpus callosum, internal 
capsule and fimbria hippocampi of TG rats compared to WT rats in our studies. HCD-induced 
MetS collectively was also associated with significant increase of white matter microgliosis.  
However, it was the comorbid rats of prodromal AD and MetS that demonstrated the most marked 
increase in white matter microglial activation in all three regions compared to all other groups, 
indicating a synergistic response of  the two diseases.  
Although the TG animals demonstrated an increase in astrocyte reactivity, there was not an 
additional increase induced by the comorbid condition with the HCD-induced MetS. This could 
be due to microgliosis in the white matter being a very early pathological change preceding 
reactive astrocytosis or alternatively a specific form of response to this comorbidity with obesity 
and metabolic changes48.  
Rats of both genotype on the HCD also had increased visceral adiposity which was even greater 
in TG rats on the diet, suggesting the establishment of pro-inflammatory environment in these 
animals.  The enhanced white matter inflammation in the comorbid rats which also had the highest 
amount of visceral fat supports the idea of systemic inflammation in MetS contributing to and 
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promoting the brain inflammatory processes and in this case, specifically the white matter 
microglial response21. Furthermore, as only the comorbid rats showed cognitive impairments this 
supports the association of high systemic inflammatory status due to increased visceral adiposity 
with cognitive dysfunction in obese individuals18–22,49–52.  
There was no apparent hippocampal neuronal loss in the comorbid rats suggesting that white 
matter pathology, specifically inflammation, is associated with the behavioral deficits and explain 
the observed profile in this model. These findings of changes in white matter inflammation and 
cognitive impairment, are also supported by the analyses that demonstrated an inverse correlation 
between white matter activated microglia and cognitive performance in total rat sample and 
especially in the comorbid animals.  A better cognitive task performance is associated with lower 
white matter microglial activation.  
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6.4 Anti-inflammatory Treatment  
Consistent evidence from the literature and the present results, of the involvement and critical role 
of neuroinflammation in MCI and AD, from prodrome to end stage, strongly suggests that 
modulation of inflammation is a promising approach to disease prevention  or slowing53,54. 
Epidemiological studies also support this idea, particularly the use of NSAIDs for blocking 
inflammation via COX enzyme inhibition associated with reduced prostaglandin, thromboxane 
and prostacyclin production55. Some clinical trials appear to support the efficacy of anti-
inflammatories in MCI and AD, whereas others show no benefit of NSAID use in control of disease 
progression56.  
These drugs are largely effective at the systemic level and have limited ability to cross BBB.  The 
transport and availability of active free drug in the CNS site of action is very limited, particularly 
due to their extensive binding to plasma proteins in systemic circulation57,58. Modification of drug 
structure can lead to favorable changes in its properties leading to enhanced transport into the CNS 
and increased concentration of biologically active compound in the brain.  
A novel engineered non-steroidal anti-inflammatory prodrug, KL, showed the ability to cross the 
BBB via LAT-1 transporter, achieve a good brain tissue distribution and drug release in the brain59. 
We have tested this brain targeted prodrug in the comorbid rat model and found that the long-term 
prophylactic treatment initiated at the time of dietary intervention at a half-therapeutic dose for 
this class of drug, did not reduce the enhanced white matter microglial activation and did not have 
an effect on the behavioral deficits. However, the chronic prodrug administration was associated 
with two lethal cases and development of widespread neuroinflammation and neuronal 
degeneration accompanied by cognitive deficits in several rats irrespective of the experimental 
group.  
Literature analysis showed that some studies reported an increased risk of adverse cardio- and also 
cerebrovascular events in patients taking NSAIDs that may have been happening in our animals 
on the prodrug60–68. The lack of positive effects of the drug on the pathology and behavioral 
deficits, and the presence of possible direct negative pathological effects could be related to the 
treatment protocol, such as the dose, time of initiation and also the prodrug properties used in our 
study. The pathological APP environment in the TG rats combined with metabolic abnormalities 
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could alter transporter-mediated influx of the prodrug in the CNS. Clinical data suggest the timing 
of drug application is the most critical condition for the success of anti-inflammatory 
treatment56,69–71.  
White matter inflammation, similar to what was developed in our model, is thought to be the 
earliest pathology seen in AD. It is possible that white matter damage due to inflammation or other 
events leading to or contributing to increased microgliosis in our TG model has been present for 
some time even at the start of pharmacological intervention, even though there is no classical 
plaque or NFT pathology. Thus, the prodrug was unable to prevent or reduce the enhanced 
pathology in the comorbid animals using the drug administration protocol in these studies.  
Prolonged exposure to the high concentration in the brain of free ketoprofen could lead to brain 
damage seen in our rats. This could be linked to insufficient inhibition of negative COX effects 
(e.g. pro-thrombotic, vasoconstrictive) in the current protocol61,62,65,72,73. Alternatively, these 
effects might be related to the inhibition of COX enzyme activity in general which aside from the 
pro-inflammatory and neurodegenerative action are involved in neuroprotection mediated by 
certain prostaglandins, docosanoids, resolvins and neuroprotectins. Beneficial effects  of COX 
include regulation of synaptic activity and plasticity, hippocampal long-term potentiation, 
neurovascular coupling and cerebral blood flow, neuronal survival, anti-thrombotic and even anti-
inflammatory properties (e.g. modulation of leukocyte trafficking, downregulation of cytokines 
expression in glia) 74–80.  
Under pathological conditions the equilibrium maintained by COX is disrupted, and effects are 
initially shifted towards the inflammatory which could eventually turn into neurodegeneration. 
Nevertheless, it is possible that there are still some protective effects in  place to counteract 
compromised homeostasis and diminishing them pharmacologically needs to be approached 
cautiously. 
The data overall supports the need in further studies to clarify the potential of anti-inflammatory 
treatment in preventing and slowing down white matter inflammation associated with AD and 
cognitive deficits. Initiation of treatment as well as the therapeutic window are critical conditions 
for the success of drug therapy and should be established by future experiments. These parameters 
could vary with the presence of concurrent chronic conditions, such as metabolic vascular 
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disorders, that might show an accelerated rate of development of brain pathology, be prone to 
complications associated with the NSAID treatment and also impact pharmacokinetics and 
dynamics of drugs60,81.  
Caution should be exercised with the drug synthesis of brain-targeted NSAIDs in the race for a 
better CNS penetration. This could in fact potentiate adverse effects, rather than increase the 
benefits of the treatment. It might also be that some systemic effects of NSAIDs would be 
beneficial such as lowering systemic inflammation present in obesity and MetS, which could 
decrease pro-inflammatory signaling to the brain and therefore CNS immunity activation, i.e. 
microgliosis. It is also possible to consider various NSAIDs and alternative drug agents with a 
different mechanism of action that will not diminish COX-mediated beneficial effects. 
 
  
220 
 
6.5 Biomarkers  
Success of the treatment appears to depend on the pathological stage it is initiated at. Early 
intervention might grant beneficial effects by acting on the prodromal pathology such as white 
matter inflammation. It is important to investigate potential biomarkers of the cerebral white matter 
inflammation that may have relevance for disease treatment. Currently, white matter lesions that 
has been linked to cognitive dysfunction can be detected on conventional MRI as hyperintensities 
or atrophy. However, these lesions might already be too advanced and not quite useful from a 
therapeutic intervention point of view82–84. Early inflammatory pathology might already be present 
even when the white matter appears normal on MRI. The DTI MRI method is more sensitive and 
could provide an insight into structural white matter changes associated with pathological changes 
to myelin and axons85–89. PET imaging can provide information specific to microglial activation90–
95. More easily obtainable and affordable markers such as blood derived substances and 
physiological measures present a more favorable approach and should be studied.  
The experiments described in this thesis examined associations between blood metabolic and 
physiological parameters and cerebral white matter activated microglia and astrocytosis using a 
preclinical rat model that included a model of comorbid hAPP TG and MetS. The amount of 
visceral fat was a very strong predictor of microgliosis and better explained its variance than body 
weight. Lipid metabolism components showed more complicated relations. While entire 
heterogenous rat sample including both diets and genotypes showed a weak positive association, 
comorbid rats demonstrated a negative relationship with every component. Chol:HDL ratio 
appeared to be the strongest contributor to the variations in microglia activity.  
Epidemiological data does not provide a single directional relationship between blood lipids and 
AD, suggesting potential effects at different disease stages. The epidemiology data actually 
suggests a beneficial role of increased cholesterol levels for the brain under pathological 
conditions96–98.   
There was a strong genotypic relationship to the amount of activated white matter microglia. The 
TG APP variant with Swedish and Indiana mutations associated with early FAD correlated with 
greater microglial activation. Thus, comorbid conditions with AD, such as metabolic vascular 
diseases including MetS and T2DM, and potentially the stage of the disease appear to complicate 
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and can significantly modulate the associations between the markers and specific pathology. Age, 
gender, ethnicity and genetics may further contribute to the relationship of certain markers with 
AD or MCI pathologies. Thus, biomarker research should consider the presence of comorbidities 
that might have a direct effect on the interpretation and subsequent clinical application of the 
biomarker.  
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6.6 Limitations 
The TG rat model of AD bears the hAPP gene mutations which are causally linked to the early 
onset autosomal dominant FAD99. However, genome studies revealed that variants of these gene 
are implicated in the sporadic LOAD as well100,101. The clinical profile of these two types of AD 
are very alike.  Although there might be different mechanisms driving the disease development, 
these forms are very similar pathologically. Particularly, white matter lesions commonly seen in 
LOAD are also attributed to the onset of FAD type82,102,103. Thus, this rat model offers valuable 
opportunities for the investigation of the roles of white matter pathology and white matter 
microglia activation in a common form of AD pathogenesis and cognitive decline. This model is 
also relevant to age-related pathology and vascular dementia.   
The dietary approach of modeling obesity and MetS provides a great advantage since it closely 
mimics human habits. These models create a complex in vivo environment to study diseases and 
their interaction in more realistic conditions. However, dietary composition for experimentation is 
not standardized and varies greatly in fat, sugar and protein amounts which introduces a certain 
variability to the systemic and brain pathology that might introduce variable responses in different 
species and strains104,105. Similarly, the duration of feeding might impact the development of 
pathologies.  
In these studies, the diet was provided for 12-15 weeks and was enough to model obesity and 
related dyslipidemia, insulin resistance and glucose intolerance characteristic of a pre-diabetic 
condition. However, the animals did not develop frank T2DM with fasting hyperglycemia. Blood 
pressure elevation was not evident in the HCD rats compared to control animals. Blood pressure 
was measured with a non-invasive technique which does not absolutely exclude a possibility of 
subtle early changes that might be developing at this stage, that could have been detected using 
sensitive invasive methods. Nevertheless, our model demonstrated characteristic features of MetS 
in a particular combination that appear relatively early in the course of the disease, and this 
provided us the opportunity to study early interaction with AD predisposition.  
Behavioral testing done in our model utilized MWM task to assess spatial learning and memory, 
as well as working memory and behavioral flexibility, which are all related to the health of the 
white matter. However, MWM is not the most sensitive or specific task for assessment of executive 
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function. Operant conditioning based set-shifting would be a much more appropriate test for this 
purpose36. However, this test requires a considerable food restriction period for motivational 
purposes prior to training and uses sugar pellets as a reward during the testing and the testing 
period might be a several weeks long. This significantly complicates the integration of the task in 
its original form into our studies when our animals are on the diet-induced pathology regimen. In 
fact, there is evidence of pathology reduction and reversibility with caloric restriction and diet 
modulation11,106–109.  
Analysis of the cerebral pathology was focused on the white matter changes, particularly glia-
mediated inflammation. Microglia and astrocyte activation, which indicates a pro-inflammatory 
environment, were detected by immunohistochemistry using a single antibody for each type of 
cell, OX-6 for MHC II (M1 pro-inflammatory phenotype) and anti-GFAP, respectively110–112. 
Although these markers may have some limitations, they have a good selectivity, are associated 
with increased activation of cells in a pro-inflammatory condition, including aging, and are 
commonly used40,113–119.  
Quantification methods included integrated density defined as a sum of pixels in the area and area 
coverage by antigen positive cells, which were analyzed on converted to black and white images, 
and allowed assessment of the cell activation level by the number of antigen-expressing cells, 
rather than the antigen expression level in cells.  Additionally, the number of Iba-1 stained 
microglia cells was used to assess the changes in the total microglia numbers. These 
complementary microglia staining analysis indicated that comorbidity was specifically associated 
with an increase in activation of cells and not due to an increase in their number. GFAP staining 
does allow a conclusive answer to whether increased transgene-dependent astrocytic response was 
due to an increase in individual cell reactivity or increased number of cells.   
We did not detect neuronal loss or additional to transgene-related synaptic density decrease in the 
hippocampal region by immunohistochemical staining suggesting depletion of neurons or 
synapses in the hippocampus is not responsible for the cognitive profile of the comorbid rats. It is 
likely that white matter microglial activation and/or other white matter pathology underlies these 
disturbances. However, this does not exclude the possibility that some functional and 
morphological neuronal changes could begin to develop at a later time. It is more likely that 
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synaptic dysfunction associated with the microglia hyperactivation and white matter damage could 
contribute to the cognitive impairments48,120.  
The conclusions of the NSAID prodrug treatment ineffectiveness were based on a single treatment 
protocol. This protocol used a half-dose of a common therapeutic dose. This was considered 
sufficient since it was initiated at the time of dietary change and was viewed as a prophylactic 
measure. It is possible that this dose, the frequency of injections, the duration and the time of 
initiation at that particular age could be insufficient to modify the observed pathological microglia 
activation. Earlier intervention in younger rats could potentially provide some benefit.  
Additional studies with brain targeted anti-inflammatory drugs need to be pursued and should rely 
on a determination of the white matter inflammation time course. However, a large increase in 
brain inflammation observed in several prodrug-recipients suggests there may be a safety concern 
for the brain-targeted agent even with the moderate dose delivered daily and a higher therapeutic 
dose may not be feasible. However, a vehicle-controlled study should be performed to rule out the 
possible effects of the chronic stress due to injections on the brain and behavior and determine the 
unique negative effect of the drug treatment. 
Correlational studies utilized a limited data sample which likely affected precision and power of 
associations, particularly between behavior and glucose metabolism and microgliosis. A limited 
number of measures were tested for relationship with white matter pathology. Nevertheless, 
observations of differential patterns seen in the whole rat sample and the comorbid group showed 
significant correlations and may be relevant to the humans.  
Finally, these studies used only male rats 8.5-10.5 months of age at the start of experiments. There 
could be sex differences in the response to the diet and in the interaction with AD early pathology, 
which are important and should be investigated.  
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6.7 Future directions 
The studies presented in this dissertation represent the basis for future experiments. The 
pathological and cognitive presentation of the MetS may slightly vary reflecting the diversity of 
components comprising the syndrome in a particular case seen among both humans and animals. 
Each of the metabolic and physiological changes in MetS may contribute to CNS pathology and 
AD-related changes either individually or as a combination. Thus, it might be important to study 
various phenotypes to observe both short-term and long-term progression of pathological events 
to unravel the dynamics of changes in the CNS, including white matter glia activation and function. 
Also, in the light of importance of understanding the early pathology, studies on the time course 
of white matter microglia activation could be carried out with initiation of the experiment at a 
younger age.  
The use of more specific and sensitive behavioral methods is required to adequately characterize 
the changes in cognitive function in the comorbid condition and the effects of the treatment. These 
behavioral methods need to be first adapted for use in diet-induced metabolic disease models.  
The detection of astrocytes and microglia was done using a single antigen expressed by activated 
cells in a pro-inflammatory condition. Greater specificity and more information could be achieved 
by using other markers of activated cells that may indirectly identify potential triggering events 
for changes in amyloid, APP or myelin debris. Such molecules of interest related to microglia 
function during inflammation to be considered are TREM-2, LRP, complement system receptors, 
galectin-3, Mac-1,2, TSPO121–125.  
While post-mortem tissue analysis is highly detailed and informative, PET and DTI MRI 
techniques can provide an advantage of indicating in vivo pathology detection and to trace the 
changes and progression over time. Glial activation, a marker of neuroinflammation, can also be 
detected using PET and might  significantly advance our understanding of pathology when 
incorporated in preclinical studies126–129. Cerebral pro-inflammatory status analysis could further 
be complemented by CSF or blood cytokine level determination.  
Brain tissue should be further analyzed in a greater detail using available immunohistochemical 
and imaging methods  in order to identify the nature and magnitude of the inflammatory events as 
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well as to determine if the white matter microglia activation is a precursor to or a consequence of 
potential vascular changes and other processes. These other processes include myelin and/or 
axonal damage and loss, oligodendrocyte dysfunction and death, are potential events that might 
take place at this early stage of dietary intervention and contribute to the cognitive dysfunction130–
136. The white matter damage or excessive microglia activation appearing at this early stage could 
affect synaptic function and number137,138. The comorbid model which addresses the early AD 
disease pathology demonstrated subtle cognitive changes. Synaptic pathology might be associated 
with these cognitive deficits and could be investigated using various methods that include 
immunohistochemistry, electron microscopy, PET imaging and electrophysiology139–143. 
These processes associated with microglia activation such as vascular, axonal, myelin, synaptic 
pathologies could be better correlated with cognitive decline and have a stronger association with 
the blood and physiological parameters associated with MetS which could further be used as 
peripheral biomarkers. Moreover, these studies on other associated pathologies and processes 
could define other potential therapeutic targets and strategies directed towards white matter 
protection.  
NSAIDs are an intensively studied class of drugs for MCI and AD treatment. They inhibit COX 
activity and downstream production of eicosanoids and docosanoids modulating both pro-
inflammatory and innate neuroprotective mechanisms144. Additionally, blockage of COX 
pathways might increase arachidonic acid which is also a substrate for lipoxynase (LOX) enzymes, 
such as 5-LOX and 12/15-LOX145. This could result in an elevated release of leukotrienes 
contributing to inflammation, oxidative stress and neuronal injury and modulation of tau and 
amyloid pathways146,147.  
Obesity, particularly when induced by hypercaloric high-fat/sugar diets, might change the brain 
lipid profile and membrane composition such as increase arachidonic acid production148. Another 
derivative of membrane phospholipids metabolism is lysophosphatidic acid (LPA) involved in 
promotion of insulin resistance and AD-specific pathology via enhancement of tau 
phosphorylation and APP processing by β-secretase into Aβ peptide, and glia activation149–152. 
LPA production is increased in obesity and AD153,154. AD is also associated with the increased 
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ATX gene expression, coding enzyme autotoxin involved in synthesis of LPA155,156. Comorbid 
conditions may aggravate these pathways.  
Thus, inhibitors of LOX and production or action of leukotrienes and LPA could be an alternative 
to NSAIDs drug choice with beneficial effects for its use in comorbid patients and should be 
investigated157–160. One of the drugs that inhibits 5-LOX leukotriene production and alleviates 
inflammation is minocycline, a tetracycline antibiotic used for treatment of infection 161,162. 
Research data suggests a strong anti-inflammatory potential of this drug mediated by a direct 
action on microglia and interference with microglia T-cell communication48,163–166. This might be 
a favourable strategy for AD and especially comorbidity with MetS as it specifically targets 
microglia, which appear to have a major role in the disease neuropathology and white matter 
inflammation in particular. Minocycline and derivatives might block excessive glia activation by 
the systemic inflammatory signalling48,111,166–168.  
Blocking or suppressing pro-inflammatory cytokine (e.g. TNF-α) action via receptor binding 
modulation is also a promising strategy79,169–174. Etanercept (Enbrel) which is a recombinant 
receptor for TNF-α cytokine, one of the major key players in AD primarily secreted by microglia 
cells, showed benefit in preclinical and clinical cases175–178. Monoclonal antibodies to TNF-α, 
MAbs, is a second group of treatment candidates175,176,179–181. Minocycline which was discussed 
earlier has also been shown to have an anti-TNF-α effect172,174. Nevertheless, TNF-α also has 
physiological functions which could be disrupted with drugs targeting this cytokine172,173. Direct 
inhibition of TNF-α receptors might be beneficial or detrimental depending on a cell type, receptor 
type and disease stage, thus more careful studies and more targeted and selective therapy should 
be developed182–184.  
In addition to pharmacological treatments, lifestyle changes are a readily available way of 
interfering with the disease development. Reduction and reversibility of the neuropathology has 
been observed with caloric restriction and diet modulation11,106–109,185. The efficacy of this 
approach on decreasing white matter microglia activity, including in the comorbid model, should 
also be studied either independently or in combination with the drug method. Moreover, poor diet 
and lack of exercise are risk factors for metabolic conditions, MCI and dementia. Thus, 
modification of lifestyle at an early age could reduce the incidence of metabolic vascular disorders 
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and possibly prevent cognitive decline with aging. It is likely that a therapeutic plan combining 
pharmacological methods targeting several key pathological events and non-pharmacological 
measures might provide successful prevention or control over the MetS, diabetes and dementia.  
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6.9 Conclusions 
The studies constituting this thesis support the initial hypothesis that comorbidity of pathogenic 
hAPP TG model of prodromal AD with MetS increases white matter inflammation, as 
demonstrated by microglia activation, and this comorbidity leads to cognitive deficits. TG CD rats 
developed some increased white matter activation compared to that in the WT group but did not 
show cognitive changes. Pathogenic hAPP also increased the total number of microglia cells. 
Comorbidity further exacerbated microglia activation, but not proliferation in TG HCD rats 
compared to TG normal rats and resulted in significant behavioral deficits. White matter 
microgliosis was further associated with the visceral fat accumulation which supports the idea of 
contribution of systemic inflammation to the cerebral glia activation.  
While there was a genotype-dependent increase in the astrocyte reactivity in TG rats, the comorbid 
condition did not have an impact on this pathology as there was no additional increase in activation 
of these cells. Thus, it appears that comorbidity with diet-induced MetS exacerbated exclusively 
white matter microgliosis which suggests this is the key element of prodromal AD-related 
pathology and it may be the point of interaction between these diseases and related to the cognitive 
health. This pathological linking event might be an extremely important target for intervention 
allowing early modulation of the disease pathogenesis and disruption of detrimental synergistic 
effects of concurrent diseases.  
While the use of a particular brain-targeted NSAID prodrug in a single protocol did not provide 
support for the anti-inflammatory intervention, it highlighted several important points for 
consideration including the importance of when treatment is started, potential serious adverse 
effects and the need for investigations of alternative drug agents. Thus, this APP21 TG rat model 
combined with the diet-provoked metabolic alterations is an important and clinically relevant 
model for studying early pathology in AD, early biomarkers and relationship with the metabolic 
vascular diseases. Furthermore, it is an important arena for testing pharmacological and 
nonpharmacological treatments and preventive measures that target the pathological link between 
these diseases, particularly white matter microgliosis, with the goal of preservation of cognitive 
function.  
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Appendices 
Appendix A: Ethics Approval  
A1 Animal Use Protocol #1 
 
From: eSiriusWebServer [mailto:esiriusadmin@uwo.ca]  
Sent: September 23, 2014 12:29 PM 
To: David.Cechetto@schulich.uwo.ca 
Cc: auspc@uwo.ca 
Subject: eSirius Notification - New Protocol Modification Has Been APPROVED2008-113::6 
  
 
AUP Number: 2008-113 
PI Name: Cechetto, David 
AUP Title: Mechanisms of Vascular Cognitive Impairment and Prevention of Stroke and Its 
consequences 
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2008-
113 has been approved. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional 
safety standards and have received all necessary approvals. Please consult directly with 
your institutional safety officers. 
Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee 
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Appendix B: Diet Composition  
B1 Hypercaloric Diet (HCD)  
 
The content of the pelleted rodent Western diet which was used to induce metabolic syndrome 
MetS in these studies (HCD groups) and its detailed fatty acid composition are provided below.  
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B2 Supplementary Syrup Drink in the hypercaloric diet (HCD) regimen 
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B3 Control Diet  
 
This rat chow from Prolab is used as a standard rodent food in the animal facility in which the rats 
included in these studies were housed. This diet continued to be used in the rats from both control 
diet groups (CD) for the entire duration of studies.  
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Appendix C: Rat Tail Cuff Blood Pressure Measurement  
Blood pressure measurements were done using the CODA High Throughput Non-Invasive Blood 
Pressure System (Kent Scientific; CODA-HT6). Complete system user guide can be found online   
https://www.kentscientific.com/Customer-Content/www/products/Files/CODA_HTManual.pdf. 
Briefly, rats are placed in the holders, plastic tubes enclosing animal’s body and exposing the tail 
for blood pressure measurements. Two cuffs are placed on the tail, occlusion cuff which is close 
to the base of the tail and distally located volume change detecting cuff. Animals are placed on the 
warming platforms to increase the blood flow. The system allows simultaneous measurement of 6 
animal. The holders are available in two sizes and have an adjustable position of the nose cone to 
accommodate rats of a different size. Prior to experiment acclimatize animals to the tube, gradually 
increasing the duration of restraint, to heating, presence of cuffs and allow a few acclimation days 
of test blood pressure measurements (5 days on average).  
Habituate rats in the room before the start of experiment for a minimum of 30min. In the meantime, 
test the cuffs for malfunctions. Preheat platforms with empty holders placed on them at 39°C (L4). 
Place rats in the holders, cover with blankets and heat for 10-15min at reduced to 38-35°C (L3-2) 
temperature. Maintain 32°C (L1) heat for the duration of experiment, monitoring the tail blood 
volume and rat behavior. Place the cuffs on the tail and begin measurements. One session (one day 
experiment) includes minimum of 25 and on average 50 cycles. Monitor position of the cuffs for 
the accurate measurement, as rats tend to move and throw off the distal cuff. Clean tubes and 
platforms from feces and urine, smell and porphyrin traces with detergent (Sparkleen) between 
rats and at the end of experiment. Repeat the session over multiple days (3-5) choosing the same 
time of a day.  
At the end of the session export measurements to excel file and set up the table to calculate systolic 
and diastolic pressure mean of multiple cycles within one day to account for the blood pressure 
variations and then across multiple days. Apply manual filtering of the accepted by the software 
cycles.  Remove readings that have a tail blood volume of 15ml or less. Use the readings with in-
day standard deviations less than 30, with the number of good cycles greater than 15 and mean 
blood volume be more than 50ml.  
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Appendix D: Ketoprofen – lysine Prodrug  
Structural formula of the Ketoprofen-lysine prodrug was designed by Jukka Leppänen at the 
University of Kuopio, Finland. The prodrug has a molecular weight of 418.92 g/mol. The structural 
formula and kinetics of the rat brain uptake of the prodrug were demonstrated in the original work 
publication (Gynther, M. et al. Brain uptake of ketoprofen-lysine prodrug in rats. (2010) Int. J. 
Pharm. 399, 121–128). Figures inserted in this chapter were adapted from the original paper and 
have not been modifyied.  
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Appendix E: Tissue Staining Protocols 
E1 Solutions 
Phosphate Buffered Saline (PBS) 0.1M pH 7.35 1L (10X) – STOCK  
Na2HPO4 (anhydrous) 10.9g 
NaH2PO4 (anhydrous) 3.2g or monohydrate (NaH2PO4
XH2O) 3.7 g  
NaCl    90g 
Distilled water (dH2O)  1000ml (˜ 980ml) 
Mix to dissolve and adjust pH to 7.35 using HCl and NaOH dropper. Store at room temperature.  
 
PBS 0.01M pH 7.35 1L (1X) – WORKING SOLUTION 
Dilute 1:10: 1 part PBS 0.1M (10X) stock solution with 9 parts of distilled water: 
PBS 0.1M   100ml 
dH2O    900ml 
Mix to dissolve and adjust pH to 7.35. Store at room temperature. 
 
Phosphate Buffer Saline with 0.2% TritonX detergent (0.2% PBST) 0.01M 
PBS 0.01M   ˜500ml 
Triton X-100   1ml 
Use 1ml syringe (without a needle) to draw 1ml of triton. Stir to dissolve completely. 
 
Parafromaldehyde (PFA) 4% pH 7.35 1L stable for 2 weeks at 4 oC   
PFA     40g 
ddH2O      500ml (stir and heat to 30 - max 50
 oC, then cool down)  
NaOH 10N   ˜ 15 drops to help dissolve 
PBS 0.1M   100ml 
ddH2O      390ml (to from 1L solution). Filter before use. 
 
Phosphate buffer (PB) 0.1M 1L pH7.2-7.3  
Na2HPO4 (anhydrous) 10.9g 
NaH2PO4 (anhydrous) 3.2g or monohydrate (NaH2PO4
XH2O) 10.7g 
dH2O  1000ml (˜ 980ml) 
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Cryoprotectant 1L 
0.1M PB   500ml 
Sucrose   300g 
Ethylene glycol  300ml 
PVP-40   10g – optional and was not used in these studies  
ddH2O    up to 1000ml  
Pour a sample of solution in an Eppendorf and put in a freezer overnight to check that 
cryoprotectant does not freeze. 
 
30% Sucrose 1L 
Sucrose                                    300g 
ddH2O                                     1000ml 
 
0.3% Gelatin for mounting brain sections on glass slides 
Dissolve 1.5g gelatin powder in 500ml ddH2O, heat (not boil) and stir for better dissolving, cool 
down to room temperature before use. Keep refrigerated. Good to use within a week. Reheat to 
room temperature before each use. 
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E2 Immunohistochemistry Protocol 
Primary antibodies:  
• Anti-Iba-1, rabbit polyclonal (1:1000; #019-19741, Wako Chemicals USA Inc., Richmond, 
 VA, USA) 
• OX-6, mouse monoclonal (1:1000; #554926, BD Pharmingen, Mississauga ON, Canada)  
• Anti-GFAP, mouse monoclonal (1:2000; #G3893 Sigma-Aldrich, St Louis MO, USA) 
• Anti-NeuN, mouse monoclonal  (1:1000; #MAB377 EMD Millipore Corp., USA) 
• Anti- synaptophysin, mouse monoclonal  (1:1000; #S5768 Sigma-Aldrich, St Louis MO, USA) 
Secondary antibody: 
• Biotinylated horse anti-mouse IgG (1:500; #31806 Thermo Fisher Scientific) 
• Biotinylated goat anti-rabbit IgG (1:500; #31820 Invitrogen, Thermo Fisher Scientific) 
Blocking solution reagents:  
• Normal horse serum (#7484 Abcam)  
• Normal goat serum (#S-100 Vector Laboratories, Inc. Burlingame, CA, USA) 
Avidin-biotin complex (ABC) Standard reagent kit (#32020 Thermo Fisher Scientific); 
(#Vectastain PK-6102,Vector Laboratories, Inc. Burlingame, CA, USA) 
 
Staining is performed on free-floating sections; all steps are done on a shaker. 
 
Day1 
• Wash 6x10min in PBS 0.01M 
• Block endogenous peroxidase with 1% H2O2 for 10 min (15min for NeuN) (prepare from 3% 
 stock H2O2 with 0.01M PBS)  
• Wash 3x5 min in PBS 0.01M 
• Block non-specific tissue binding with 2% blocking solution (1.5% for NeuN) prepared with 
horse serum (goat serum for Iba-1) in PBST for 1h at room temperature   
• Incubate with primary diluted in blocking solution (prepared as in a previous step) for 30min at 
a room temperature following overnight in fridge (4°C cold room on a shaker) 
Day2 
• Continue incubation in primary for 30 min at a room temperature  
• Wash 3x5 min in PBS 0.01M  
255 
 
• Incubate with secondary diluted in blocking solution (prepared as in day 1) for 1h at room 
temperature  
• Wash 3x5 min in PBS 0.01M 
• Incubate with horseradish peroxidase (ACB kit - 2 drops A, 2 drops B in 10ml 0.01M PBST – 
prepare 1h before use) 1h at room temperature 
• Wash 3x5 min in PBS 0.01M 
• Incubate in 0.05% diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich #D5637) 
solution.  Toxic! Dissolve 10mg DAB, 1 tablet or powder, in 20mL of 0.01M PBS (add 5ml 
more PBS as will lose later when filtering). Stir for ˜ 15min for a tablet; powder form much 
faster, and filter through filter paper (Whatman Grade 2/8μm). Add 3% H2O2 immediately 
before use (20uL of 3% stock H2O2 in 20mL DAB solution). Dispose properly after. 
• Wash 3x5 min in PBS 0.01M 
• Mount with 0.3% Gelatin on glass slides and leave to air-dry overnight 
Day3  
• Step done in fumehood. Dehydrate slides sequentially in 50%, 70%, 95%, 100% Ethyl Alcohol 
(EtOH,) 50/50 EtOH/Xylene for 5 min in each Then 10 min in 100% Xylene. Coverslip with Depex 
(BDH Chemicals, Poole, UK), remove air bubbles, dry overnight in the fumehood, clean slides the next 
day. 
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E3 Luxol Fast Blue Staining Protocol 
Solutions: 
 
0.1% Luxol fast blue solution  
Luxol fast blue powder, MBS  0.1g 
Ethyl Alcohol, 95%   100ml 
Glacial acetic acid    0.5ml 
Filter after preparation. Can be stored and reused for 5 years.  
 
0.05% Lithium carbonate solution  
Lithium carbonate   0.05g 
ddH2O     100ml 
 
Day1 
• Wash 6x10min in PBS 0.01M 
• Mount sections on (non ‘+’) slides using water. Do not use gelatin! Fully dry overnight 
Day2 
• Step done in fumehood. Dehydrate slides sequentially in 50% →  70% → 95% EtOH for 3 
min in each 
• Incubate in Luxol fast Blue solution for 16-18h at 56 oC. Make sure the boats are properly 
sealed to prevent solution evaporation. Better use screw-cap jars, lid should be tightly sealed! 
Day3  
• Rinse off excess Luxol fast Blue with 70%EtOH for 1.5-2 min (thicker cut sections use more 
time), continuously dip and agitate slides in a boat  
• Rinse carefully with ddH2O (2 times x1 min) – dip and agitate in a boat, NOT under running 
water (sections may detach from slide) 
• Differentiate slides in 0.05% Lithium Carbonate solution for 1.5min in the 1st run, then 1min 
in each following run. Thicker sections require more time (1.5-2min per step). This step takes 
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as long as necessary to distinguish white matter, can take between 5 and 30 min. On average 3 
runs are enough. If in doubt, take out a bit earlier rather than later.  
• Rinse with distilled water (2 times x1min) – dip, agitate in a boat 
• Dehydrate in 100% EtOH (2 times x 5min), then in Xylene (2 times x 5min) 
• Coverslip with Depex resinous medium. 
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Appendix F: Microscopy and Image Analysis  
F1 Image Acquisition on the Microscope 
Tissue sections were imaged on the Nikon Eclipse Ni-E upright microscope with a Nikon DS Fi2 
color camera head (NIS Elements Imaging; Mississauga, ON) using NIS-Elements Imaging 
Software Version 4.30.02 (Nikon Instruments Inc., Melville, NY).  
Microscope settings:  
Lamps (DIA enabled, fixed) at 43-48, LUT function disabled, Exposure 10ms, Analogue gain 1.0, 
Zoom 1.0x, no Filters on Turet1, FL1 fluorescent shutter is off. 
Using 2X objective: Aperture 30.6mm, Field Stop 30.6mm, condenser 5 2/4x; 10X objective: 
Aperture 11.5mm, Field Stop 10.5mm, condenser 7N1; 20X objective: Aperture 19.1mm, Field 
Stop 5.2mm, condenser 6N2.  
Scanning image:  
For every tissue section set white balance using a probe (rectangle icon) on a no-tissue spot on a 
slide (direct light) and applying AWB (auto white balance) function found on the tool bar at the 
top.  
Adjust focus manually prior to scanning either a single focus for the entire image or using a focus 
surface which allows to pre-set different focus on multiple points on the tissue, particularly when 
the slide preparation resulted in uneven  surface and requires different focus depth to create a sharp 
image. 
Select on a top tool bar Acquire → Scan Large Image: set scanning objectives (i.e. capture 2x – 
scan 10x), set area of scanning manually defining number and position of fields, set stitching 
overlap at 20%, shading off, automatic postprocessing off, select Focus manually at start (or Focus 
surface). Extended depth of focus (EDF) is available for creating a Z-stacked image scanned at 
various depth (select steps in um, range) and combining sharp signal from multiple layers into one 
image.  
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Capture function can be used for smaller images which do not require stitching (camera button on 
top tool bar). This option is also available with EDF→ Real time EDF – select range (top and 
bottom sharp focus) and step length (e.g. 0.9um) for Z-series acquisition.  
Save an image as TIFF for publication purposes, as JPEG for large images and JPEG or TIFF for 
small image for Image J or microscope software analysis. 
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F2 Image Acquisition using Aperio 
Aperio digital entire-slide scanner (Department of Pathology, Western University, London, 
Ontario, Canada), allowing 20x magnification, was used to acquire images of entire series of brain 
sections for initial scanning of activated microglia location and of Luxol Fast Blue stained tissue 
for myelination analysis. Aperio ImageScope software (Leica Biosystems Pathology Imaging), 
version 12.3.2.8013 was used to extract images of specific regions of interest for further  ImageJ 
analysis. 
Choose magnification (zoom slider) and select Camera button on the top tool bar (Scanshot) to 
acquire image of the region at a fixed resolution and with a scale bar which can not be removed 
from the image. Image can be saved as TIFF/JPEG, however, is suitable for analysis and a low 
magnification full-section image, but not publication. Extract region tool (floppy disk and arrow 
icon on the top tool bar) allows to obtain an image of a selected region with variable resolution: 
click and drag on the image, in the opened window define output format – TIFF or JPEG, LZW 
compression, % extraction (80-100 on average), extract. This function does not capture scale bar. 
Both methods can be used together to create a high-quality image with defined scale bar. 
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F3 Image Analysis 
White matter analysis 
Image analysis was done in the ImageJ program (Version 1.48u4, Wayne Rasband, National 
Institutes of Health, Bethesda, MD, USA). Prior to quantification set a scale: use a line tool to 
outline the scale on the image and measure its length in pixels (Analyze→ Measure or Ctrl+M); 
open Analyze→ Set scale, input measured and known length (in um), set pixel aspect ratio to 1.0 
and apply Global to use this scale (pixel/um) for a series of images in one ImageJ session. Then 
Analyze→ Set measurements: area, min and max gray value, integrated density (include raw 
integrated density = sum of pixel values), mean gray value and area fraction. 
To create selection for the region of interest (ROI), use the stereotaxic atlas to define ROI’s 
boundaries. Outline the ROI with a polygon tool avoiding edges (DAB accumulates) and excluding 
artifacts overlapping with the ROI. To add selection to the ROI Manager use Edit→ Selection→ 
Add to manager (Ctrl+T), then save all ROIs for an animal by selecting all and ROI Manager→ 
More→ Save. ROI shape and size can be changed by manipulating individual points on selection 
(hold and drag, add point Shift+left mouse click, remove point Ctrl+left click) and ROI can be 
updated in the Manager (ROI should be selected in the manager list prior to changes). If you click 
outside of the selection, it will disappear from the image. To bring it back, use Edit→ Selection→ 
Restore selection (Ctrl+Shift+E). Do not crop the image to minimize the field to ROI, as such ROI 
saved will not match the region boundaries on the original image when re-opening the image.  
If a part of the original full selection is needed for a separate analysis (e.g. PVCC regions from the 
entire corpus callosum selection), use rectangle/polygon outline tool to draw a selection around 
the region to be cropped out, and add this new selection to ROI Manager. Select a newly added 
ROI and Edit → Selection → Make inverse (note a fine colored line at the perimeter of the image) 
program window), add to manager, select both full and inverse selections in the Manager→ 
More→ AND → this will generate a new selection with undesired region cropped from the full 
selection. In the case of bilateral analysis (e.g. fimbria), combine several individual ROIs by 
selecting those ROIs in Manager→ More→  OR (combine). Add newly created ROI to the 
Manager and save. 
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Convert image to black-white format: Image→ Type→ 8-bit. Measure ROI area.  Process→ 
Subtract background (select “light” as the signal is dark; rolling ball radius 50 pixels) and finally 
Image→ Adjust→ Threshold (Ctrl+Shift+T) to an adequate maximum (233-248 depending on the 
stain). Do not apply threshold, limit measurement to threshold (area should not be 100%) and do 
the measurement. Copy all measurements and paste into excel file to calculate weighted average 
for each of the ROIs per animal and a final sum.   
Automatic cell count  
Neuronal cell count was done using the NIS-Elements Imaging Software Version 4.30.02 (Nikon 
Instruments Inc., Melville, NY). Follow the following steps: select Binary→ Spot detection: dark 
spots (spot 9pixels, typical diameter 13.5um or size of cell body, contrast 20.1); methods – select 
dark, clustered, blue channel, apply to current frame, preview. ROI→ Move binary to ROI→ see 
the number appearing when right- click on image – number of selected ROIs represent number of 
cell bodies. If only a selection from entire image area needs to be analyzed, go to measure using 
rectangle tool (record the area and dimensions of the selection for consistent application), crop at 
the end of a measured box, delete the box and do same later.  
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